



Mistry, Shailesh N. and Jörg, Manuela and Lim, Herman and Vinh, Natalie B. and Sexton, Patrick M. and Capuano, Ben and Christopoulos, Arthur and Lane, J. Robert and Scammells, Peter J. (2015) 4-Phenylpyridin-2-one derivatives: a novel class of positive allosteric modulator of the M1 muscarinic acetylcholine receptor. *Journal of Medicinal Chemistry* . ISSN 1520-4804

**Access from the University of Nottingham repository:**

<http://eprints.nottingham.ac.uk/31240/1/572C81F3-E478-407D-B15B-ECEFF1B1750C.pdf>

**Copyright and reuse:**

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see: [http://eprints.nottingham.ac.uk/end\\_user\\_agreement.pdf](http://eprints.nottingham.ac.uk/end_user_agreement.pdf)

**A note on versions:**

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact [eprints@nottingham.ac.uk](mailto:eprints@nottingham.ac.uk)

## 4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M Muscarinic Acetylcholine Receptor

Shailesh N. Mistry, Manuela Jörg, Herman Lim, Natalie B. Vinh, Patrick M. Sexton, Ben Capuano, Arthur Christopoulos, J. Robert Lane, and Peter J. Scammells

*J. Med. Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.5b01562 • Publication Date (Web): 01 Dec 2015

Downloaded from <http://pubs.acs.org> on December 10, 2015

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

# 4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M<sub>1</sub> Muscarinic Acetylcholine Receptor

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Shailesh N. Mistry,<sup>†,§,#</sup> Manuela Jörg,<sup>†,§</sup> Herman Lim,<sup>‡</sup> Natalie B. Vinh,<sup>†</sup> Patrick M. Sexton,<sup>‡</sup> Ben Capuano,<sup>†</sup> Arthur Christopoulos,<sup>‡</sup> J. Robert Lane,<sup>‡,\*</sup> and Peter J. Scammells<sup>†,\*</sup>

<sup>†</sup> Medicinal Chemistry and <sup>‡</sup>Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia.

**ABSTRACT:** Positive allosteric modulators (PAMs) of the M<sub>1</sub> muscarinic acetylcholine receptor (M<sub>1</sub> mAChR) are a promising strategy for the treatment of the cognitive deficits associated with diseases including Alzheimer's and schizophrenia. Herein, we report the design, synthesis and characterization of a novel family of M<sub>1</sub> mAChR PAMs. The most active compounds of the 4-phenylpyridin-2-one series exhibited comparable binding affinity to the reference compound, 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (BQCA) (**1**), but markedly improved positive cooperativity with acetylcholine, and retained exquisite selectivity for the M<sub>1</sub> mAChR. Furthermore, our pharmacological characterization revealed ligands with a diverse range of activities, including modulators that displayed both high intrinsic efficacy and PAM activity, those that showed no detectable agonism but robust PAM activity, and ligands that displayed robust allosteric agonism but little modulatory activity. Thus the 4-phenylpyridin-2-one scaffold offers an attractive starting point for further lead optimization.

## ■ INTRODUCTION

Selective activation of the M<sub>1</sub> mAChR may provide a useful approach for the treatment of the cognitive deficits associated with Alzheimer's disease (AD) and schizophrenia (SZ).<sup>1,2</sup> Evidence of cholinergic loss in the cortex of AD patients and in the striatum of SZ patients suggested a link between mAChR function and disease pathology.<sup>3-5</sup> The M<sub>1</sub> mAChR has received particular attention for its role in cognition. It is expressed predominantly in the hippocampus, striatum and cortex, and activation of the receptor causes cognition-enhancing effects in animal models and M<sub>1</sub> mAChR knock-out mice display a range of cognitive deficits.<sup>6-15</sup> In addition, both acetylcholinesterase (AChE) inhibitors and the M<sub>1</sub>/M<sub>4</sub> mAChR preferring agonist, xanomeline, improved cognitive function and/or have antipsychotic efficacy in human patients of AD and SZ.<sup>16-18</sup> Unfortunately, both AChE inhibitors and xanomeline display limiting gastrointestinal side effects, likely due to their lack of selectivity across the muscarinic receptor subtype family and, in particular, action at the M<sub>2</sub> and M<sub>3</sub> mAChRs, which are widely expressed in the periphery.


Unfortunately, the development of subtype-selective drugs that target the orthosteric site (i.e. the ACh binding site) remains challenging because this site is highly conserved across the mAChR receptor family. Therefore, considerable research efforts have focused upon targeting less conserved and spatially distinct allosteric sites with allosteric modulators, allosteric agonists and bitopic ligands.<sup>7-9, 14, 19-21</sup> 1-(4-Methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (BQCA) (**1**) is a prototypical example of a highly selective positive allosteric modulator (PAM) for the M<sub>1</sub> mAChR.<sup>9, 22, 23</sup> Although **1** has a low affinity for the allosteric site on the M<sub>1</sub> mAChR, it nonetheless displays *in vivo* activity in animal models of cognitive deficits, an action most likely driven by very high positive cooperativity with ACh when both molecules are co-bound on the receptor. We have recently published a SAR study of **1** that incorporated analytical modeling into our pharmacological analysis to relate PAM structural features to changes in allosteric ligand binding affinity ( $pK_B$ ), intrinsic efficacy ( $\tau_B$ ), cooperativity with ACh binding ( $\alpha$ ) and/or modulatory

1  
2  
3 effects upon ACh efficacy ( $\beta$ ). The standout analogue of this series, 5,8-difluoro-*N*-((1*S*,2*S*)-2-  
4 hydroxycyclohexyl)-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (2),  
5  
6 demonstrated higher affinity, intrinsic efficacy and functional cooperativity with ACh, compared to  
7  
8 **1**.<sup>20</sup> Furthermore, the studies revealed a strong correlation between the intrinsic efficacy and  
9  
10 cooperativity of this series of ligands, whereby the greater the level of allosteric agonism displayed  
11  
12 by the modulator, the greater the level of observed cooperativity when combined with ACh.  
13  
14  
15

16 The findings with **1** and the aforementioned analogues adhere to the classic Monod-Wyman-  
17  
18 Changeux (MWC) two-state model of allostery, which predicts a correlation between allosteric  
19  
20 agonism and allosteric modulation.<sup>22</sup> As with orthosteric agonists, the degree of allosteric agonism  
21  
22 can also be dependent upon the pathway stimulus-response coupling efficiency and/or receptor  
23  
24 density. However, in order to truly understand the relationship between in vitro measures of  
25  
26 allosteric ligand behaviour and the actual in vivo efficacy of such modulators, one needs a broader  
27  
28 suite of M<sub>1</sub> mAChR PAMs that display a range of different allosteric behaviours. Indeed, a recent  
29  
30 study revealed that two selective M<sub>1</sub> mAChR agonists could differentially regulate coupling of the  
31  
32 M<sub>1</sub> mAChR to specific signalling pathways and lead to selective actions on some, but not all, M<sub>1</sub>  
33  
34 mAChR mediated responses in brain circuits important for memory, learning and psychosis – a  
35  
36 property not consistent with the MWC model and instead suggestive of pathway-biased allosteric  
37  
38 modulation.<sup>14</sup> Such region-specific effects may be therapeutically advantageous.  
39  
40  
41  
42

43 We have recently combined site-directed mutagenesis and molecular modelling/docking  
44  
45 experiments to infer the structural nature of the M<sub>1</sub> mAChR allosteric binding site to which  
46  
47 compound **1** binds.<sup>24</sup> In particular, our results highlighted the role of Tyr179 within the second  
48  
49 extracellular loop (ECL2) of the M<sub>1</sub> mAChR for binding via formation of hydrophobic/edge-to-face  
50  
51  $\pi$ - $\pi$  interactions with both the bicyclic 4-oxo-1,2-dihydroquinoline core and the benzylic pendant  
52  
53 moiety of **1**. Similarly, Trp400 at the top of transmembrane domain 7 (TM7) was predicted to make  
54  
55 a  $\pi$ - $\pi$  interaction with the benzylic pendant. Herein, we report the design, synthesis and detailed  
56  
57 pharmacological characterization of a novel family of positive allosteric modulators at the M<sub>1</sub>  
58  
59  
60

1  
2  
3 mAChR. The compound design was based on the desire to explore simpler heterocyclic cores that  
4  
5 can maintain the key receptor-ligand interactions described above, in combination with formalizing  
6  
7 the presence of the pseudo third ring present in **1** (due to intramolecular hydrogen bonding between  
8  
9 the carboxylic acid and ketone moieties).<sup>25</sup> Accordingly we devised the general scaffold depicted in  
10  
11 Figure 1.



27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1.** Conceptual development of the novel  $M_1$  mAChR PAM scaffold starting from **1**<sup>9,22,23</sup> via 5,8-difluoro-*N*-((1*S*,2*S*)-2-hydroxycyclohexyl)-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (**2**)<sup>20</sup> to evolve to the general structure of the novel 4-phenylpyridin-2-one based compounds reported herein.

## ■ RESULTS AND DISCUSSION

**Chemistry.** The commercial availability of both 4-bromo-2-hydroxypyridine (**3**) and 1,2-cyclohexene oxide allowed easy access to both the pyridine derivative **4a** and the pyridin-2-one **4b** (Scheme 1). Initially, we adapted a literature procedure that reported alkylation of **3** in the presence of K<sub>2</sub>CO<sub>3</sub> in DMF giving a mixture of the O- and N-alkyl products.<sup>26</sup> More specifically, heating compound **3** in a 2.5-fold excess of both K<sub>2</sub>CO<sub>3</sub> and 1,2-cyclohexene oxide in DMF at 120 °C overnight gave a mixture of the 2-alkoxypyridine (**4a**) and the *N*-alkylpyridin-2-one (**4b**). These isomers were easily separated based on their contrasting solubility profiles in EtOAc and the ability to remove remaining impurities through aqueous washing. Whilst the overall yield was good, no selectivity was observed in terms of the site of alkylation with **4a** and **4b** being formed in a ~1:1 ratio. In each case only the *trans*-isomer was observed as a racemic mixture. The target alkylation products arose from the tautomeric nature of compound **3**, with the ability to exist in both the 2-hydroxypyridine (**3a**) and pyridin-2(1*H*)-one (**3b**) forms. Although crystallization studies on 2-pyridone have demonstrated the amide tautomer to predominate in the solid state,<sup>27,28</sup> tautomerism in solution is heavily dependent on solvent nature.<sup>29,30</sup> As a consequence, a solvent screen was performed to evaluate the preferred product formation (**4a** versus **4b**) after addition of 1,2-cyclohexene oxide. The non-polar solvent toluene formed exclusively the 2-alkoxypyridine **4a** within 1 hour at reflux. Polar solvents including DMF, ethanol, DME, DMSO exhibited ratios between 30:70 to 70:30 of compounds **4a** and **4b** and reaction times were generally about 1 day (as assessed by LC-MS). In water, no reaction was observed, while under neat conditions (using 10 equivalents of reagent) after 1 hour reaction time at 120 °C a product ratio of ~30:70 of compound **4a** versus **4b** was obtained. Hence, when the reaction was performed under neat conditions using 5 equivalents of 1,2-cyclohexene oxide the *N*-alkylpyridin-2-one (**4b**) was obtained in an improved isolated yield of 77%.

1  
2  
3 With the aim of identifying a tractable scaffold, we elected to first synthesize comparable  
4 examples incorporating the scaffold of molecules **4a** and **4b**, before embarking on a more in-depth  
5 SAR campaign. Initially, we carried out parallel Suzuki coupling of both **4a** and **4b** with 2-  
6 hydroxyphenylboronic acid, in the presence of 10% PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> in 1 M Na<sub>2</sub>CO<sub>3(aq)</sub>/THF at  
7 100 °C, giving the 2-arylphenol derivatives **5** and **7** in excellent yield after flash column  
8 chromatography. A 4-phenylbenzylic pendant was attached to the phenolic group of compounds **5**  
9 and **7**, on the basis of such a moiety imparting improvements in affinity ( $K_B$ ) and binding  
10 cooperativity ( $\alpha$ ) with ACh in our previously reported enriched SAR study of **1**.<sup>20</sup> This was  
11 achieved using Finkelstein-type modification of standard alkylation conditions, with catalytic KI, 4-  
12 (bromomethyl)biphenyl and K<sub>2</sub>CO<sub>3</sub> in DMF at room temperature, to give the desired ethers **6** and  
13 **8a**.

14  
15  
16 Subsequent analogues **8b-t** were synthesised as a parallel series in the same manner as  
17 compound **8a**, by varying the nature of the alkyl halide used to alkylate phenol **7**. The methyl  
18 benzoate compounds **8o** and **8p** offered an ideal starting point to generate the corresponding  
19 benzoic acid (**9a** and **9b**) and benzamide (**9c** and **9d**) analogues, through basic hydrolysis and direct  
20 aminolysis with NH<sub>4</sub>OH, respectively.


21  
22  
23 Whilst the 4-bromobenzyl derivative **8t**, was of interest in building SAR around this series in its  
24 own right, it was also an attractive moiety to further elaborate the core structure. This was achieved  
25 through a second series of Suzuki couplings, with selected boronic acids and boronate esters, to  
26 give 4-arylbenzyl ether compounds **10a-d**.

27  
28  
29 Finally, a focussed selection of aniline derivatives **13a-e** was also synthesised, to compare  
30 directly to the corresponding phenol analogue **8a** as well as **10a-d** and investigate activity in  
31 relation to the nature of atom used to link the benzylic pendant to the parent core. Installation of the  
32 aniline moiety was carried out using Suzuki chemistry as before, coupling 4-bromo-1-(2-  
33 hydroxycyclohexyl)pyridin-2(*1H*)-one (**4b**) with 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
34 yl)aniline. Selective monoalkylation of the free aniline was achieved through established reductive  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



alkylation methodology reported by Abdel-Magid *et al.*,<sup>31</sup> employing 4-bromobenzaldehyde to introduce the benzylic pendant, giving 4-bromobenzylamino derivative **12**. Suzuki coupling of compound **12** with the previously selected group of boronic acids and boronate esters gave the desired analogues **13a-e**.

**Scheme 1.** Synthesis of initial series of 4-phenylpyridin-2-one derivatives<sup>a</sup>




<sup>a</sup>Reagents and conditions: (a) 1,2-cyclohexene oxide, K<sub>2</sub>CO<sub>3</sub>, 120 °C, 77% (rac-*trans*); (b) 2-hydroxyphenylboronic acid or 2-(4,4,5,5-tetramethyl-1,2,3-dioxaborolan-2-yl)aniline, cat. PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 1 M Na<sub>2</sub>CO<sub>3(aq)</sub>/THF degassed, 100 °C, 83-100%; (c) substituted benzyl halide, K<sub>2</sub>CO<sub>3</sub>, cat. KI, DMF, rt, 18-93%; (d) NaOH, EtOH/H<sub>2</sub>O, 50 °C, 82-93%; (e) NH<sub>4</sub>OH/MeOH, rt, 14-52%; (f) boronic acid or boronate ester, cat. PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 1 M Na<sub>2</sub>CO<sub>3(aq)</sub>/THF degassed, 100 °C, 29-77%; (g) 4-bromobenzaldehyde, AcOH, NaB(OAc)<sub>3</sub>H, 1,2-dichloroethane, rt, 50%.

A smaller second series of compounds was synthesized to investigate changes to the pyrazole moiety of compound **10d** (Scheme 2). Therefore, the unsubstituted pyrazole derivative **14** was obtained via Suzuki reaction of intermediate **8t** with the *N*-Boc protected pyrazole boronic ester.

These reaction conditions afforded the Boc deprotected product **14**, circumventing the need for an additional acid-mediated cleavage procedure to remove the Boc group. It is worth noting that compound **14** could not be synthesized efficiently when using (1*H*-pyrazol-4-yl)boronic acid hence the use of the *N*-Boc protected pyrazole boronate ester. In the next step, alkylation of compound **14** afforded analogues **15a-j** in yields varying from 6-82%. Depending on the steric bulk of the alkyl halide the alkylation reactions proceeded at room temperature or at elevated temperatures of up to 100 °C. The alkylation with bromocyclobutane was unsuccessful even at elevated temperature and extended reaction time.


**Scheme 2.** Synthesis of a series of *N*-substituted pyrazole derivatives<sup>a</sup>



<sup>a</sup>Reagents and conditions: (a) 1-(*tert*-butoxycarbonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole, cat. PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 1 M Na<sub>2</sub>CO<sub>3</sub>(aq)/THF degassed, 100 °C, 77%; (b) alkyl halide, K<sub>2</sub>CO<sub>3</sub>, cat. KI, DMF, rt to 100 °C, 6-82%.

We subsequently synthesized two additional compounds, **17** and **19**, incorporating modifications to the benzyl component of the 1-methylpyrazol-4-yl)benzyl pendant of **10d** (Scheme 3). This was achieved through initial alkylation of intermediate **7** with 2-chloro-5-(chloromethyl)pyridine or 4-bromo-1-(bromomethyl)-2-fluorobenzene, giving **16** and **18** respectively. The desired analogues **17** and **19** were subsequently obtained via Suzuki coupling of **16** and **18** with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole.


**Scheme 3.** Synthesis of analogues with modifications to the 4-(1-methylpyrazol-4-yl)benzyl pendant<sup>a</sup>



<sup>a</sup> Reagents and conditions: (a) substituted benzyl halide,  $K_2CO_3$ , cat. KI, DMF, rt, 63% for **16**, 62% for **18**; (b) boronic acid / boronate ester, cat.  $PdCl_2(PPh_3)_2$ , 1 M  $Na_2CO_3(aq)$ , THF degassed, 100 °C, 32% for **17**, 30% for **19**.


Next, we synthesized analogue **23** (Scheme 4), incorporating fluoro substituents in analogous positions to those present in **2** (Figure 1), which were previously shown to influence intrinsic efficacy in compounds of the 4-oxo-1,4-dihydroquinoline class.<sup>20</sup> The intermediate **4b** was coupled with the commercially available (3,6-difluoro-2-methoxyphenyl)boronic acid to afford a 1:1 mixture of **20** and an unidentified side product in an overall yield of 23% (Scheme 4). *O*-Demethylation of intermediate **20** was achieved with  $BBr_3$ , to afford the corresponding phenol (**21**), in good yield. Purification of **21** via flash column chromatography (FCC) permitted separation of the unidentified side product from the previous step. Alkylation with 1-bromo-4-(bromomethyl)benzene was performed at room temperature to give ether **22**, followed by a Suzuki coupling reaction with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole at 100 °C to give **23** in modest yield.

**Scheme 4.** Synthesis of difluoro-substituted 4-phenylpyridin-2-one **23**<sup>a</sup>



<sup>a</sup>Reagents and conditions: (a) boronate ester, cat.  $\text{PdCl}_2(\text{PPh}_3)_2$ , 1 M  $\text{Na}_2\text{CO}_3(\text{aq})/\text{THF}$  degassed, 100 °C, 23% for **20**, 31% for **23**; (b) 1 M  $\text{BBr}_3$  in hexane, DCM, 0 °C to rt, 72%; (c) 4-bromobenzyl bromide,  $\text{K}_2\text{CO}_3$ , cat. KI, DMF, rt, 73%.

Finally, we synthesized the 6-phenylpyrimidin-4-one analogue **29** (Scheme 5). This analogue allowed us to probe if further interaction with the allosteric pocket of the  $M_1$  mAChR can be achieved through the introduction of an additional hydrogen bond acceptor (tertiary nitrogen) to the scaffold. In the case of **29** the order of the reaction steps was altered, since the epoxide ring opening reaction with 1,2-cyclohexene oxide and 6-chloropyrimidin-4(3*H*)-one (**24**) did not afford the desired intermediate. The failure of this reaction may be explained by the preference for polymerization through the 6-chloro group over the epoxide ring opening reaction with 1,2-cyclohexene oxide. As a consequence, starting material **24** was first coupled with (2-methoxyphenyl)boronic acid to afford intermediate **25** in modest yield (20%), before subsequent reaction with 1,2-cyclohexene oxide to give compound **26**. LC-MS indicated the formation of the 4-alkoxypyrimidine and *N*-alkylpyrimidin-4-one (**26**) in an approximately 1:3 ratio. Nonetheless, only the *N*-alkylpyrimidin-4-one (**26**) could be isolated after FCC due to side products interfering with the 4-alkoxypyrimidine product. We then converted the 2-methoxyphenyl moiety to a phenol using boron tribromide to give intermediate **27** in good yield (87%). The last two steps involved alkylation with 1-bromo-4-(bromomethyl)benzene and Suzuki coupling with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole under the same conditions as reported for the pyridinone analogues, to give the desired 6-phenylpyrimidin-2-one **29**.

**Scheme 5.** Synthesis of the 6-phenylpyrimidin-4-one analogue **29**<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) (2-methoxyphenyl)boronic acid, cat. PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 1 M Na<sub>2</sub>CO<sub>3(aq)</sub>, THF degassed, 100 °C, 20%; (b) 1,2-cyclohexene oxide, K<sub>2</sub>CO<sub>3</sub>, 120 °C, 38%; (c) 1 M BBr<sub>3</sub> in hexane, DCM, 0 °C to rt, 87%; (d) 4-bromobenzyl halide, K<sub>2</sub>CO<sub>3</sub>, cat. KI, DMF, rt, 55%; (e) boronate ester, cat. PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 1 M Na<sub>2</sub>CO<sub>3(aq)</sub>, THF degassed, 100 °C, 11%.

**Pharmacology.** Our recent SAR study of **1** allowed us to correlate chemical modifications to changes in parameters that describe allosteric action at the M<sub>1</sub> mAChR. We applied the same approach in this study for selected intermediates and all final compounds. Competition binding studies between ACh and the radiolabelled antagonist [<sup>3</sup>H]NMS at the M<sub>1</sub> mAChR expressed in FlpIN CHO cells were performed in the absence and presence of increasing concentrations of test compound, and data were analysed with an allosteric ternary complex model to determine the binding affinity of the test compound ( $K_B$ ) for the unoccupied M<sub>1</sub> mAChR and its cooperativity with ACh ( $\alpha$ ). To assess the ability of our test compounds to modulate ACh function, we used myo-inositol 1 phosphate (IP<sub>1</sub>) accumulation as a measure of M<sub>1</sub> mAChR activation resulting from preferential activation of canonical G<sub>q</sub> proteins. Concentration response curves of ACh were generated in the presence of increasing concentrations of test compound, and an operational model of allosterism was applied to the data, with the  $K_B$  parameter fixed to that determined in the binding

1  
2  
3 studies, thus allowing an overall estimate of functional cooperativity with ACh ( $\alpha\beta$ , where  $\beta$   
4 describes the modulatory effect upon ACh efficacy) and any intrinsic efficacy ( $\tau_B$ ) of the allosteric  
5 ligand. Values of  $\alpha$  or  $\beta > 1$  describe a positive modulatory effect upon ACh, whereas values  $< 1$   
6 (but greater than 0) describe a negative allosteric effect. Since it is well established that the  
7 logarithms of affinity and cooperativity values are normally distributed, whereas their absolute  
8 values (antilogarithms) are not<sup>32</sup>, all statistical comparisons for interpretation of the SAR described  
9 below (Tables 1-3) were performed on the logarithmic values. For ease of interpretation, however,  
10 allosteric parameter antilogarithms are also highlighted in the main text for selected key derivatives.  
11  
12

13  
14  
15  
16  
17  
18  
19  
20  
21 As described in Figure 1, we devised a general molecular scaffold, distinct from that of **1**, that  
22 we hypothesized would maintain key receptor-ligand interactions. As a starting point, we compared  
23 the ether analogue **6** with the pyridinone analogue **8a** (both of which incorporate the 4-  
24 phenylbenzylic pendant). Compound **8a** displayed an affinity for the M<sub>1</sub> mAChR of approximately  
25 10  $\mu$ M and positive cooperativity with ACh binding and function. The affinity and cooperativity  
26 displayed by **8a** (Table 1) were not significantly different from that of **1** ( $p > 0.05$ , one way  
27 ANOVA), while the intrinsic efficacy of **8a** ( $\tau_B = 1.38$ ) was superior to that of **1** ( $\tau_B = 0.22$ ). In  
28 contrast analogue **6** was inactive. As a consequence, compounds based on the 1-(2-  
29 hydroxycyclohexyl)pyridin-2(1*H*)-one moiety were further investigated (Table 1), whereas the  
30 development of analogues containing a 2-(pyridin-2-yloxy)cyclohexan-1-ol moiety was  
31 discontinued.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Intermediate **7** exhibited a binding affinity not significantly different from that of **1** but  
essentially neutral binding cooperativity with ACh ( $\alpha = 0.91$ ), demonstrating that the 4-  
phenylbenzylic pendant is important for the positive cooperativity of compound **8a** with ACh.  
Interestingly, analogue **8b**, with an unsubstituted benzylic pendant (i.e. lacking the additional 4-  
phenyl group), maintained binding affinity and positive cooperativity with ACh comparable to that  
displayed by compound **8a**. Therefore, we investigated the effect of incorporating a range of

1  
2  
3 substituted monocyclic ligands (compounds **8c-p** and **9a-d**) instead of the 4-phenylbenzylic pendant  
4  
5 present in compound **8a**.


6  
7 While affinity was unchanged across these compounds, phenyl rings substituted at the *ortho*-  
8  
9 position with methoxy, trifluoromethyl or nitrile groups (**8f**, **8i** and **8l**, respectively) exhibited lower  
10  
11 binding ( $\alpha$ ) and functional ( $\alpha\beta$ ) cooperativity compared to the respective *meta*- and *para*-substituted  
12  
13 analogues (**8g-h**, **8j-k** and **8m-n**). While a similar trend was observed for the fluoro-substituted  
14  
15 analogues (**8c-e**), this change was not significant. However, for the ester and carboxylic acid  
16  
17 analogues (**8o-p** and **9a-b**) the *meta*-substituted analogue displayed similar activity to the  
18  
19 corresponding *para*-substituted compound. The stand out compound of this series was the *para*-  
20  
21 substituted carboxamide **9d**, which exhibited a binding affinity comparable to **1**, but significantly  
22  
23 improved binding ( $\alpha = 320$ ) and functional ( $\alpha\beta = 230$ ) cooperativity with ACh. The observed  
24  
25 intrinsic efficacy ( $\tau_B$ ) of compound **9d** was 4-fold greater than that of **1**. While the *meta*-substituted  
26  
27 carboxamide analogue **9c** displayed binding and functional cooperativity with ACh comparable to  
28  
29 that of **1**, it did not display any detectable allosteric agonism. Due to the promising properties of the  
30  
31 carboxamide analogue **9d**, the structurally related oxazole **8q** and thiazole **8r** were also synthesized.  
32  
33 However, both bioisosteres (**8q** and **8r**) displayed a significant reduction in binding cooperativity  
34  
35 with ACh ( $\alpha = 27$  and  $\alpha = 25$  respectively) as compared to **9d**.

36  
37  
38  
39  
40 Next, we investigated the effect of replacing the distal phenyl ring of the 4-phenylbenzyl moiety  
41  
42 present on **8a**, with a variety of bioisosteres. These included 6-membered heterocycles (**10a-c**), a 5-  
43  
44 membered heterocycle (**10d**), and a simple bromo substituent (**8t**) that has previously been used as a  
45  
46 phenyl isostere. All the compounds displayed a binding affinity not significantly different from that  
47  
48 of **1** and comparable binding and functional cooperativity with ACh and intrinsic efficacy, with the  
49  
50 notable exception of the pyrazole analogue **10d**, which displayed significantly improved binding  
51  
52 cooperativity ( $\alpha = 370$ ) as compared to that of **1**. Incorporation of an oxygen atom between the two  
53  
54 ring systems, as for the phenoxy analogue **8s**, resulted in total loss of the binding cooperativity with  
55  
56 ACh but maintenance of affinity for the M<sub>1</sub> mAChR.  
57  
58  
59  
60


1  
2  
3 We next investigated modification of the linker atom between the benzylic pendant and the  
4 parent core. A comparison of aniline analogues **12** and **13a-e** with the corresponding ether  
5 analogues **8t**, **10a-d** and **8a**, respectively, revealed that this modification resulted in a reduction in  
6 binding and functional cooperativity with ACh but no change in affinity for the M<sub>1</sub> mAChR. The  
7 unsubstituted aniline intermediate **11** exhibited both an 8-fold reduction in binding affinity to that of  
8 **1** and neutral binding cooperativity ( $\alpha = 0.98$ ) with ACh, demonstrating the importance of the  
9 presence of the benzylic pendant linked to the parent core for the allosteric action of this series.  
10 Furthermore, in terms of binding cooperativity with ACh, the trend seen for the different ligands of  
11 the aniline series (**13d** > **13a** = **13c** = **13b** > **13e** = **12**) is similar to the trend observed for the ether  
12 analogues (**10d** > **10a** = **10c** = **10b** = **8a** = **8t**), whereby the 4-(1-methylpyrazol-4-yl) analogue was  
13 the most active compound in both series.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 None of the compounds in Table 1 showed a significant improvement in intrinsic efficacy  
28 compared to **1**. However, it is interesting to note that both **8j** and **8k**, which display neutral  
29 functional cooperativity with ACh, still displayed robust allosteric agonism comparable to that of **1**  
30 ( $\tau_B = 1.02$  and  $0.77$ , respectively). Taking compound **10d** as the most active from this initial series,  
31 we then tested whether the novel compound displayed selectivity towards the M<sub>1</sub> mAChR. As  
32 shown in Figure 2, while both **1** and **10d** display robust modulatory activity at the M<sub>1</sub> mAChR in a  
33 [<sup>3</sup>H]NMS binding assay, they exhibit no activity up to a concentration of 10  $\mu$ M at the other  
34 mAChR subtypes. As such, the novel 4-phenylpyridin-2-one scaffold appears to share the same  
35 exquisite selectivity for the M<sub>1</sub> mAChR as the benzyl-4-oxo-1,4-dihydroquinoline scaffold.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





**Figure 2.** (a-d) (a-d) Pharmacological characterization of **1** and **10d** in binding and function at the mACHRs. (a-b) Radioligand binding experiments were performed using FlpIn-CHO cells expressing the M<sub>1</sub> mACHR, 0.1 nM of the radiolabeled antagonist [<sup>3</sup>H]NMS, increasing concentrations of ACh, with or without increasing concentrations of either **1** (a) or **10d** (b). (c-d) IP<sub>1</sub> accumulation experiments were performed using FlpIn-CHO cells expressing the M<sub>1</sub> mACHR and increasing concentrations of ACh with or without increasing concentrations of either compound **1** (c) or **10d** (d). 100% represents the maximal stimulation of ACh in the absence of test compound. (e-h) Activity of **1** and **10d** at the human M<sub>2-5</sub> mACHRs in a [<sup>3</sup>H]NMS binding assay. No detectable effect of these compounds was observed at the other mACHR subtypes up to a concentration of 10 μM.

Table 1: Binding and functional parameters of 4-phenylpyridin-2-one analogues 7-13e at the M<sub>1</sub> mAChR.

	X	R	Radioligand binding ([ <sup>3</sup> H]NMS)			IP <sub>1</sub> accumulation	
			p <i>K</i> <sub>B</sub> ( <i>K</i> <sub>B</sub> , μM)	Log <i>α</i> <sup>a</sup>	Log <i>α</i> ( <i>α</i> ) <sup>b</sup>	Log <i>αβ</i> ( <i>αβ</i> ) <sup>c</sup>	Log <i>τ</i> <sub>B</sub> ( <i>τ</i> <sub>B</sub> ) <sup>d</sup>
<b>1</b>	-	-	4.78 ± 0.06 (17)	-3	1.77 ± 0.13 (58)	1.84 ± 0.08 (69)	-0.60 ± 0.10 (0.22)
<b>7</b>	OH	-	4.10 ± 0.08 (79)*	-3	-0.04 ± 0.11 (0.91)*	n.d.	
<b>8a</b>	O	4-Ph	4.99 ± 0.10 (10)	-0.27 ± 0.06	1.22 ± 0.07 (17)	1.09 ± 0.15 (12)	0.14 ± 0.04 (1.38)
<b>8b</b>	O	H	4.55 ± 0.10 (28)	-3	1.20 ± 0.08 (15)	0.94 ± 0.21 (9)	-0.24 ± 0.13 (0.58)
<b>8c</b>	O	2-F	4.52 ± 0.07 (30)	-3	1.30 ± 0.10 (20)	0.62 ± 0.26 (4)*	-0.36 ± 0.16 (0.44)
<b>8d</b>	O	3-F	4.38 ± 0.07 (41)	-3	1.50 ± 0.07 (31)	0.85 ± 0.26 (7)	-0.11 ± 0.12 (0.78)
<b>8e</b>	O	4-F	4.22 ± 0.01 (60)	-3	1.63 ± 0.07 (43)	1.15 ± 0.10 (14)	0.00 ± 0.24 (1)
<b>8f</b>	O	2-OMe	4.53 ± 0.15 (30)	-3	0.53 ± 0.14 (3)	n.d.	
<b>8g</b>	O	3-OMe	4.19 ± 0.02 (65)	-3	1.37 ± 0.05 (23)	0.84 ± 0.14 (7)	0.16 ± 0.04 (1.45)
<b>8h</b>	O	4-OMe	4.28 ± 0.10 (52)	-3	1.67 ± 0.09 (47)	0.80 ± 0.06 (6)	-1.10 ± 0.17 (0.08)
<b>8i</b>	O	2-CF <sub>3</sub>	4.48 ± 0.12 (33)	-3	-0.07 ± 0.22 (1)*	n.d.	
<b>8j</b>	O	3-CF <sub>3</sub>	4.53 ± 0.17 (30)	-3	0.90 ± 0.10 (7.9)*	= 0	0.01 ± 0.12 (1.02)
<b>8k</b>	O	4-CF <sub>3</sub>	4.44 ± 0.10 (36)	-3	1.36 ± 0.11 (23)	0.40 ± 0.31 (2.5)*	-0.11 ± 0.18 (0.77)
<b>8l</b>	O	2-CN	4.38 ± 0.07 (42)	-0.65 ± 0.04	0.59 ± 0.08 (3.8)*	n.d.	
<b>8m</b>	O	3-CN	4.06 ± 0.14 (87)*	-3	1.55 ± 0.11 (35)	0.88 ± 0.35 (8)	-0.59 ± 0.35 (0.25)
<b>8n</b>	O	4-CN	4.85 ± 0.13 (14)*	-0.29 ± 0.05	0.84 ± 0.09 (7)*	0.49 ± 0.16 (3)*	-0.73 ± 0.16 (0.19)
<b>8o</b>	O	3-CO <sub>2</sub> Me	3.99 ± 0.08 (100)*	-3	1.49 ± 0.10 (31)	0.52 ± 0.22 (3)*	-0.82 ± 0.28 (0.15)


1								
2								
3								
4	<b>8p</b>	O	4-CO <sub>2</sub> Me	4.06 ± 0.14 (87)*	-3	1.32 ± 0.09 (21)	0.96 ± 0.28 (9)	-0.26 ± 0.18 (0.54)
5	<b>8q</b>	O	4-(oxazol-2-yl)	4.56 ± 0.08 (28)	-0.68 ± 0.06	1.43 ± 0.09 (27)	1.61 ± 0.18 (41)	-0.24 ± 0.24 (0.57)
6	<b>8r</b>	O	4-(thiazol-2-yl)	4.96 ± 0.05 (11)	-0.45 ± 0.09	1.40 ± 0.08 (25)	0.80 ± 0.19 (6)	-0.35 ± 0.13 (0.45)
7	<b>8s</b>	O	4-O-Ph	4.71 ± 0.08 (19)	-0.30 ± 0.02	0.08 ± 0.10 (1)*	n.d.	
8	<b>8t</b>	O	4-Br	4.24 ± 0.11 (58)	-3	1.26 ± 0.15 (18)	n.d.	
9	<b>9a</b>	O	3-COOH	4.04 ± 0.10 (91)*	-3	1.38 ± 0.11(24)	1.08 ± 0.06 (12)	-0.69 ± 0.09 (0.20)
10	<b>9b</b>	O	4-COOH	3.88 ± 0.06 (130)*	-3	1.31 ± 0.09 (20)	0.92 ± 0.08 (8)	-1.24 ± 0.34
11	<b>9c</b>	O	3-CONH <sub>2</sub>	4.04 ± 0.05 (91)*	-3	1.46 ± 0.11 (29)	0.87 ± 0.09 (7)	-3
12	<b>9d</b>	O	4-CONH <sub>2</sub>	4.66 ± 0.12 (22)	-0.86 ± 0.15	2.51 ± 0.10 (320)*	2.36 ± 0.08 (230)	0.05 ± 0.08 (0.89)
13	<b>10a</b>	O	4-(pyrid-3-yl)	4.72 ± 0.09 (19)	-3	1.76 ± 0.11 (58)	1.29 ± 0.12 (19)	-0.42 ± 0.37 (0.38)
14	<b>10b</b>	O	4-(pyrid-4-yl)	4.95 ± 0.14 (11)	-0.76 ± 0.07	1.49 ± 0.09 (31)	1.01 ± 0.29 (10)	-0.37 ± 0.19 (0.43)
15	<b>10c</b>	O	4-(pyrimid-5-yl)	4.45 ± 0.09 (35)	-0.37 ± 0.05	1.56 ± 0.07 (36)	1.34 ± 0.28 (22)	-0.80 ± 0.35 (0.16)
16	<b>10d</b>	O	4-(1-methyl pyrazol-4-yl)	4.37 ± 0.07 (43)	-3	2.57 ± 0.17 (370)*	2.30 ± 0.08 (200)	-0.68 ± 0.15 (0.21)
17	<b>11</b>	NH <sub>2</sub>	-	3.86 ± 0.06 (138)*	-3	-0.01 ± 0.14 (1)*	n.d.	
18	<b>12</b>	NH	4-Br	4.35 ± 0.10 (45)	-3	0.33 ± 0.08 (2)*	n.d.	
19	<b>13a</b>	NH	4-(pyrid-3-yl)	4.67 ± 0.04 (21)	-0.57 ± 0.02	1.08 ± 0.05 (12)	0.47 ± 0.11 (3)*	-0.13 ± 0.04 (0.74)
20	<b>13b</b>	NH	4-(pyrid-4-yl)	5.03 ± 0.02 (9.3)	-0.69 ± 0.05	0.90 ± 0.08 (8)*	n.d.	
21	<b>13c</b>	NH	4-(pyrimid-5-yl)	3.86 ± 0.10 (138)*	-3	0.97 ± 0.19 (9)*	0.68 ± 0.16 (5)*	0.04 ± 0.05 (1.10)
22	<b>13d</b>	NH	4-(1-methyl pyrazol-4-yl)	4.18 ± 0.07 (66)	-0.58 ± 0.14	1.97 ± 0.04 (93)	1.44 ± 0.09 (28)	-0.36 ± 0.08 (0.44)
23	<b>13e</b>	NH	4-Ph	4.16 ± 0.15 (69)	-0.30 ± 0.04	0.44 ± 0.11 (2.8)*	n.d.	



<sup>a</sup> Binding cooperativity with [<sup>3</sup>H]NMS; for instances where a complete inhibition of [<sup>3</sup>H]NMS binding by the allosteric modulator was observed (consistent with a high level of negative cooperativity), logα' was fixed to -3; <sup>b</sup> binding cooperativity with ACh; <sup>c</sup> functional cooperativity with ACh; <sup>d</sup> intrinsic efficacy of the modulator; for instances where no intrinsic efficacy was observed, Logτ<sub>B</sub> was fixed to -3. \* = significant difference (*p* < 0.05) relative to same parameter determined for **1**, one-way ANOVA with Dunnett's post-test. n.d. = inactive at concentrations up to 30 μM; values represent the mean ± SEM from at least three experiments performed in duplicate.

1  
2  
3 Further studies were performed around the 4-(1-methylpyrazol-4-yl) analogue **10d**, which,  
4 together with carboxamide analogue **9d**, displayed the greatest level of positive cooperativity with  
5 ACh of the first series of compounds in both binding and function. We initially investigated the  
6 exchange of the methyl group with a hydrogen atom (**14**), linear and branched aliphatic carbon  
7 chains (**15a-e**) as well as cyclic unsaturated and aromatic substituents (**15f-15j**) (Scheme 2, Table  
8 2). The removal of the methyl group (compound **14**) caused a 120-fold loss in positive binding  
9 cooperativity with ACh in comparison to the methylpyrazole analogue **10d**. This dramatic effect  
10 could potentially be explained by the loss of an important hydrophobic interaction within the  
11 allosteric binding pocket or the change of the tautomeric properties of the pyrazole moiety. Of  
12 interest, this loss of binding and functional cooperativity was accompanied by a significant 5-fold  
13 increase in intrinsic efficacy ( $\tau_B = 1.10$ ). Elongation of the chain length from the methyl (**10d**) to the  
14 ethyl (**15a**) derivative had no effect upon affinity or cooperativity with ACh. However, a loss in  
15 binding cooperativity was observed with further extension to the propyl (**15c**,  $\alpha = 40$ ; 10-fold loss)  
16 and isopropyl (**15d**,  $\alpha = 120$ ; 3-fold loss) and, most dramatically, the *n*-butyl derivate (**15e**,  $\alpha = 6$ ;  
17 120-fold loss). In contrast, no significant change in intrinsic efficacy was observed. The  
18 hydroxethyl derivative **15b** showed comparable cooperativity with ACh compared to that of the  
19 methyl and ethyl pyrazole (**10d** and **15a**). The incorporation of cyclic unsaturated and aromatic  
20 substituents (**15f-15j**) caused a decrease in binding cooperativity with ACh as compared to **10d**  
21 with the most dramatic effect being the 170-fold decrease observed upon incorporation of a benzyl  
22 group (**15j**). Interestingly, compounds with larger cyclic aliphatic substituents attached to the  
23 pyrazole moiety, such as compounds **15f** and **15g**, exhibited higher ligand binding affinity ( $K_B < 10$   
24  $\mu\text{M}$ ), but with no improvement of binding and functional cooperativity. In the case of **15h**, the lack  
25 of intrinsic efficacy was also noteworthy.


26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54 We subsequently investigated compounds with small changes to the parent core of the 4-(1-  
55 methylpyrazol-4-yl) analogue **10d** (Scheme 3, Table 3). Compound **17**, which incorporates a 2-(1-  
56 methylpyrazol-4-yl)pyridinyl moiety, exhibited comparable binding cooperativity with ACh as  
57  
58  
59  
60

1  
2  
3 compared to that of **10d** but, of particular interest, displayed no detectable intrinsic efficacy. The 2-  
4 fluorobenzyl analogue **19** did not exhibit a change in binding cooperativity or intrinsic efficacy as  
5 compared to compound **10d**. Intermediate **18** displayed a substantial reduction in binding  
6 cooperativity as compared to **10d**, demonstrating the importance of the 4-(1-methylpyrazol-4-yl)  
7 substituent of compound **19**. In comparison, the introduction of fluoro groups to analogues of **1** at  
8 the corresponding positions to those in compound **2** (see Figure 1), translated to a small  
9 improvement of potency.<sup>33</sup> Our earlier work demonstrated that the introduction of 5,8-difluoro  
10 groups to the 4-oxo-1,4-dihydroquinoline core of **1** increased intrinsic activity.<sup>20</sup> The introduction  
11 of the corresponding 3,6-difluoro groups to our novel 4-phenylpyridin-2-one scaffold (compound  
12 **23**) caused a 60-fold decrease in binding cooperativity ( $\alpha = 6$ ) but a significant 6-fold increase in  
13 intrinsic efficacy ( $\tau_B = 1.34$ ). Finally, we investigated the effect of adding an additional nitrogen  
14 atom, therefore changing the pyridine-2(*1H*)-one core to a pyrimidin-4(*3H*)-one core. Although no  
15 gain in affinity for the M<sub>1</sub> mAChR was observed, **29** was the standout compound of the series  
16 displaying a 4-fold increase in binding cooperativity with ACh and a 11-fold increase in intrinsic  
17 efficacy as compared to **10d** (Figure 3). Furthermore, compound **29** displays a similar affinity as  
18 reference compound **1**, but a significant 24-fold increase in binding cooperativity with ACh and a  
19 11-fold increase in intrinsic activity.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2: Binding and functional allosteric parameters of pyrazole analogues 14-15j at the M<sub>1</sub> mAChR.**

	R	Radioligand binding ( <sup>3</sup> H]NMS)			IP <sub>1</sub> accumulation	
		pK <sub>B</sub> (K <sub>B</sub> , μM)	Logα <sup>a</sup>	Logα (α) <sup>b</sup>	Logαβ (αβ) <sup>c</sup>	Logτ <sub>B</sub> (τ <sub>B</sub> ) <sup>d</sup>
<b>10d</b>	-CH <sub>3</sub>	4.37 ± 0.07 (43)	-3	2.57 ± 0.17 (370)	2.30 ± 0.08 (200)	-0.68 ± 0.15 (0.21)
<b>14</b>	-H	4.56 ± 0.26 (28)	-0.10 ± 0.11	0.53 ± 0.22 (3.4)*	0.68 ± 0.16 (4.8)*	0.04 ± 0.05 (1.1)*
<b>15a</b>	-CH <sub>2</sub> CH <sub>3</sub>	4.38 ± 0.15 (41)	0.03 ± 0.07	2.47 ± 0.12 (295)	2.26 ± 0.11 (181)	-0.05 ± 0.08 (0.89)*
<b>15b</b>	-(CH <sub>2</sub> ) <sub>2</sub> OH	4.43 ± 0.09 (37)	-3	2.76 ± 0.13 (575)	2.49 ± 0.11 (310)	-0.11 ± 0.06 (0.77)*
<b>15c</b>	-(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>	4.64 ± 0.12 (23)	-0.18 ± 0.07	1.60 ± 0.25 (40)*	1.78 ± 0.08 (60)	-0.52 ± 0.09 (0.3)
<b>15d</b>	-CH(CH <sub>3</sub> ) <sub>2</sub>	4.57 ± 0.21 (27)	-0.41 ± 0.21	2.08 ± 0.10 (120)	1.93 ± 0.11 (85)	-0.33 ± 0.07 (0.47)
<b>15e</b>	-(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	4.86 ± 0.11 (14)	-0.10 ± 0.06	0.78 ± 0.23 (6)*	0.75 ± 0.13 (6)*	-0.30 ± 0.08 (0.50)
<b>15f</b>	-cyclopentyl	5.45 ± 0.03 (4)	-0.50 ± 0.02	1.08 ± 0.04 (12)*	1.92 ± 0.10 (83)	-0.42 ± 0.07 (0.38)
<b>15g</b>	-cyclohexyl	5.67 ± 0.07 (2)*	-0.50 ± 0.02	1.05 ± 0.09 (11)*	0.63 ± 0.17 (4)*	-0.29 ± 0.09 (0.51)
<b>15h</b>	-CH <sub>2</sub> - 	5.13 ± 0.05 (7)	-0.39 ± 0.04	1.38 ± 0.15 (24)*	0.58 ± 0.12 (3.8)*	-3
<b>15i</b>	-CH <sub>2</sub> - 	4.52 ± 0.31 (30)	-0.19 ± 0.05	0.21 ± 0.10 (1.6)*	n.d.	
<b>15j</b>	-CH <sub>2</sub> Ph	4.68 ± 0.49 (21)	-0.12 ± 0.03	0.33 ± 0.04 (2.1)*	n.d.	


<sup>a</sup>Binding cooperativity with [<sup>3</sup>H]NMS; for instances where a complete inhibition of [<sup>3</sup>H]NMS binding by the allosteric modulator was observed (consistent with a high level of negative cooperativity), logα' was fixed to -3; <sup>b</sup>binding cooperativity with ACh; <sup>c</sup>functional cooperativity with ACh; <sup>d</sup>intrinsic efficacy of the modulator; for instances where no intrinsic efficacy of the modulator was observed Logτ<sub>B</sub> was fixed to -3. \* = significant difference (*p* < 0.05) relative to same parameter determined for **10d**, one-way ANOVA with Dunnett's post-test. n.d. = inactive at concentrations up to 30 μM; values represent the mean ± SEM from at least three experiments performed in duplicate.



**Figure 3.** Pharmacological characterization of **29** in binding and function at the mAChRs. (a) Radioligand binding experiments were performed using FlpIn-CHO cells stably expressing the M<sub>1</sub> mAChR, 0.1 nM of the radiolabeled antagonist [<sup>3</sup>H]NMS, increasing concentrations of ACh, with or without increasing concentrations of **29**. (b) IP<sub>1</sub> accumulation experiments were performed using FlpIn-CHO cells stably expressing the M<sub>1</sub> mAChR, increasing concentrations of ACh with or without increasing concentrations of **29**. 100% represents the maximal stimulation of ACh in the absence of **29**.

It is interesting to note that compound **1** exhibited equivalent values for both binding ( $\alpha = 60$ ) and functional ( $\alpha\beta = 62$ ) cooperativity, suggesting that it is the allosteric effect on ACh binding affinity that underlies the cooperativity measured in our functional assay. Similarly, there was no significant difference between values of binding ( $\alpha$ ) and functional ( $\alpha\beta$ ) cooperativity determined for any compound in this novel series based around the 4-phenylpyridin-2-one scaffold (Tables 1-3, Student's t-test,  $p < 0.05$ ). Indeed, we observed a strong correlation between  $\text{Log}\alpha\beta$  and  $\text{Log}\alpha$  (Figure 4a), demonstrating that binding cooperativity mediates the modulatory effect upon ACh in the functional assay observed for the compounds in this series. Another key observation from our characterization the compounds based around the 4-phenylpyridin-2-one scaffold was the apparent “uncoupling” of the correlation between positive cooperativity with ACh and allosteric ligand intrinsic efficacy, in contrast to our previous SAR study of compound **1** (Figure 4b & c). Although the most active compound of the current series (**29**) displayed both the largest positive cooperativity with ACh and the largest intrinsic efficacy (Figure 4), we also identified analogues ranging from **17**, which displayed no intrinsic efficacy but robust positive cooperativity with ACh ( $\alpha = 125$ , Figure


1  
2  
3 4e), to **14**, which displayed intrinsic efficacy comparable to that of **1** ( $\tau_B = 1.1$ , Figure 4d) but only  
4  
5 very weak positive cooperativity with ACh ( $\alpha = 3$ ). This range of different ligand activities suggests  
6  
7 that the action of some ligands within the current series no longer adhere to a simple two-state  
8  
9 allosteric model of action. Further evidence of this is provided by our binding assay. In the majority  
10  
11 of cases, a robust inhibition of the orthosteric antagonist, [<sup>3</sup>H]NMS, by increasing concentrations of  
12  
13 test compound was observed, consistent with these ligands displaying positive cooperativity with  
14  
15 agonists but high negative cooperativity with the binding of antagonists. This is consistent with a  
16  
17 two-state mode of action and our previous observations of the action of **1** or analogues.<sup>20,22</sup>  
18  
19 However, in the present series we observed a number of compounds (for example **15a**, **15c-e**) that  
20  
21 displayed neutral cooperativity with [<sup>3</sup>H]NMS but robust positive cooperativity with the agonist  
22  
23 ACh. As such, these observations suggest that a simple two-state model can no longer  
24  
25 accommodate the action of these ligands.  
26  
27  
28  
29



30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
**Figure 4.** (a) Correlation between binding and functional cooperativity for 4-phenylpyridin-2-one derivatives generated in the present study (Pearson's test,  $r = 0.84$ ,  $p < 0.05$ , slope =  $1.00 \pm 0.01$ ). (b) Plots of functional cooperativity (Log $\alpha\beta$ ) versus intrinsic efficacy (Log $\tau_B$ ) for derivatives of **1** generated and characterized in our previous study reveal a positive correlation (Pearson's test,  $r = 0.65$ ,  $p < 0.05$ ) between these two parameters. (c) A similar plot for 4-phenylpyridin-2-one



1  
2  
3 derivatives generated in the present study reveals no such correlation. (**d** & **e**) IP<sub>1</sub> accumulation  
4 experiments were performed using FlpIn-CHO cells stably expressing the M<sub>1</sub> mAChR, increasing  
5 concentrations of ACh with or without increasing concentrations of **14** (**d**) and **17** (**e**). (**d**) **14**  
6 displays intrinsic activity comparable to that of **1**, but very weak positive cooperativity with ACh  
7 (**e**) **17** displays no intrinsic activity but robust positive cooperativity with ACh. 100% represents the  
8 maximal stimulation of ACh in the absence of test compound.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 3: Binding and functional allosteric parameters at the M<sub>1</sub> mAChR of 4-(1-methylpyrazol-4-yl) analogues.**

					Radioligand binding ( $[^3\text{H}]\text{NMS}$ )			IP <sub>1</sub> accumulation	
	W	X	Y	Z	$\text{p}K_{\text{B}}$ ( $K_{\text{B}}$ , $\mu\text{M}$ )	$\text{Log}\alpha^a$	$\text{Log}\alpha$ ( $\alpha$ ) <sup>b</sup>	$\text{Log}\alpha\beta$ ( $\alpha\beta$ ) <sup>c</sup>	$\text{Log}\tau_{\text{B}}$ ( $\tau_{\text{B}}$ ) <sup>d</sup>
<b>10d</b>	CH	H	H	CH	$4.37 \pm 0.07$ (43)	-3	$2.57 \pm 0.17$ (370)	$2.30 \pm 0.08$ (200)	$-0.68 \pm 0.15$ (0.21)
<b>14</b>	CH	H	H	CH	$4.45 \pm 0.26$ (35)	$-0.09 \pm 0.11$	$0.48 \pm 0.19$ (3)*	$0.68 \pm 0.16^*$ (5)	$0.04 \pm 0.05$ (1.09)*
<b>17</b>	CH	H	H	N	$4.50 \pm 0.04$ (32)	-3	$2.10 \pm 0.02$ (125)	$2.15 \pm 0.09$ (141)	= -3
<b>18</b>	CH	H	F	CH	$4.75 \pm 0.10$ (18)	-3	$0.75 \pm 0.14$ (6)*	n.d.	
<b>19</b>	CH	H	F	CH	$4.51 \pm 0.08$ (31)	-3	$2.24 \pm 0.17$ (174)	$1.93 \pm 0.11$ (85)	$-0.37 \pm 0.14$ (0.43)
<b>23</b>	CH	F	H	CH	$4.38 \pm 0.12$ (42)	-3	$0.76 \pm 0.30$ (6)*	$-0.41 \pm 0.43$ (0.39)*	$0.13 \pm 0.03$ (1.34)*
<b>29</b>	N	H	H	CH	$4.88 \pm 0.04$ (13)	-3	$3.14 \pm 0.09$ (1380)	$2.75 \pm 0.15$ (562)	$0.40 \pm 0.15$ (2.51)*

<sup>a</sup> Binding cooperativity with [<sup>3</sup>H]NMS; for instances where a complete inhibition of [<sup>3</sup>H]NMS binding by the allosteric modulator was observed (consistent with a high level of negative cooperativity),  $\text{log}\alpha'$  was fixed to -3; <sup>b</sup> binding cooperativity with ACh; <sup>c</sup> functional cooperativity with ACh; <sup>d</sup> intrinsic efficacy of the modulator; for instances where no intrinsic efficacy of the modulator was observed  $\text{Log}\tau_{\text{B}}$  was fixed to -3. \* = significant difference ( $p < 0.05$ ) relative to same parameter determined for **10d**, one-way ANOVA with Dunnett's post-test. n.d. = inactive at concentrations up to 30  $\mu\text{M}$ ; values represent the mean  $\pm$  SEM from at least three experiments performed in duplicate.

## ■ CONCLUSIONS

In this study, we report the design and characterization of a structurally novel series of M<sub>1</sub> mAChR PAMs based on the novel 4-phenylpyridin-2-one scaffold, that offer potentially greater scope for future development than the extensively investigated BQCA core. Our previous studies have revealed that, while **1** displays low affinity for the M<sub>1</sub> mAChR, it displays high positive cooperativity with agonist binding and has exquisite subtype selectivity.<sup>22</sup> However, BQCA does contain a carboxylic acid group that is often associated with poor permeability.<sup>34-36</sup>

The majority of active compounds displayed both comparable binding affinities and intrinsic efficacy to those of **1**. Indeed, the lack of significant gains in affinity may be due to the nature of the binding pocket, which if it is indeed the same as that of **1**, lies at the extracellular interface of the M<sub>1</sub> mAChR and is largely defined by aromatic residues. However, we also generated a number of compounds that displayed markedly higher binding and functional cooperativity with ACh than **1**. Furthermore, compound **10d** displayed high selectivity towards the M<sub>1</sub> mAChR over other mAChR subtypes (Figure 1). Bioisosteric replacement of the carboxamide functionality of compound **9d** with an oxazole (**8q**) or thiazole (**8r**) was not well tolerated, whereas small changes to the pyrazole moiety of compound **10d** were generally better accommodated. However, replacement of the *N*-methyl group (compound **14**) with longer chains and bulkier alkyl as well as aromatic-bearing groups (compounds **15e**, **15i** and **15j**) had a detrimental effect on the cooperativity with ACh in comparison to the *N*-methylpyrazole analogue **10d**. The standout PAM in terms of binding cooperativity with ACh was the 6-phenylpyrimid-4-one analogue **29** with an  $\alpha$  value of 1380, i.e., a 1380-fold potentiation of ACh affinity. Consequently, compound **29** represents a promising lead for future investigations of the previously unreported 6-phenylpyrimidin-4-one scaffold.

We have previously shown that **1** adheres to a two-state mode of action, whereby the degree of agonism of **1** is dependent upon the pathway stimulus-response coupling efficiency and/or receptor density.<sup>22</sup> Furthermore, in an SAR exploration of analogues of **1**, we have shown a strong positive correlation between the degree of cooperativity and the level of allosteric agonism.<sup>20</sup> We have also

1  
2  
3 made similar observations in an SAR study of M<sub>4</sub> mAChR allosteric modulators.<sup>37</sup> However, in the  
4  
5 case of the present series of 6-phenylpyrimidin-4-one derivatives we observe no such correlation.  
6  
7 Instead, our characterization revealed a range of behaviours from ligands that displayed little or  
8  
9 weak positive cooperativity with ACh but robust allosteric agonism to those that displayed no  
10  
11 agonism but a high level of positive cooperativity with ACh (Tables 1-3, Figure 3). This range of  
12  
13 behaviours may, in the future, allow us to explore the relationship between *in vivo* efficacy and *in*  
14  
15 *vitro* parameters that describe the functional cooperativity and intrinsic efficacy of allosteric M<sub>1</sub>  
16  
17 mAChR ligands. This is particularly relevant given recent observations of M<sub>1</sub> mAChR agonists  
18  
19 displaying signalling-pathway and brain-region specific effects that may be of therapeutic  
20  
21 relevance.<sup>14</sup>  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ■ EXPERIMENTAL SECTION

**Chemistry.** Chemicals and solvents were purchased from standard suppliers and used without further purification. Davisil<sup>®</sup> silica gel (40-63  $\mu\text{m}$ ) for flash column chromatography was supplied by Grace Davison Discovery Sciences (Victoria, Australia) and deuterated solvents were purchased from Cambridge Isotope Laboratories, Inc. (USA, distributed by Novachem PTY. Ltd, Victoria, Australia).

Unless otherwise stated, reactions were carried out at ambient temperature. Reactions were monitored by thin layer chromatography on commercially available pre-coated aluminium-backed plates (Merck Kieselgel 60 F<sub>254</sub>). Visualisation was by examination under UV light (254 and 366 nm). General staining was carried out with KMnO<sub>4</sub> or phosphomolybdic acid. A solution of ninhydrin (in ethanol) was used to visualize primary and secondary amines. All organic extracts collected after aqueous work-up procedures were dried over anhydrous MgSO<sub>4</sub> or Na<sub>2</sub>SO<sub>4</sub> before gravity filtering and evaporation to dryness. Organic solvents were evaporated *in vacuo* at  $\leq 40^\circ\text{C}$  (water bath temperature). Purification using preparative layer chromatography (PLC) was carried out on Analtech preparative TLC plates (200 mm  $\times$  200 mm  $\times$  2 mm).

<sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance Nanobay III 400MHz Ultrashield Plus spectrometer at 400.13 MHz and 100.62 MHz respectively. Chemical shifts ( $\delta$ ) are recorded in parts per million (ppm) with reference to the chemical shift of the deuterated solvent. Coupling constants (*J*) and carbon-fluorine coupling constants (*J<sub>CF</sub>*) are recorded in Hz and the significant multiplicities described by singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), multiplet (m), doublet of doublets (dd), doublet of triplets (dt). Spectra were assigned using appropriate COSY, distortionless enhanced polarisation transfer (DEPT), HSQC and HMBC sequences.

LCMS were run to verify reaction outcome and purity using an Agilent 6120 Series Single Quad coupled to an Agilent 1260 Series HPLC. The following buffers were used; buffer A: 0.1% formic

1  
2  
3 acid in H<sub>2</sub>O; buffer B: 0.1% formic acid in MeCN. The following gradient was used with a  
4  
5 Poroshell 120 EC-C18 50 × 3.0 mm 2.7 micron column, and a flow rate of 0.5 mL/min and total run  
6  
7 time of 5 min; 0–1 min 95% buffer A and 5% buffer B, from 1–2.5 min up to 0% buffer A and  
8  
9 100% buffer B, held at this composition until 3.8 min, 3.8–4 min 95% buffer A and 5% buffer B,  
10  
11 held until 5 min at this composition. Mass spectra were acquired in positive and negative ion mode  
12  
13 with a scan range of 100–1000 *m/z*. UV detection was carried out at 214 and 254 nm. All retention  
14  
15 times (*t<sub>R</sub>*) are quoted in minutes.  
16  
17  
18

19  
20 Preparative HPLC was performed using an Agilent 1260 infinity coupled with a binary  
21  
22 preparative pump and Agilent 1260 FC-PS fraction collector, using Agilent OpenLAB CDS  
23  
24 software (Rev C.01.04), and an Altima 5μM C8 22 × 250 mm column. The following buffers were  
25  
26 used; buffer A: H<sub>2</sub>O; buffer B: MeCN, with sample being run at a gradient of 5% buffer B to 100%  
27  
28 buffer B over 20 min, at a flow rate of 20 mL/min. All screening compounds were of > 95% purity  
29  
30 unless specified in the individual monologue.  
31  
32

33  
34 All NMR experiments were performed in *d*<sub>6</sub>-DMSO allowing comparison of the spectra of the  
35  
36 various analogues. It is important to point out that the <sup>13</sup>C NMR signals of the hydroxycyclohexane  
37  
38 moiety were often difficult to be obtained in *d*<sub>6</sub>-DMSO. Especially one tertiary carbon of the  
39  
40 hydroxycyclohexane moiety was not observed in the <sup>13</sup>C NMR spectra of all the respective  
41  
42 analogues even with extended relaxation time and another tertiary aromatic carbon was only ever  
43  
44 observed by using HSQC experiments. However, additional experiments were performed on  
45  
46 selected compounds to confirm the integrity of the presented NMR data. These results have shown  
47  
48 that the all the signals can be observed when the NMR solvent was changed to CDCl<sub>3</sub>.<sup>38</sup>  
49  
50 Furthermore, the quaternary carbon of the pyrazole moiety was not always observed depending on  
51  
52 individual analogue.  
53  
54  
55

56  
57 **General Procedure A: Suzuki coupling of aryl halides and boronic acids.** A mixture of the  
58  
59 aryl halide (1.0 eq) and boronic acid (1.5 eq) in degassed (by sonication followed by a stream of  
60

1  
2  
3 nitrogen) THF/1 M Na<sub>2</sub>CO<sub>3(aq)</sub> (3:1 4 mL/100 mg) was evacuated and flushed with nitrogen.  
4  
5 PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.1 eq) was added and the reaction mixture boiled under reflux for 3 h. THF was  
6  
7 evaporated under reduced pressure. The mixture was diluted with water (20 mL) and extracted with  
8  
9 EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over  
10  
11 anhydrous MgSO<sub>4</sub> and filtered, before concentration under reduced pressure. The crude product  
12  
13 was purified by flash column chromatography.  
14  
15

16  
17 **General Procedure B: O-Alkylation of 1-(2-hydroxycyclohexyl)-4-(2-**  
18 **hydroxyphenyl)pyridin-2(1H)-one (7).** 1-(2-Hydroxycyclohexyl)-4-(2-hydroxy-phenyl)pyridin-  
19  
20 2(1H)-one (7) (1.0 eq), K<sub>2</sub>CO<sub>3</sub> (1.1 eq), KI (0.1 eq) and the appropriately substituted benzyl halide  
21  
22 (1.1 eq) were stirred in DMF (2 mL/100 mg) at rt overnight. Reaction progress was monitored  
23  
24 through TLC analysis, with further addition of K<sub>2</sub>CO<sub>3</sub> (0.5 eq) and substituted benzyl halide (0.5  
25  
26 eq) every 24 h until the reaction appeared complete. The reaction mixture was poured onto  
27  
28 ice/water and stirred for 30 min, before extraction with EtOAc (3 × 20 mL). The combined organic  
29  
30 layers were washed with 2 M NaOH<sub>(aq)</sub> (20 mL), water (20 mL) and brine (20 mL), before  
31  
32 concentration under reduced pressure. The resulting crude product was purified by flash column  
33  
34 chromatography.  
35  
36  
37  
38  
39

40 **General Procedure C: Ester hydrolysis with NaOH.** To a solution of the ester (1.0 eq) in  
41  
42 EtOH/H<sub>2</sub>O (1:1, 2 mL/0.1 mmol) was added NaOH (4.0 eq). The reaction mixture was heated at  
43  
44 50 °C for 2 h. EtOH was evaporated under reduced pressure, before acidifying with 1 M HCl<sub>(aq)</sub> to  
45  
46 pH 2. The resulting precipitate was filtered (vacuum) to give the desired product as the free acid.  
47  
48  
49

50 **General Procedure D: Ester aminolysis with ammonium hydroxide.** A mixture of ester  
51  
52 (1.0 eq) in MeOH/NH<sub>4</sub>OH (1:1, 1.0 mL/100 mg) in a sealed tube was stirred at rt for 3 d. The  
53  
54 resulting precipitate was collected by filtration (vacuum) and washed with EtOAc to give the  
55  
56 desired carboxamide product.  
57  
58  
59  
60

1  
2  
3       **General Procedure E: N-Alkylation of 4-(2-((4-(1*H*-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-**  
4  
5 **hydroxycyclohexyl)pyridin-2(1*H*)-one (14).** 4-(2-((4-(1*H*-Pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-  
6  
7 hydroxycyclohexyl)pyridin-2(1*H*)-one (1.0 eq), K<sub>2</sub>CO<sub>3</sub> (1.1 eq), KI (0.1 eq) and the appropriate  
8  
9 organohalide (1.1 eq) were stirred in DMF (2 mL/100 mg) at the indicated temperature. Reaction  
10  
11 progress was monitored through TLC analysis, with further addition of K<sub>2</sub>CO<sub>3</sub> and organohalide  
12  
13 until the reaction appeared complete or conversion remained stagnant. The reaction mixture was  
14  
15 poured onto ice/water and stirred for 30 min, before extraction with EtOAc (3 × 20 mL). The  
16  
17 combined organic layers were washed with 2 M NaOH<sub>(aq)</sub> (20 mL), water (20 mL) and brine  
18  
19 (20 mL), before concentration under reduced pressure. The resulting crude product was purified by  
20  
21 flash column chromatography.  
22  
23

24  
25  
26       **(±)-trans-2-((4-Bromopyridin-2-yl)oxy)cyclohexan-1-ol (4a) and (±)-trans-4-bromo-1-(2-**  
27  
28 **hydroxycyclohexyl)pyridin-2(1*H*)-one (4b).** A mixture of 4-bromo-2-hydroxypyridine (**1**) (10.0 g,  
29  
30 57.5 mmol), 1,2-cyclohexene oxide (29.1 mL, 287 mmol, 5.0 eq) and K<sub>2</sub>CO<sub>3</sub> (19.9 g, 144 mmol,  
31  
32 2.5 eq) was heated at 120 °C for 4 h. The reaction mixture was cooled to rt and concentrated to  
33  
34 dryness under reduced pressure. The remaining residue was diluted with EtOAc (50 mL) and  
35  
36 sonicated for 15 min at rt before the resulting suspension was collected by filtration (vacuum), and  
37  
38 washed with EtOAc (filter cake 1). The EtOAc washings were concentrated under reduced  
39  
40 pressure, then taken up in DCM (15 mL) and sonicated for 15 min at rt before the resulting  
41  
42 suspension was collected by filtration (vacuum) (filter cake 2). Filter cake 2 was washed with  
43  
44 further DCM, to give 2-((4-bromopyridin-2-yl)oxy)cyclohexan-1-ol (**4a**) as 1.11 g of a beige solid  
45  
46 (7%). <sup>1</sup>H NMR δ 8.15–7.89 (m, 1H), 7.17 (dd, *J* = 5.5/1.7 Hz, 1H), 7.10–6.93 (m, 1H), 4.93–4.66  
47  
48 (m, 2H), 3.67–3.42 (m, 1H), 2.11–1.94 (m, 1H), 1.94–1.75 (m, 1H), 1.74–1.47 (m, 2H), 1.44–1.07  
49  
50 (m, 4H); <sup>13</sup>C NMR δ 164.2, 147.9, 133.3, 119.8, 114.0, 78.6, 70.5, 33.1, 29.2, 23.3, 23.2; *m/z* MS  
51  
52 (TOF ES<sup>+</sup>) C<sub>11</sub>H<sub>15</sub>BrNO<sub>2</sub> [M+H]<sup>+</sup> calcd 272.0; found 272.1; LC-MS *t*<sub>R</sub>: 3.72 min.  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Filter cake 1, was taken up in water (70 mL) and stirred for 15 min at rt. Any remaining solid  
4  
5 was collected by filtration (vacuum) and washed with water to give 4-bromo-1-(2-  
6  
7 hydroxycyclohexyl)pyridin-2(1*H*)-one (**4b**) as 12.1 g of a white solid (77%). <sup>1</sup>H NMR δ 7.68 (d, *J*  
8  
9 = 7.4 Hz, 1H), 6.67 (d, *J* = 2.2 Hz, 1H), 6.44 (dd, *J* = 7.4/2.3 Hz, 1H), 4.79 (d, *J* = 5.8 Hz, 1H), 4.44  
10  
11 (br s, 1H), 3.74 (br s, 1H), 2.04–1.88 (m, 1H), 1.76–1.60 (m, 3H), 1.51 (m, 1H), 1.40–1.18 (m, 3H);  
12  
13 <sup>13</sup>C NMR δ 160.8, 136.6, 134.1, 121.0, 108.9, 69.1, 35.2, 30.8, 24.9, 23.9; resonance at δ 136.6 ppm  
14  
15 was taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>11</sub>H<sub>15</sub>BrNO<sub>2</sub> [M+H]<sup>+</sup> calcd 272.0;  
16  
17 found 272.1; LC-MS *t*<sub>R</sub>: 3.33 min.  
18  
19

20  
21  
22 **2-(2-((2-Hydroxycyclohexyl)oxy)pyridin-4-yl)phenol (5).** 2-((4-Bromopyridin-2-  
23  
24 yl)oxy)cyclohexan-1-ol (**4a**) (500 mg, 1.84 mmol) and 2-hydroxyphenylboronic acid (380 mg, 2.76  
25  
26 mmol, 1.5 eq) were dispersed in 1 M Na<sub>2</sub>CO<sub>3(aq)</sub> (5 mL) and THF (10 mL) in a 30 mL microwave  
27  
28 vial. The mixture was sonicated at rt, then degassed with a stream of nitrogen for 10 min.  
29  
30 PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (129 mg, 0.18 mmol, 0.1 eq) was added and the vial sealed, before heating at 100 °C  
31  
32 for 2.5 h. The mixture was cooled, before adding water (30 mL) and extracting with EtOAc (3 × 30  
33  
34 mL). The combined organic layers were washed with brine (30 mL) before concentration under  
35  
36 reduced pressure. The resulting residue was purified by FCC (eluent EtOAc/PE 10:90 to 100:0, wet  
37  
38 load in DCM), to give 609 mg of a pale yellow solid (quantitative). <sup>1</sup>H NMR δ 9.80 (s, 1H), 8.11  
39  
40 (dd, *J* = 5.4/0.5 Hz, 1H), 7.33 (dd, *J* = 7.7/1.7 Hz, 1H), 7.23 (ddd, *J* = 8.2/7.4/1.7 Hz, 1H), 7.12 (dd,  
41  
42 *J* = 5.4/1.5 Hz, 1H), 6.97 (dd, *J* = 8.2/1.0 Hz, 1H), 6.94 (d, *J* = 0.8 Hz, 1H), 6.90 (ddd, *J* =  
43  
44 7.5/7.5/1.1 Hz, 1H), 4.83 (td, *J* = 8.5/4.6 Hz, 1H), 3.56 (td, *J* = 9.0/4.2 Hz, 1H), 2.19–2.01 (m, 1H),  
45  
46 1.96–1.83 (m, 1H), 1.70–1.50 (m, 2H), 1.43–1.20 (m, 4H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 163.5,  
47  
48 154.7, 149.0, 146.0, 129.9, 129.9, 124.8, 119.6, 117.2, 116.3, 110.8, 77.6, 70.6, 33.2, 29.3, 23.3,  
49  
50 23.2; *m/z* MS (TOF ES<sup>+</sup>) C<sub>17</sub>H<sub>20</sub>NO<sub>3</sub> [MH]<sup>+</sup> calcd 286.1; found 286.2; LC-MS *t*<sub>R</sub>: 3.23 min.  
51  
52  
53  
54  
55

56 **2-((4-(2-([1,1'-Biphenyl]-4-ylmethoxy)phenyl)pyridin-2-yl)oxy)cyclohexan-1-ol (6).** 2-(2-((2-  
57  
58 Hydroxycyclohexyl)oxy)pyridin-4-yl)phenol (**5**) (100 mg, 0.35 mmol), K<sub>2</sub>CO<sub>3</sub> (53 mg, 0.39 mmol,  
59  
60

1  
2  
3 1.1 eq), KI (7 mg, 0.04 mmol, 0.1 eq) and 4-(bromomethyl)biphenyl (95 mg, 0.39 mmol, 1.1 eq)  
4  
5 were dispersed in DMF (2 mL). The mixture was stirred at rt overnight. The mixture was diluted  
6  
7 with water/ice and stirred for 10 min, before collecting the resulting precipitate by filtration  
8  
9 (vacuum) and washing with water. The crude solid product was further purified by FCC (eluent  
10  
11 MeOH/DCM 0:100 to 10:90, with a plateau at 5:95). Mixed fractions were combined and  
12  
13 repurified by FCC (eluent EtOAc/PE 0:100 to 30:70). A combined total of 87 mg of glassy solid  
14  
15 (55%) was obtained.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.11 (d,  $J = 5.4$  Hz, 1H), 7.69–7.51 (m, 4H), 7.51–7.29  
16  
17 (m, 7H), 7.19 (dd,  $J = 5.4/1.3$  Hz, 1H), 7.13–6.99 (m, 3H), 5.16 (s, 2H), 4.78 (ddd,  $J = 10.9/8.9/4.7$   
18  
19 Hz, 1H), 3.70 (ddd,  $J = 11.0/8.9/4.7$  Hz, 1H), 2.24–2.08 (m, 2H), 1.85–1.62 (m, 2H), 1.59–1.14 (m,  
20  
21 4H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  164.1, 155.8, 150.6, 144.8, 141.0, 140.8, 135.8, 130.6, 130.5, 128.9,  
22  
23 128.1, 127.6, 127.5, 127.4, 127.2, 121.7, 118.8, 113.5, 112.6, 81.5, 74.2, 70.5, 33.7, 31.0, 24.3,  
24  
25 24.0;  $m/z$  MS (TOF  $\text{ES}^+$ )  $\text{C}_{30}\text{H}_{30}\text{NO}_3$   $[\text{MH}]^+$  calcd 452.2; found 452.3; LC-MS  $t_{\text{R}}$ : 4.18 min.  
26  
27  
28  
29

30 **1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7)**. 4-Bromo-1-(2-  
31  
32 hydroxycyclohexyl)pyridin-2(1H)-one (**4b**) (2.00 g, 7.35 mmol) was coupled to 2-hydroxyphenyl  
33  
34 boronic acid (1.52 g, 11.0 mmol) according to General Procedure A. After the THF was evaporated  
35  
36 under reduced pressure, the resulting brown precipitate was filtered (vacuum). The precipitate was  
37  
38 taken up in MeOH and adsorbed onto Telos bulk sorbent and dry loaded onto the column (no  
39  
40 extractive workup was necessary). FCC purification (eluent MeOH/DCM 0:100 to 20:80) gave  
41  
42 1.75 g of a white solid (83%).  $^1\text{H}$  NMR  $\delta$  9.84 (s, 1H), 7.65 (d,  $J = 7.3$  Hz, 1H), 7.30 (dd,  $J =$   
43  
44 7.7/1.7 Hz, 1H), 7.22 (ddd,  $J = 8.2/7.4/1.7$  Hz, 1H), 6.94 (dd,  $J = 8.1/1.0$  Hz, 1H), 6.87 (td,  $J =$   
45  
46 7.5/1.1 Hz, 1H), 6.52 (d,  $J = 1.9$  Hz, 1H), 6.45 (dd,  $J = 7.2/2.0$  Hz, 1H), 4.75 (d,  $J = 6.0$  Hz, 1H),  
47  
48 4.54 (br s, 1H), 3.79 (br s, 1H), 2.07–1.93 (m, 1H), 1.80–1.63 (m, 3H), 1.53 (br s, 1H), 1.44–1.22  
49  
50 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.9, 154.8, 148.5, 134.0, 130.0, 129.6, 124.5, 119.5, 118.0, 116.3, 106.8,  
51  
52 69.2, 35.4, 31.1, 25.0, 24.0; resonance at  $\delta$  134.0 ppm was taken from the HSQC experiment;  $m/z$   
53  
54 MS (TOF  $\text{ES}^+$ )  $\text{C}_{17}\text{H}_{20}\text{NO}_3$   $[\text{M}+\text{H}]^+$  calcd 286.1; found 286.2; LC-MS  $t_{\text{R}}$ : 3.33 min.  
55  
56  
57  
58  
59  
60

**4-(2-([1,1'-Biphenyl]-4-ylmethoxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (8a).**

1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (100 mg, 0.35 mmol) was alkylated with 4-(bromomethyl)biphenyl (95 mg, 0.39 mmol) according to General Procedure B. A precipitate formed after pouring the reaction mixture into ice/water. The precipitate was collected by filtration (vacuum), then purified by FCC (eluent EtOAc/PE 30:70 to 100:0, wet load in DCM) to give 97 mg of a white solid (61%). <sup>1</sup>H NMR δ 7.74–7.60 (m, 5H), 7.58–7.43 (m, 4H), 7.43–7.31 (m, 3H), 7.22 (d, *J* = 8.2 Hz, 1H), 7.11–6.99 (m, 1H), 6.52 (d, *J* = 1.9 Hz, 1H), 6.46 (dd, *J* = 7.2/2.0 Hz, 1H), 5.25 (s, 2H), 4.75 (d, *J* = 6.0 Hz, 1H), 4.54 (s, 1H), 3.80 (s, 1H), 2.09–1.87 (m, 1H), 1.85–1.43 (m, 4H), 1.43–1.21 (m, 3H); <sup>13</sup>C NMR δ 161.8, 155.3, 148.3, 139.8, 139.6, 136.2, 134.3, 130.3, 129.9, 129.0, 127.9, 127.5, 127.2, 126.8, 126.7, 121.2, 118.5, 113.4, 107.0, 69.3, 69.2, 35.4, 31.1, 25.0, 24.0; *m/z* MS (TOF ES<sup>+</sup>) C<sub>30</sub>H<sub>30</sub>NO<sub>3</sub> [MH]<sup>+</sup> calcd 452.2; found 452.30; LC-MS *t*<sub>R</sub>: 3.60 min.

**4-(2-(Benzyloxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (8b).**

1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (80 mg, 0.28 mmol) was alkylated with benzyl bromide (37 μL, 0.31 mmol) according to General Procedure B. After a total of 72 h of stirring with two further additions of K<sub>2</sub>CO<sub>3</sub> and benzyl bromide, the mixture was heated at 90 °C for 2 h, cooled then worked up. The crude product was purified by FCC (eluent EtOAc/PE 50:50 to 100:0) to give 19.4 mg of a colourless oil (18%). <sup>1</sup>H NMR δ 7.67 (d, *J* = 7.2 Hz, 11H), 7.47–7.26 (m, 7H), 7.19 (d, *J* = 8.3 Hz, 1H), 7.04 (ddd, *J* = 7.6/7.6/0.7 Hz, 1H), 6.50 (d, *J* = 1.9 Hz, 1H), 6.44 (dd, *J* = 7.2/2.0 Hz, 1H), 5.19 (s, 2H), 4.53 (br s, 1H), 3.79 (br s, 1H), 2.08–1.91 (m, 1H), 1.81–1.62 (m, 3H), 1.53 (m, 1H), 1.43–1.11 (m, 3H); <sup>13</sup>C NMR δ 161.8, 155.3, 148.3, 137.0, 134.1, 130.3, 129.9, 128.5, 127.7, 127.3, 127.1, 121.2, 118.5, 113.4, 107.0, 69.6, 69.2, 35.4, 31.1, 25.0, 24.0; resonance at δ 134.1 ppm was taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>17</sub>H<sub>20</sub>NO<sub>3</sub> [M+H]<sup>+</sup> calcd 376.2; found 376.2; LC-MS *t*<sub>R</sub>: 3.74 min.

**4-(2-((2-Fluorobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (8c).**

1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (80 mg, 0.28 mmol) was alkylated

1  
2  
3 with 2-fluorobenzyl bromide (37  $\mu\text{L}$ , 0.31 mmol) according to General Procedure B. After a total  
4  
5 of 72 h of stirring with two further additions of  $\text{K}_2\text{CO}_3$  and 2-fluorobenzyl bromide, the mixture  
6  
7 was heated at 90  $^\circ\text{C}$  for 2 h, cooled then worked up. The crude product was purified by FCC  
8  
9 (eluent EtOAc/PE 30:70 to 100:0) to give 47 mg of a pale yellow solid (43%).  $^1\text{H}$  NMR  $\delta$  7.64 (d,  $J$   
10  
11 = 7.3 Hz, 1H), 7.50 (ddd,  $J$  = 7.6/7.6/1.7 Hz, 1H), 7.44–7.35 (m, 3H), 7.28–7.17 (m, 3H), 7.06 (ddd,  
12  
13  $J$  = 7.5/7.5/0.9 Hz, 1H), 6.47 (d,  $J$  = 1.9 Hz, 1H), 6.40 (dd,  $J$  = 7.2/2.0 Hz, 1H), 5.22 (s, 2H), 4.52  
14  
15 (br s, 1H), 3.79 (br s, 1H), 2.06–1.92 (m, 1H), 1.80–1.61 (m, 3H), 1.54 (m, 1H), 1.41–1.20 (m, 3H);  
16  
17  $^{13}\text{C}$  NMR  $\delta$  161.8, 160.2 (d,  $J_{\text{CF}}$  = 245.9 Hz), 155.1, 148.2, 134.1, 130.4, 130.3 (d,  $J_{\text{CF}}$  = 6.2 Hz),  
18  
19 130.3 (d,  $J_{\text{CF}}$  = 6.0 Hz), 129.9, 127.1, 124.6 (d,  $J_{\text{CF}}$  = 3.4 Hz), 123.7 (d,  $J_{\text{CF}}$  = 14.4 Hz), 121.4,  
20  
21 118.4, 115.4 (d,  $J_{\text{CF}}$  = 20.9 Hz), 113.3, 106.8, 69.2, 64.1 (d,  $J_{\text{CF}}$  = 3.8 Hz), 35.4, 31.0, 25.0, 24.0;  
22  
23 resonance at  $\delta$  134.1 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{24}\text{H}_{25}\text{FNO}_3$   
24  
25  $[\text{M}+\text{H}]^+$  calcd 394.2; found 394.2; LC-MS  $t_{\text{R}}$ : 3.73 min.  
26  
27  
28  
29

30  
31 **4-(2-((3-Fluorobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (8d).** 1-(2-  
32  
33 Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (80 mg, 0.28 mmol) was alkylated  
34  
35 with 3-fluorobenzyl bromide (38  $\mu\text{L}$ , 0.31 mmol) according to General Procedure B. The crude  
36  
37 product was purified by FCC (eluent EtOAc/PE 50:50 to 100:0) to give 82 mg of a yellow oil  
38  
39 (74%).  $^1\text{H}$  NMR  $\delta$  7.68 (d,  $J$  = 7.2 Hz, 2H), 7.46–7.34 (m, 3H), 7.28–7.10 (m, 4H), 7.09–7.02 (m,  
40  
41 1H), 6.50 (d,  $J$  = 1.9 Hz, 1H), 6.44 (dd,  $J$  = 7.2/2.0 Hz, 1H), 5.21 (s, 2H), 4.74 (br s, 1H), 4.54 (br s,  
42  
43 1H), 3.80 (br s, 1H), 2.07–1.92 (m, 1H), 1.82–1.62 (m, 3H), 1.54 (m, 1H), 1.43–1.12 (m, 3H);  $^{13}\text{C}$   
44  
45 NMR  $\delta$  162.2 (d,  $J_{\text{CF}}$  = 243.7 Hz), 161.8, 155.1, 148.3, 139.9 (d,  $J_{\text{CF}}$  = 7.4 Hz), 134.2, 130.5 (d,  $J_{\text{CF}}$   
46  
47 = 8.3 Hz), 130.3, 129.9, 127.2, 123.1 (d,  $J_{\text{CF}}$  = 2.7 Hz), 121.3, 118.5, 114.5 (d,  $J_{\text{CF}}$  = 20.9 Hz), 113.9  
48  
49 (d,  $J_{\text{CF}}$  = 22.0 Hz), 113.4, 107.0, 69.2, 68.8 (d,  $J_{\text{CF}}$  = 1.4 Hz), 35.4, 31.1, 25.0, 24.0; resonance at  $\delta$   
50  
51 134.2 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{24}\text{H}_{25}\text{FNO}_3$   $[\text{M}+\text{H}]^+$  calcd  
52  
53 394.2; found 394.2; LC-MS  $t_{\text{R}}$ : 3.75 min.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **4-(2-((4-Fluorobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (8e).** 1-(2-  
4 Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (100 mg, 0.35 mmol) was  
5 alkylated with 4-fluorobenzyl chloride (46  $\mu$ L, 0.39 mmol) according to General Procedure B, with  
6 the reaction temperature changed to 90  $^{\circ}$ C. Purification by FCC (eluent EtOAc/PE 50:50 to 100:0)  
7 gave 90 mg of a yellow solid (65%).  $^1\text{H}$  NMR  $\delta$  7.66 (d,  $J = 7.3$  Hz, 1H), 7.49–7.42 (m, 2H), 7.42–  
8 7.34 (m, 2H), 7.23–7.15 (m, 3H), 7.08–7.01 (m, 1H), 6.47 (d,  $J = 1.7$  Hz, 1H), 6.42 (dd,  $J = 7.2/1.8$   
9 Hz, 1H), 5.16 (s, 2H), 4.75 (d,  $J = 6.0$  Hz, 1H), 4.52 (br s, 1H), 3.79 (br s, 1H), 2.06–1.93 (s, 1H),  
10 1.79–1.62 (m, 3H), 1.53 (m, 1H), 1.42–1.23 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.7 (d,  $J_{\text{CF}} = 243.4$  Hz), 161.8,  
11 155.2, 148.3, 134.1, 133.1 (d,  $J_{\text{CF}} = 3.0$  Hz), 130.3, 129.8, 129.6 (d,  $J_{\text{CF}} = 8.3$  Hz), 127.2, 121.2,  
12 118.4, 115.3 (d,  $J_{\text{CF}} = 21.4$  Hz), 113.5, 107.0, 69.2, 69.0, 35.4, 30.8, 25.0, 24.0; resonances at  $\delta$   
13 134.1 and 30.8 ppm were taken from the HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{24}\text{H}_{25}\text{FNO}_3$   
14 [M+H] $^+$  calcd 394.2; found 394.2; LC-MS  $t_{\text{R}}$ : 3.73 min.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 **1-(2-Hydroxycyclohexyl)-4-(2-((2-methoxybenzyl)oxy)phenyl)pyridin-2(1H)-one (8f).** 1-(2-  
31 Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (80 mg, 0.28 mmol) was  
32 alkylated with 2-methoxybenzyl chloride (43  $\mu$ L, 0.31 mmol) according to General Procedure B.  
33 After a total of 48 h of stirring with one further addition of  $\text{K}_2\text{CO}_3$  and 2-methoxybenzyl chloride,  
34 the mixture was worked up. Purification by FCC (eluent EtOAc/PE 30:70 to 80:20) gave 66 mg of a  
35 white solid (58%).  $^1\text{H}$  NMR  $\delta$  7.64 (d,  $J = 7.1$  Hz, 1H), 7.43–7.28 (m, 4H), 7.18 (d,  $J = 8.1$  Hz,  
36 1H), 7.09–6.99 (m, 2H), 6.93 (t,  $J = 7.3$  Hz, 1H), 6.52 (s, 1H), 6.44 (d,  $J = 6.9$  Hz, 1H), 5.12 (s,  
37 2H), 4.73 (d,  $J = 5.7$  Hz, 1H), 4.52 (br s, 1H), 3.84 (s, 3H), 3.80 (br s, 1H), 1.98 (br s, 1H), 1.80–  
38 1.61 (m, 3H), 1.54 (m, 1H), 1.42–1.18 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.8, 157.0, 155.5, 148.2, 134.0,  
39 130.3, 129.8, 129.4, 129.0, 127.0, 124.3, 121.0, 120.2, 118.5, 113.2, 110.9, 106.9, 69.2, 65.4, 55.4,  
40 35.4, 31.1, 25.0, 24.0; resonance at  $\delta$  134.0 ppm was taken from the HSQC experiment;  $m/z$  MS  
41 (TOF ES $^+$ )  $\text{C}_{25}\text{H}_{28}\text{NO}_4$  [M+H] $^+$  calcd 406.2; found 406.2; LC-MS  $t_{\text{R}}$ : 3.76 min.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1-(2-Hydroxycyclohexyl)-4-(2-((3-methoxybenzyl)oxy)phenyl)pyridin-2(1H)-one (8g).** 1-(2-  
4 Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (**7**) (100 mg, 0.35 mmol) was  
5 alkylated with 3-methoxybenzyl chloride (56  $\mu$ L, 0.39 mmol) according to General Procedure B  
6 with the reaction temperature changed to 90  $^{\circ}$ C. Purification by FCC (eluent EtOAc/PE 50:50 to  
7 100:0) gave 110 mg of a yellow oil (77%).  $^1\text{H}$  NMR  $\delta$  7.68 (d,  $J$  = 7.2 Hz, 1H), 7.41–7.35 (m, 2H),  
8 7.27 (t,  $J$  = 7.9 Hz, 1H), 7.21–7.17 (m, 1H), 7.04 (ddd,  $J$  = 7.6/7.6/0.9 Hz, 1H), 7.01–6.94 (m, 2H),  
9 6.88–6.83 (m, 1H), 6.53 (d,  $J$  = 1.9 Hz, 1H), 6.45 (dd,  $J$  = 7.2/2.0 Hz, 1H), 5.17 (s, 2H), 4.54 (br s,  
10 1H), 3.77 (br s, 1H), 3.74 (s, 3H), 2.05–1.94 (m, 1H), 1.79–1.63 (m, 3H), 1.54 (m, 1H), 1.41–1.23  
11 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.8, 159.4, 155.2, 148.3, 138.6, 134.2, 130.3, 129.9, 129.5, 127.1, 121.1,  
12 119.1, 118.5, 113.7, 113.3, 112.0, 107.0, 69.4, 69.2, 55.0, 35.4, 31.1, 25.0, 24.0; resonance at  $\delta$   
13 134.2 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES $^+$ ) C $_{25}$ H $_{28}$ NO $_4$  [M+H] $^+$  calcd  
14 406.2; found 406.3; LC-MS  $t_R$ : 3.72 min.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30 **1-(2-Hydroxycyclohexyl)-4-(2-((4-methoxybenzyl)oxy)phenyl)pyridin-2(1H)-one (8h).** 1-(2-  
31 Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (**7**) (80 mg, 0.28 mmol) was alkylated  
32 with 4-methoxybenzyl chloride (42  $\mu$ L, 0.31 mmol) according to General Procedure B. Purification  
33 by FCC (eluent EtOAc/PE 50:50 to 100:0) gave 66 mg of a beige solid (58%).  $^1\text{H}$  NMR  $\delta$  7.65 (d,  
34  $J$  = 7.2 Hz, 1H), 7.40–7.31 (m, 4H), 7.21 (d,  $J$  = 8.0 Hz, 1H), 7.06–7.00 (m, 1H), 6.95–6.8 (m, 2H),  
35 6.48 (d,  $J$  = 1.9 Hz, 1H), 6.41 (dd,  $J$  = 7.2/2.0 Hz, 1H), 5.10 (s, 2H), 4.74 (d,  $J$  = 5.9 Hz, 1H), 4.52  
36 (br s, 1H), 3.79 (br s, 1H), 3.74 (s, 3H), 2.05–1.92 (m, 1H), 1.78–1.52 (m, 3H), 1.54 (m, 1H), 1.41–  
37 1.20 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.8, 158.9, 155.4, 148.3, 134.1, 130.3, 129.9, 129.2, 128.7, 127.1,  
38 121.1, 118.4, 113.8, 113.5, 106.9, 69.4, 69.2, 55.1, 35.4, 31.1, 25.0, 24.0; resonance at  $\delta$  134.1 ppm  
39 was taken from the HSQC experiment;  $m/z$  MS (TOF ES $^+$ ) C $_{25}$ H $_{28}$ NO $_4$  [M+H] $^+$  calcd 406.2; found  
40 406.2; LC-MS  $t_R$ : 3.74 min.

41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56 **1-(2-Hydroxycyclohexyl)-4-(2-((2-(trifluoromethyl)benzyl)oxy)phenyl)pyridin-2(1H)-one**  
57 **(8i).** 1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (**7**) (80 mg, 0.28 mmol) was  
58  
59  
60

1  
2  
3 alkylated with 2-(trifluoromethyl)benzyl chloride (45  $\mu$ L, 0.31 mmol) according to General  
4  
5 Procedure B. After a total of 48 h of stirring with one further addition of  $K_2CO_3$  and 2-  
6  
7 (trifluoromethyl)benzyl chloride, the mixture was worked up. Purification by FCC (eluent  
8  
9 EtOAc/PE 50:50 to 100:0) gave 85 mg of a white solid (68%).  $^1H$  NMR  $\delta$  7.78 (d,  $J$  = 7.8 Hz, 1H),  
10  
11 7.73–7.62 (m, 3H), 7.60–7.52 (m, 1H), 7.45–7.36 (m, 2H), 7.15 (d,  $J$  = 8.0 Hz, 1H), 7.11–7.06 (m,  
12  
13 1H), 6.48 (d,  $J$  = 1.9 Hz, 7H), 6.41 (dd,  $J$  = 7.2/2.0 Hz, 7H), 5.30 (s, 2H), 4.74 (d,  $J$  = 5.7 Hz, 1H),  
14  
15 4.53 (br s, 1H), 3.79 (br s, 1H), 2.04–1.93 (m, 1H), 1.78–1.62 (m, 3H), 1.53 (m, 1H), 1.41–1.20 (m,  
16  
17 3H);  $^{13}C$  NMR  $\delta$  161.8, 155.0, 148.2, 134.9 (app. d,  $J_{CF}$  = 1.5 Hz), 134.2, 132.9, 130.4, 130.0,  
18  
19 129.6, 128.5, 127.3, 126.3 (q,  $J_{CF}$  = 30.4 Hz), 126.1 (q,  $J_{CF}$  = 5.6 Hz), 124.3 (q,  $J_{CF}$  = 274.0 Hz),  
20  
21 121.6, 118.5, 113.2, 106.9, 69.2, 66.5 (d,  $J_{CF}$  = 2.6 Hz), 35.4, 31.0, 25.0, 24.0; resonance at  $\delta$  134.2  
22  
23 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $C_{25}H_{25}F_3NO_3$   $[M+H]^+$  calcd 444.2;  
24  
25 found 444.3; LC-MS  $t_R$ : 3.89 min.

26  
27  
28  
29  
30  
31 **1-(2-Hydroxycyclohexyl)-4-(2-((3-(trifluoromethyl)benzyl)oxy)phenyl)pyridin-2(1H)-one**

32  
33 **(8j)**. 1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (**7**) (80 mg, 0.28 mmol) was  
34  
35 alkylated with 3-(trifluoromethyl)benzyl bromide (47  $\mu$ L, 0.31 mmol) according to General  
36  
37 Procedure B. After a total of 72 h of stirring with two further additions of  $K_2CO_3$  and 3-  
38  
39 (trifluoromethyl)benzyl bromide, the mixture was worked up. Purification by FCC (eluent  
40  
41 EtOAc/PE 50:50 to 100:0) gave 79 mg of a yellow solid (64%).  $^1H$  NMR  $\delta$  7.77 (s, 1H), 7.73–7.58  
42  
43 (m, 4H), 7.45–7.35 (m, 2H), 7.20 (d,  $J$  = 7.9 Hz, 1H), 7.07 (ddd,  $J$  = 7.5/7.5/0.8 Hz, 1H), 6.48 (d,  $J$   
44  
45 = 1.8 Hz, 1H), 6.45 (dd,  $J$  = 7.1/2.0 Hz, 1H), 5.30 (s, 2H), 4.54 (br s, 1H), 3.79 (br s, 1H), 3.38 (br  
46  
47 s, 1H), 2.05–1.94 (m, 1H), 1.79–1.64 (m, 3H), 1.53 (m, 1H), 1.41–1.20 (m, 3H);  $^{13}C$  NMR  $\delta$  161.8,  
48  
49 155.0, 148.3, 138.6, 134.2, 131.1, 130.4, 129.9, 129.6, 129.2 (app. d,  $J_{CF}$  = 31.6 Hz), 127.3, 124.4  
50  
51 (q,  $J_{CF}$  = 3.8 Hz), 124.2 (q,  $J_{CF}$  = 272.3 Hz), 123.5 (q,  $J_{CF}$  = 3.9 Hz), 121.4, 118.5, 113.4, 107.0,  
52  
53 69.3, 68.8, 35.4, 31.0, 25.0, 24.0; resonance at  $\delta$  134.2 ppm was taken from the HSQC experiment;  
54  
55  $m/z$  MS (TOF ES $^+$ )  $C_{25}H_{25}F_3NO_3$   $[M+H]^+$  calcd 444.2; found 444.3; LC-MS  $t_R$ : 3.82 min.  
56  
57  
58  
59  
60

**1-(2-Hydroxycyclohexyl)-4-(2-((4-(trifluoromethyl)benzyl)oxy)phenyl)pyridin-2(1H)-one**

(8k). 1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (80 mg, 0.28 mmol) was alkylated with 4-(trifluoromethyl)benzyl bromide (48  $\mu$ L, 0.31 mmol) according to General Procedure B. After a total of 48 h of stirring with one further addition of  $K_2CO_3$  and 4-(trifluoromethyl)benzyl chloride, the mixture was worked up. Purification by FCC (eluent EtOAc/PE 50:50 to 100:0) gave 41 mg of a white solid (33%).  $^1H$  NMR  $\delta$  7.74 (d,  $J$  = 8.2 Hz, 2H), 7.69 (d,  $J$  = 7.2 Hz, 1H), 7.62 (d,  $J$  = 8.1 Hz, 2H), 7.42–7.35 (m, 2H), 7.19–7.15 (m, 1H), 7.06 (ddd,  $J$  = 7.5/7.5/0.8 Hz, 1H), 6.50 (d,  $J$  = 1.9 Hz, 1H), 6.45 (dd,  $J$  = 7.2/2.0 Hz, 1H), 5.31 (s, 2H), 4.54 (br s, 1H), 3.81 (br s, 1H), 3.43 (br s, 1H), 2.06–1.94 (m, 1H), 1.80–1.64 (m, 3H), 1.54 (m, 1H), 1.42–1.12 (m, 3H);  $^{13}C$  NMR  $\delta$  161.8, 155.0, 148.3, 141.9, 134.2, 130.3, 129.9, 128.2 (app. d,  $J_{CF}$  = 31.7 Hz), 127.6, 127.2, 125.3 (q,  $J_{CF}$  = 3.7 Hz), 124.2 (q,  $J_{CF}$  = 271.9 Hz), 121.4, 118.5, 113.4, 107.0, 69.2, 68.8, 35.4, 29.0, 25.0, 24.0;  $m/z$  MS (TOF ES $^+$ )  $C_{25}H_{25}F_3NO_3$  [M+H] $^+$  calcd 444.2; found 444.2; LC-MS  $t_R$ : 3.83 min.

**2-((2-(1-(2-Hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)methyl)benzonitrile (8l).**

1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (100 mg, 0.35 mmol) was alkylated with 2-(bromomethyl)benzonitrile (76 mg, 0.39 mmol) according to General Procedure B. A precipitate formed after pouring the reaction mixture into ice/water. The precipitate was collected by filtration (vacuum) to give 125 mg of beige solid (89%).  $^1H$  NMR  $\delta$  7.91 (dd,  $J$  = 7.7/0.8 Hz, 1H), 7.73 (ddd,  $J$  = 7.6/7.6/1.2 Hz, 1H), 7.69–7.61 (m, 2H), 7.57 (ddd,  $J$  = 7.6/7.6/1.2 Hz, 1H), 7.47–7.37 (m, 2H), 7.26 (d,  $J$  = 8.1 Hz, 1H), 7.13–7.08 (m, 1H), 6.47 (d,  $J$  = 1.8 Hz, 1H), 6.45 (dd,  $J$  = 7.1/2.0 Hz, 1H), 5.32 (s, 2H), 4.73 (d,  $J$  = 6.0 Hz, 1H), 4.52 (br s, 1H), 3.79 (br s, 1H), 2.06–1.92 (m, 1H), 1.8–1.62 (m, 3H), 1.53 (m, 1H), 1.42–1.22 (m, 3H);  $^{13}C$  NMR  $\delta$  161.7, 155.0, 148.1, 139.9, 134.1, 133.5, 133.2, 130.4, 130.0, 129.3, 129.1, 127.3, 121.7, 118.5, 117.2, 113.4, 111.0, 106.9, 69.2, 68.1, 35.4, 31.0, 25.0, 24.0; resonance at  $\delta$  134.1 ppm was taken



1  
2  
3 from the HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>25</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 401.2; found 401.2;  
4  
5 LC-MS  $t_R$ : 3.60 min.  
6  
7

### 3-((2-(1-(2-Hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)methyl)

8  
9  
10 **benzonitrile (8m)**. 1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1*H*)-one (7) (100 mg,  
11 0.35 mmol) was alkylated with 3-(bromomethyl)benzonitrile (76 mg, 0.39 mmol) according to  
12 General Procedure B. Purification by FCC (eluent EtOAc/PE 50:50 to 100:0) gave 130 mg of a  
13 white foam (93%). <sup>1</sup>H NMR δ 7.88–7.85 (m, 1H), 7.80 (ddd,  $J = 7.7/1.3/1.3$  Hz, 1H), 7.77–7.73  
14 (m, 1H), 7.68 (d,  $J = 7.2$  Hz, 1H), 7.60 (dd,  $J = 7.7/7.7$  Hz, 1H), 7.45–7.36 (m, 2H), 7.19 (d,  $J = 7.9$   
15 Hz, 1H), 7.08 (ddd,  $J = 7.5/7.5/0.9$  Hz, 1H), 6.49 (d,  $J = 1.8$  Hz, 1H), 6.45 (dd,  $J = 7.2/2.0$  Hz, 1H),  
16 5.25 (s, 2H), 4.75 (d,  $J = 6.0$  Hz, 1H), 4.55 (br s, 1H), 3.80 (br s, 1H), 2.10–1.93 (m, 1H), 1.85–1.63  
17 (m, 3H), 1.54 (m, 1H), 1.44–1.22 (m, 3H); <sup>13</sup>C NMR δ 161.8, 155.0, 148.2, 138.7, 134.1, 132.0,  
18 131.6, 130.7, 130.4, 129.9, 129.8, 127.3, 121.5, 118.7, 118.5, 113.4, 111.4, 107.0, 69.2, 68.6, 35.4,  
19 31.1, 25.0, 24.0; resonance at δ 134.1 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF  
20 ES<sup>+</sup>) C<sub>25</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 401.2; found 401.2; LC-MS  $t_R$ : 3.64 min.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 4-((2-(1-(2-Hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)methyl)

36  
37  
38 **benzonitrile (8n)**. 1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1*H*)-one (7) (100 mg,  
39 0.35 mmol) was alkylated with 4-(bromomethyl)benzonitrile (76 mg, 0.39 mmol) according to  
40 General Procedure B. A precipitate formed after pouring the reaction mixture into ice/water.  
41 Filtration (vacuum) of the precipitate gave 122 mg of a beige solid (87%). <sup>1</sup>H NMR δ 7.87–7.81  
42 (m, 2H), 7.68 (d,  $J = 7.2$  Hz, 1H), 7.58 (d,  $J = 8.5$  Hz, 1H), 7.44–7.34 (m, 2H), 7.15 (dd,  $J = 8.8/0.8$   
43 Hz, 1H), 7.06 (ddd,  $J = 7.5/7.5/0.9$  Hz, 1H), 6.48 (d,  $J = 1.8$  Hz, 1H), 6.44 (dd,  $J = 7.2/2.0$  Hz, 1H),  
44 5.30 (s, 2H), 4.77 (br s, 1H), 4.54 (br s, 1H), 3.80 (br s, 1H), 2.07–1.95 (m, 1H), 1.80–1.63 (m, 3H),  
45 1.55 (m, 1H), 1.43–1.24 (m, 3H); <sup>13</sup>C NMR δ 161.8, 154.9, 148.3, 142.9, 134.2, 132.4, 130.3,  
46 129.9, 127.7, 127.3, 121.5, 118.8, 118.5, 113.4, 110.4, 107.0, 69.3, 68.8, 35.4, 31.1, 25.0, 24.0;  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 resonance at  $\delta$  134.2 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>25</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub>  
4  
5 [M+H]<sup>+</sup> calcd 401.2; found 401.3; LC-MS  $t_R$ : 3.63 min.  
6  
7

8                    **Methyl**                    **3-((2-(1-(2-hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-**  
9                    **yl)phenoxy)methyl)benzoate (8o).** 1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1*H*)-  
10 one (7) (200 mg, 0.70 mmol) was alkylated with methyl 3-(bromomethyl)benzoate (177 mg, 0.77  
11 mmol) according to General Procedure B. Purification by FCC (eluent EtOAc/PE 50:50 to 100:0)  
12 gave 256 mg of a white foam (84%). <sup>1</sup>H NMR  $\delta$  8.03–8.01 (m, 1H), 7.92–7.87 (m, 1H), 7.71–7.64  
13 (m, 2H), 7.53 (dd,  $J = 7.7/7.7$  Hz, 1H), 7.42–7.35 (m, 2H), 7.19 (dd,  $J = 8.8/0.7$  Hz, 1H), 7.05 (ddd,  
14  $J = 7.5/7.5/0.9$  Hz, 1H), 6.49 (d,  $J = 1.9$  Hz, 1H), 6.45 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.28 (s, 2H), 4.75  
15 (d,  $J = 6.0$  Hz, 1H), 4.54 (br s, 1H), 3.85 (s, 3H), 3.80 (br s, 1H), 2.06–1.92 (m, 1H), 1.79–1.64 (m,  
16 3H), 1.54 (m, 1H), 1.42–1.21 (m, 3H); <sup>13</sup>C NMR  $\delta$  166.1, 161.8, 155.1, 148.3, 137.9, 134.1, 131.9,  
17 130.3, 129.9, 129.8, 129.0, 128.4, 127.7, 127.3, 121.3, 118.5, 113.5, 107.0, 69.2, 69.0, 52.2, 35.4,  
18 31.1, 25.0, 24.0; resonance at  $\delta$  134.1 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF  
19 ES<sup>+</sup>) C<sub>26</sub>H<sub>28</sub>NO<sub>5</sub> [M+H]<sup>+</sup> calcd 434.2; found 434.2; LC-MS  $t_R$ : 3.73 min.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36                    **Methyl**                    **4-((2-(1-(2-hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)**  
37 **methyl)benzoate (8p).** 1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1*H*)-one (7) (400  
38 mg, 1.40 mmol) was alkylated with methyl 4-(bromomethyl)benzoate (354 mg, 1.54 mmol)  
39 according to General Procedure B. Purification by FCC (eluent EtOAc/PE 50:50 to 100:0) gave  
40 329 mg of a white foam (54%). <sup>1</sup>H NMR  $\delta$  8.00–7.93 (m, 1H), 7.69 (d,  $J = 7.2$  Hz, 1H), 7.55 (d,  $J$   
41 = 8.5 Hz, 2H), 7.41–7.36 (m, 2H), 7.17 (dd,  $J = 8.7/0.8$  Hz, 1H), 7.06 (ddd,  $J = 7.5/7.5/0.9$  Hz, 1H),  
42 5.28 (s, 1H), 4.76 (d,  $J = 6.1$  Hz, 1H), 4.54 (br s, 1H), 3.85 (s, 3H), 3.81 (br s, 1H), 2.06–1.95 (m,  
43 1H), 1.80–1.63 (m, 3H), 1.55 (m, 1H), 1.42–1.23 (m, 3H); <sup>13</sup>C NMR  $\delta$  166.0, 161.8, 155.1, 148.2,  
44 142.6, 134.2, 130.3, 129.9, 129.3, 128.9, 127.2, 127.2, 121.4, 118.5, 113.3, 107.0, 69.2, 69.0, 52.2,  
45 35.4, 31.1, 25.0, 24.0; resonance at  $\delta$  134.2 ppm was taken from the HSQC experiment;  $m/z$  MS  
46 (TOF ES<sup>+</sup>) C<sub>26</sub>H<sub>28</sub>NO<sub>5</sub> [M+H]<sup>+</sup> calcd 434.2; found 434.3; LC-MS  $t_R$ : 3.72 min.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**1-(2-Hydroxycyclohexyl)-4-(2-((4-(oxazol-2-yl)benzyl)oxy)phenyl)pyridin-2(1H)-one (8q).**

1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (100 mg, 0.35 mmol) was alkylated with 2-(4-(bromomethyl)phenyl)oxazole (92 mg, 0.39 mmol) according to General Procedure B. Purification by FCC (eluent MeOH/DCM 0:100 to 10:90) gave 69 mg of a white solid (45%). <sup>1</sup>H NMR δ 8.23 (d, *J* = 0.8 Hz, 1H), 8.02–7.96 (m, 2H), 7.69 (d, *J* = 7.2 Hz, 1H), 7.58 (d, *J* = 8.5 Hz, 2H), 7.43–7.36 (m, 3H), 7.23–7.16 (m, 1H), 7.06 (td, *J* = 7.5/0.9 Hz, 1H), 6.53 (d, *J* = 1.9 Hz, 1H), 6.48 (dd, *J* = 7.2/2.0 Hz, 1H), 5.27 (s, 2H), 4.78 (d, *J* = 6.1 Hz, 1H), 4.55 (br s, 1H), 3.83 (br s, 1H), 2.07–1.95 (m, 1H), 1.80–1.64 (m, 3H), 1.62–1.44 (m, 1H), 1.43–1.24 (m, 3H); <sup>13</sup>C NMR δ 162.3, 161.1, 155.6, 148.8, 140.6, 140.0, 134.7, 130.8, 130.3, 129.0, 128.3, 127.6, 126.8, 126.5, 121.8, 119.0, 113.8, 107.5, 69.7, 69.6, 35.9, 31.5, 25.5, 24.5; resonance at δ 134.7 ppm was taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>27</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup> calcd 443.2; found 443.3; LC-MS *t*<sub>R</sub>: 3.58 min.

**1-(2-Hydroxycyclohexyl)-4-(2-((4-(thiazol-2-yl)benzyl)oxy)phenyl)pyridin-2(1H)-one (8r).**

1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (100 mg, 0.35 mmol) was alkylated with 2-(4-(chloromethyl)phenyl)thiazole (81 mg, 0.39 mmol) according to General Procedure B. Purification by FCC (eluent MeOH/DCM 0:100 to 10:90) gave 154 mg of a white solid (96%). <sup>1</sup>H NMR δ 8.02–7.90 (m, 3H), 7.80 (d, *J* = 3.2 Hz, 1H), 7.70 (d, *J* = 7.2 Hz, 1H), 7.55 (d, *J* = 8.4 Hz, 2H), 7.46–7.34 (m, 2H), 7.21 (dd, *J* = 8.8/0.7 Hz, 1H), 7.06 (td, *J* = 7.5/0.9 Hz, 1H), 6.52 (d, *J* = 1.9 Hz, 1H), 6.47 (dd, *J* = 7.2/2.0 Hz, 1H), 5.26 (s, 2H), 4.77 (d, *J* = 6.0 Hz, 1H), 4.56 (s, 1H), 3.81 (s, 1H), 2.07–1.94 (m, 1H), 1.84–1.64 (m, 3H), 1.61–1.47 (m, 1H), 1.42–1.22 (m, 3H); <sup>13</sup>C NMR δ 167.2, 162.3, 155.7, 148.8, 144.3, 139.6, 132.9, 130.8, 130.4, 128.5, 127.6, 126.8, 121.7, 121.0, 118.9, 113.9, 107.5, 69.6, 69.5, 35.9, 31.3, 25.5, 24.5; resonances at δ 134.7, 69.5 and 31.3 ppm were taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>27</sub>H<sub>27</sub>N<sub>2</sub>O<sub>3</sub>S [M+H]<sup>+</sup> calcd 459.2; found 459.3; LC-MS *t*<sub>R</sub>: 3.66 min.

**1-(2-Hydroxycyclohexyl)-4-(2-((4-phenoxybenzyl)oxy)phenyl)pyridin-2(1H)-one (8s).** 1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (60 mg, 0.21 mmol) was alkylated

1  
2  
3 with 1-(bromomethyl)-4-phenoxybenzene (61 mg, 0.23 mmol) according to General Procedure B.  
4  
5 After a total of 4 d of stirring with one further addition of K<sub>2</sub>CO<sub>3</sub> and 1-(bromomethyl)-4-  
6  
7 phenoxybenzene, the mixture was worked up. Purification by FCC (eluent MeOH/DCM 0:100 to  
8  
9 8:92) gave 43 mg of a white solid (43%). <sup>1</sup>H NMR δ 7.67 (d, *J* = 7.2 Hz, 1H), 7.47–7.34 (m, 6H),  
10  
11 7.22 (d, *J* = 8.2 Hz, 1H), 7.15 (t, *J* = 7.4 Hz, 1H), 7.09–6.96 (m, 5H), 6.50 (d, *J* = 1.1 Hz, 1H), 6.45  
12  
13 (d, *J* = 7.1 Hz, 1H), 5.16 (s, 2H), 4.77 (d, *J* = 5.9 Hz, 1H), 4.54 (br s, 1H), 3.80 (br s, 1H), 2.06–1.94  
14  
15 (m, 1H), 1.80–1.64 (m, 3H), 1.62–1.43 (m, 1H), 1.42–1.24 (m, 3H); <sup>13</sup>C NMR δ 162.3, 156.9,  
16  
17 156.7, 155.8, 148.8, 134.7, 132.3, 130.8, 130.5, 130.3, 129.8, 127.7, 124.0 (2×), 121.7, 119.2,  
18  
19 118.9, 114.0, 107.5, 69.7, 69.7, 35.9, 31.5, 25.5, 24.5; resonance at δ 134.7 ppm was taken from the  
20  
21 HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>30</sub>H<sub>30</sub>NO<sub>4</sub> [M+H]<sup>+</sup> calcd 468.2; found 468.3; LC-MS *t*<sub>R</sub>:  
22  
23 3.87 min.  
24  
25  
26  
27

28 **4-(2-((4-Bromobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (8t).** 1-(2-  
29  
30 hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (759 mg, 2.66 mmol) was alkylated  
31  
32 with 4-bromobenzyl bromide (731 mg, 2.93 mmol) according to General Procedure B. A precipitate  
33  
34 formed after pouring the reaction mixture into ice/water, with 2 M NaOH<sub>(aq)</sub> (15 mL) being added.  
35  
36 This was stirred at room temperature for 10 min, before collecting the precipitate by filtration  
37  
38 (vacuum). Further purification by FCC (eluent EtOAc/PE 10:90 to 100:0) gave 1.12 g of a white  
39  
40 solid (93%). <sup>1</sup>H NMR δ 7.67 (d, *J* = 7.2 Hz, 1H), 7.59–7.54 (m, 2H), 7.41–7.34 (m, 4H), 7.17 (d, *J*  
41  
42 = 8.1 Hz, 1H), 7.05 (ddd, *J* = 7.6/7.6/0.9 Hz, 1H), 6.48 (d, *J* = 1.9 Hz, 1H), 6.43 (dd, *J* = 7.2/2.0 Hz,  
43  
44 1H), 5.16 (s, 2H), 4.76 (d, *J* = 6.0 Hz, 1H), 4.54 (br s, 1H), 3.80 (br s, 1H), 2.08–1.93 (m, 1H),  
45  
46 1.81–1.62 (m, 3H), 1.54 (m, 1H), 1.43–1.23 (m, 3H); <sup>13</sup>C NMR δ 161.8, 155.1, 148.3, 136.4, 134.1,  
47  
48 131.4, 130.3, 129.9, 129.5, 127.2, 121.3, 120.8, 118.5, 113.4, 107.0, 69.2, 68.9, 35.4, 31.0, 25.0,  
49  
50 24.0; resonance at δ 134.1 ppm was taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>)  
51  
52 C<sub>24</sub>H<sub>25</sub>BrNO<sub>3</sub> [M+H]<sup>+</sup> calcd 454.1; found 454.2; LC-MS *t*<sub>R</sub>: 3.84 min.  
53  
54  
55  
56  
57  
58  
59  
60

**3-((2-(1-(2-Hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)methyl)benzoic**

**acid (9a).** Methyl 3-((2-(1-(2-hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)methyl)benzoate (**8o**) (92 mg, 0.21 mmol) was hydrolysed according to General Procedure C to give 73 mg of a white solid (82%). <sup>1</sup>H NMR δ 13.04 (br s, 1H), 8.01 (s, 1H), 7.88 (d, *J* = 7.7 Hz, 1H), 7.65 (d, *J* = 7.3 Hz, 2H), 7.50 (t, *J* = 7.7 Hz, 1H), 7.43–7.34 (m, 2H), 7.19 (d, *J* = 8.6 Hz, 1H), 7.05 (t, *J* = 7.4 Hz, 1H), 6.51–6.44 (m, 2H), 5.27 (s, 2H), 4.54 (br s, 1H), 3.79 (br s, 1H), 3.60 (s, 6H), 2.04–1.93 (m, 1H), 1.80–1.63 (m, 3H), 1.55 (m, 1H), 1.42–1.20 (m, 3H); <sup>13</sup>C NMR δ 167.1, 161.8, 155.2, 148.4, 137.6, 134.0, 131.5, 131.0, 130.4, 129.9, 128.8, 128.6, 127.9, 127.2, 121.3, 118.4, 113.4, 107.1, 69.2, 69.1, 35.4, 31.0, 25.0, 24.0; resonance at δ 134.1 ppm was taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>25</sub>H<sub>26</sub>NO<sub>5</sub> [M+H]<sup>+</sup> calcd 420.2; found 420.3; LC-MS *t*<sub>R</sub>: 3.54 min.

**4-((2-(1-(2-Hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)methyl)benzoic**

**acid (9b).** Methyl 4-((2-(1-(2-hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)methyl)benzoate (**8p**) (100 mg, 0.23 mmol) was hydrolysed according to General Procedure C to give 90 mg of a white solid (93%). <sup>1</sup>H NMR δ 12.98 (br s, 1H), 7.94 (d, *J* = 8.3 Hz, 2H), 7.69 (d, *J* = 7.2 Hz, 1H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.45–7.34 (m, 2H), 7.18 (d, *J* = 8.1 Hz, 1H), 7.06 (ddd, *J* = 7.5/7.5/0.8 Hz, 1H), 6.51 (d, *J* = 1.9 Hz, 1H), 6.46 (dd, *J* = 7.2/2.0 Hz, 1H), 5.28 (s, 2H), 4.54 (br s, 1H), 3.80 (br s, 1H), 2.06–1.93 (m, 1H), 1.81–1.63 (m, 3H), 1.55 (m, 1H), 1.43–1.21 (m, 3H); <sup>13</sup>C NMR δ 167.1, 161.8, 155.1, 148.3, 142.1, 134.2, 130.3, 130.1, 129.9, 129.5, 127.2, 127.0, 121.3, 118.5, 113.3, 107.0, 69.2, 69.1, 35.4, 31.1, 25.0, 24.0; resonance at δ 134.2 ppm was taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>25</sub>H<sub>26</sub>NO<sub>5</sub> [M+H]<sup>+</sup> calcd 420.2; found 420.3; LC-MS *t*<sub>R</sub>: 3.50 min.

**3-((2-(1-(2-Hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)methyl) benzamide**

**(9c).** Methyl 3-((2-(1-(2-hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)methyl)benzoate (**8o**) (90 mg, 0.21 mmol) was treated with ammonium hydroxide

1  
2  
3 according to General Procedure D to give 45 mg of a white solid (52%).  $^1\text{H}$  NMR  $\delta$  7.98 (s, 1H),  
4 7.94 (s, 1H), 7.81 (d,  $J = 7.8$  Hz, 1H), 7.67 (d,  $J = 7.2$  Hz, 1H), 7.56 (d,  $J = 7.7$  Hz, 1H), 7.46 (dd,  $J$   
5 = 7.7/7.7 Hz, 1H), 7.43–7.35 (m, 3H), 7.23–7.17 (m, 1H), 7.06 (ddd,  $J = 7.5/7.5/0.8$  Hz, 1H), 6.52  
6 (d,  $J = 1.9$  Hz, 1H), 6.47 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.24 (s, 2H), 4.77 (d,  $J = 6.0$  Hz, 1H), 4.54 (br s,  
7 1H), 3.80 (br s, 1H), 2.07–1.94 (m, 1H), 1.81–1.64 (m, 3H), 1.54 (m, 1H), 1.42–1.21 (m, 3H);  $^{13}\text{C}$   
8 NMR  $\delta$  167.8, 161.8, 155.3, 148.3, 137.1, 134.6, 134.1, 130.4, 130.0, 129.9, 128.5, 127.1, 126.8,  
9 126.5, 121.3, 118.5, 113.4, 107.0, 69.5, 69.2, 35.4, 31.0, 25.0, 24.0; resonance at  $\delta$  134.1 ppm was  
10 taken from the HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{25}\text{H}_{27}\text{N}_2\text{O}_4$   $[\text{M}+\text{H}]^+$  calcd 419.2; found  
11 419.3; LC-MS  $t_{\text{R}}$ : 3.44 min.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 **4-((2-(1-(2-Hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-yl)phenoxy)methyl)benzamide**

25  
26 **(9d).** Methyl 4-((2-(1-(2-hydroxycyclohexyl)-2-oxo-1,2-dihydropyridin-4-  
27 yl)phenoxy)methyl)benzoate (**8p**) (105 mg, 0.24 mmol) was treated with ammonium hydroxide  
28 according to General Procedure D to give 15 mg of a white solid (14%).  $^1\text{H}$  NMR  $\delta$  7.97 (s, 1H),  
29 7.86 (d,  $J = 8.3$  Hz, 2H), 7.68 (d,  $J = 7.2$  Hz, 1H), 7.47 (d,  $J = 8.3$  Hz, 2H), 7.42–7.33 (m, 3H),  
30 7.20–7.15 (m, 1H), 7.05 (ddd,  $J = 7.5/7.5/0.8$  Hz, 1H), 6.51 (d,  $J = 1.9$  Hz, 1H), 6.45 (dd,  $J =$   
31 7.2/2.0 Hz, 1H), 5.25 (s, 2H), 4.76 (d,  $J = 6.0$  Hz, 1H), 4.54 (br s, 1H), 3.80 (br s, 1H), 2.05–1.94  
32 (m, 1H), 1.80–1.63 (m, 3H), 1.55 (m, 1H), 1.42–1.25 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  167.6, 161.8, 155.2,  
33 148.3, 140.2, 134.2, 133.6, 130.3, 129.9, 127.7, 127.1, 126.9, 121.3, 118.5, 113.4, 107.0, 69.2, 69.1,  
34 35.4, 31.1, 25.0, 24.0; resonance at  $\delta$  134.1 ppm was taken from the HSQC experiment;  $m/z$  MS  
35 (TOF ES $^+$ )  $\text{C}_{25}\text{H}_{27}\text{N}_2\text{O}_4$   $[\text{M}+\text{H}]^+$  calcd 419.2; found 419.3; LC-MS  $t_{\text{R}}$ : 3.40 min.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 **1-(2-Hydroxycyclohexyl)-4-(2-((4-(pyridin-3-yl)benzyl)oxy)phenyl)pyridin-2(1H)-one (10a).**

50 4-(2-((4-Bromobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (**8t**) (100 mg, 0.22  
51 mmol) was coupled to pyridine-3-boronic acid (41 mg, 0.33 mmol) according to General Procedure  
52 A. Purification by FCC (eluent MeOH/DCM 0:100 to 7.5:92.5) gave 48 mg of a white solid (48%).  
53  $^1\text{H}$  NMR  $\delta$  8.90 (d,  $J = 2.1$  Hz, 1H), 8.57 (dd,  $J = 4.7/1.5$  Hz, 1H), 8.10–8.05 (m, 1H), 7.74 (d,  $J =$   
54  
55  
56  
57  
58  
59  
60

1  
2  
3 8.2 Hz, 2H), 7.68 (d,  $J = 7.2$  Hz, 1H), 7.54 (d,  $J = 8.2$  Hz, 2H), 7.49 (dd,  $J = 7.9/4.8$  Hz, 1H), 7.43–  
4  
5 7.94 (m, 2H), 7.22 (d,  $J = 8.2$  Hz, 1H), 7.05 (t,  $J = 7.4$  Hz, 1H), 6.51 (d,  $J = 1.9$  Hz, 1H), 6.46 (dd,  $J$   
6  
7 = 7.2/1.9 Hz, 1H), 5.26 (s, 2H), 4.77 (d,  $J = 6.0$  Hz, 1H), 4.54 (br s, 1H), 3.80 (br s, 1H), 2.05–1.93  
8  
9 (m, 1H), 1.81–1.61 (m, 3H), 1.53 (m, 1H), 1.41–1.25 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.8, 155.3, 148.6,  
10  
11 148.4, 147.7, 137.0, 136.5, 135.2, 134.2, 134.1, 130.3, 129.9, 128.1, 127.2, 127.0, 123.9, 121.2,  
12  
13 118.5, 113.5, 107.0, 69.2, 69.0, 35.4, 31.1, 25.0, 24.0; resonances at  $\delta$  134.2 and 69.0 ppm were  
14  
15 taken from the HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>29</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 453.2; found  
16  
17 453.3; LC-MS  $t_R$ : 3.39 min.  
18  
19

20  
21  
22 **1-(2-Hydroxycyclohexyl)-4-(2-((4-(pyridin-4-yl)benzyl)oxy)phenyl)pyridin-2(1H)-one (10b).**  
23  
24 4-(2-((4-Bromobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (**8t**) (100 mg, 0.22  
25  
26 mmol) was coupled to pyridine-4-boronic acid (41 mg, 0.33 mmol) according to General Procedure  
27  
28 A. Purification by FCC (eluent MeOH/DCM 0:100 to 7.5:92.5) gave 43 mg of a white solid (43%).  
29  
30  $^1\text{H}$  NMR  $\delta$  8.63 (d,  $J = 5.5$  Hz, 2H), 7.81 (d,  $J = 8.1$  Hz, 2H), 7.75–7.65 (m, 3H), 7.56 (d,  $J = 8.1$   
31  
32 Hz, 2H), 7.43–7.34 (m, 2H), 7.21 (d,  $J = 8.5$  Hz, 1H), 7.05 (t,  $J = 7.4$  Hz, 1H), 6.53–6.50 (m, 1H),  
33  
34 6.46 (dd,  $J = 7.1/1.3$  Hz, 1H), 5.27 (s, 2H), 4.77 (d,  $J = 5.9$  Hz, 1H), 4.54 (br s, 1H), 3.80 (br s, 1H),  
35  
36 2.05–1.93 (m, 1H), 1.81–1.62 (m, 3H), 1.54 (m, 1H), 1.42–1.24 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.8, 155.2,  
37  
38 150.3, 148.4, 146.6, 138.2, 136.5, 134.2, 130.3, 129.9, 128.0, 127.2, 127.0, 121.3, 121.2, 118.5,  
39  
40 113.4, 107.0, 69.2, 69.2, 35.4, 31.1, 25.0, 24.0; resonance at  $\delta$  134.2 was taken from the HSQC  
41  
42 experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>29</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 453.2; found 453.3; LC-MS  $t_R$ : 3.31  
43  
44 min.  
45  
46  
47  
48

49  
50 **1-(2-Hydroxycyclohexyl)-4-(2-((4-(pyrimidin-5-yl)benzyl)oxy)phenyl)pyridin-2(1H)-one**  
51  
52 **(10c).** 4-(2-((4-Bromobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (**8t**)  
53  
54 (100 mg, 0.22 mmol) was coupled to pyrimidine-5-boronic acid (41 mg, 0.33 mmol) according to  
55  
56 General Procedure A. Purification by FCC (eluent MeOH/DCM 0:100 to 5:95) gave 38 mg of a  
57  
58 white solid (38%).  $^1\text{H}$  NMR  $\delta$  9.19 (s, 1H), 9.15 (s, 2H), 7.85–7.79 (m, 2H), 7.68 (d,  $J = 7.2$  Hz,  
59  
60

1  
2  
3 1H), 7.57 (d,  $J = 8.3$  Hz, 2H), 7.42–7.35 (m, 2H), 7.21 (d,  $J = 8.0$  Hz, 1H), 7.05 (ddd,  $J =$   
4 7.6/7.6/0.9 Hz, 1H), 6.51 (d,  $J = 1.9$  Hz, 1H), 6.46 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.28 (s, 2H), 4.77 (d,  $J$   
5 = 5.9 Hz, 1H), 4.54 (br s, 1H), 3.80 (br s, 1H), 2.05–1.94 (m, 1H), 1.80–1.62 (m, 3H), 1.54 (m, 1H),  
6 1.42–1.24 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.8, 157.3, 155.2, 155.2, 148.3, 137.8, 134.2, 133.1, 132.9, 130.3,  
7 129.9, 128.1, 127.2, 127.1, 121.3, 118.5, 113.5, 107.0, 69.2, 69.1, 35.4, 31.1, 25.0, 24.0; resonance  
8 at  $\delta$  134.2 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>28</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>  
9 calcd 454.2; found 454.3; LC-MS  $t_R$ : 3.56 min.  
10  
11  
12  
13  
14  
15  
16  
17  
18

19  
20 **1-(2-Hydroxycyclohexyl)-4-(2-((4-(1-methyl-1H-pyrazol-4-yl)benzyl)oxy)phenyl)pyridin-**  
21 **2(1H)-one (10d).** 4-(2-((4-Bromobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one  
22 (**8t**) (100 mg, 0.22 mmol) was coupled to 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-  
23 1H-pyrazole (69 mg, 0.33 mmol) according to General Procedure A. Purification by FCC (eluent  
24 MeOH/DCM 0:100 to 5:95) gave 43 mg of a white solid (43%).  $^1\text{H}$  NMR  $\delta$  8.12 (s, 1H), 7.85 (s,  
25 1H), 7.67 (d,  $J = 7.2$  Hz, 1H), 7.55 (d,  $J = 8.1$  Hz, 2H), 7.42–7.34 (m, 2H), 7.21 (d,  $J = 8.3$  Hz, 1H),  
26 7.04 (t,  $J = 7.5$  Hz, 1H), 6.51 (d,  $J = 1.9$  Hz, 1H), 6.44 (dd,  $J = 7.2/1.9$  Hz, 1H), 5.16 (s, 2H), 4.75  
27 (d,  $J = 6.0$  Hz, 1H), 4.53 (br s, 1H), 3.85 (s, 3H), 3.80 (br s, 1H), 2.04–1.94 (m, 1H), 1.82–1.67 (m,  
28 3H), 1.54 (m, 1H), 1.41–1.25 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.8, 155.4, 148.3, 136.1, 134.4, 134.2, 132.2,  
29 130.3, 129.9, 128.1, 127.9, 127.1, 125.0, 121.5, 121.1, 118.5, 113.4, 107.0, 69.5, 69.2, 38.9, 35.4,  
30 31.1, 25.0, 24.0; resonance at  $\delta$  134.2 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF  
31 ES<sup>+</sup>) C<sub>28</sub>H<sub>30</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 456.2; found 456.3; LC-MS  $t_R$ : 3.61 min.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 **4-(2-Aminophenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (11).** 4-Bromo-1-(2-  
48 hydroxycyclohexyl)pyridin-2(1H)-one (**4b**) (200 mg, 0.73 mmol) was coupled to 2-(4,4,5,5-  
49 tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (244 g, 1.10 mmol) according to General Procedure A.  
50 Purification by FCC (eluent MeOH/DCM 0:100 to 20:80) gave 181 mg of a brown solid (87%).  $^1\text{H}$   
51 NMR  $\delta$  7.71 (d,  $J = 7.2$  Hz, 1H), 7.11–7.00 (m, 2H), 6.75 (dd,  $J = 8.1/0.9$  Hz, 1H), 6.62 (td,  $J =$   
52 7.5/1.1 Hz, 1H), 6.37 (d,  $J = 1.8$  Hz, 1H), 6.30 (dd,  $J = 7.1/2.0$  Hz, 1H), 4.98 (s, 2H), 4.73 (d,  $J =$   
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 5.6 Hz, 1H), 4.54 (br s, 1H), 3.80 (br s, 1H), 2.05–1.94 (m, 1H), 1.80–1.65 (m, 3H), 1.55 (m, 1H),  
4  
5 1.42–1.24 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.0, 150.0, 145.2, 135.2, 129.4, 129.0, 122.5, 117.5, 116.6, 115.6,  
6  
7 106.2, 69.3, 35.3, 31.0, 25.0, 24.0; resonance at  $\delta$  135.2 ppm was taken from HSQC experiment;  
8  
9  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{17}\text{H}_{21}\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$  calcd 285.2; found 285.2; LC-MS  $t_{\text{R}}$ : 3.35 min.

10  
11  
12 **4-(2-((4-Bromobenzyl)amino)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (12).** To a  
13  
14 mixture of 4-(2-aminophenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (11) (100 mg,  
15  
16 0.35 mmol) and 4-bromobenzaldehyde (65 mg, 0.35 mmol, 1.0 eq) in 1,2-dichloroethane (3.5 mL)  
17  
18 was added AcOH (0.20 mL) and  $\text{NaB}(\text{OAc})_3\text{H}$  (149 mg, 0.70 mmol, 2.0 eq). After 2 h, the reaction  
19  
20 mixture was diluted with DCM (20 mL) washed with 10%  $\text{K}_2\text{CO}_3(\text{aq})$  (20 mL) and brine (20 mL).  
21  
22 The organic layer was dried over  $\text{MgSO}_4$ , filtered and concentrated under reduced pressure.  
23  
24 Purification by FCC (eluent EtOAc/PE 50:50 to 100:0) gave 81 mg of a yellow oil (50%).  $^1\text{H}$  NMR  
25  
26  $\delta$  7.75 (d,  $J = 7.2$  Hz, 1H), 7.53–7.47 (m, 2H), 7.30 (d,  $J = 8.4$  Hz, 2H), 7.11–7.01 (m, 2H), 6.63  
27  
28 (ddd,  $J = 7.4/7.4/0.9$  Hz, 1H), 6.46–6.40 (m, 2H), 6.31 (dd,  $J = 7.1/2.0$  Hz, 1H), 5.72 (t,  $J = 5.9$  Hz,  
29  
30 1H), 4.73 (d,  $J = 5.6$  Hz, 1H), 4.56 (br s, 1H), 4.30 (d,  $J = 5.9$  Hz, 2H), 3.82 (br s, 1H), 2.05–1.96  
31  
32 (m, 1H), 1.82–1.65 (m, 3H), 1.56 (m, 1H), 1.43–1.25 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.0, 149.7, 144.4,  
33  
34 139.7, 135.4, 131.2, 129.5, 129.1, 129.1, 123.9, 119.5, 118.2, 116.4, 111.0, 106.6, 69.3, 45.8, 35.3,  
35  
36 30.7, 25.1, 24.0; resonances at  $\delta$  135.4 and 30.7 ppm were taken from HSQC experiment;  $m/z$  MS  
37  
38 (TOF ES $^+$ )  $\text{C}_{24}\text{H}_{26}\text{BrN}_2\text{O}_2$   $[\text{M}+\text{H}]^+$  calcd 453.1; found 453.2; LC-MS  $t_{\text{R}}$ : 3.89.

39  
40  
41 **1-(2-Hydroxycyclohexyl)-4-(2-((4-(pyridin-3-yl)benzyl)amino)phenyl)pyridin-2(1H)-one**  
42  
43 **(13a).** 4-(2-((4-Bromobenzyl)amino)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (12) (80  
44  
45 mg, 0.18 mmol) was coupled to pyridine-3-boronic acid (33 mg, 0.26 mmol) according to General  
46  
47 Procedure A. Purification by FCC (eluent MeOH/DCM 0:100 to 5:95) gave 33 mg of a yellow oil  
48  
49 (41%).  $^1\text{H}$  NMR  $\delta$  8.87 (d,  $J = 1.8$  Hz, 1H), 8.55 (dd,  $J = 4.7/1.5$  Hz, 1H), 8.05 (ddd,  $J = 8.0/2.4/1.6$   
50  
51 Hz, 1H), 7.77 (d,  $J = 7.2$  Hz, 1H), 7.69 (d,  $J = 8.3$  Hz, 2H), 7.50–7.44 (m, 3H), 7.12–7.06 (m, 1H),  
52  
53 7.05 (dd,  $J = 7.5/1.5$  Hz, 1H), 6.63 (ddd,  $J = 7.4/7.4/0.9$  Hz, 1H), 6.52 (d,  $J = 8.2$  Hz, 1H), 6.45 (d,  $J$   
54  
55  
56  
57  
58  
59  
60

1  
2  
3 = 1.9 Hz, 1H), 6.34 (dd,  $J = 7.1/2.0$  Hz, 1H), 5.74 (t,  $J = 6.0$  Hz, 1H), 4.74 (d,  $J = 5.6$  Hz, 1H), 4.57  
4 (br s, 1H), 4.40 (d,  $J = 5.9$  Hz, 2H), 3.83 (br s, 1H), 2.07–1.95 (m, 1H), 1.84–1.65 (m, 3H), 1.57 (m,  
5 1H), 1.44–1.26 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.0, 149.8, 148.3, 147.6, 144.6, 140.3, 135.4, 135.4, 134.0,  
6 129.5, 129.1, 127.6, 126.9, 123.9, 123.9, 118.1, 116.3, 111.1, 106.6, 69.3, 46.0, 35.3, 31.1, 25.0,  
7 24.0; resonance at  $\delta$  135.4 ppm was taken from HSQC experiment. Missing an aromatic quaternary  
8 carbon resonance not observed in 2D NMR experiments;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>29</sub>H<sub>30</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup>  
9 calcd 452.2; found 452.3; LC-MS  $t_R$ : 3.44 min.  
10  
11  
12  
13  
14  
15  
16  
17  
18

19  
20 **1-(2-Hydroxycyclohexyl)-4-(2-((4-(pyridin-4-yl)benzyl)amino)phenyl)pyridin-2(1H)-one**

21 (13b). 4-(2-((4-Bromobenzyl)amino)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (12) (80  
22 mg, 0.18 mmol) was coupled to pyridine-4-boronic acid (33 mg, 0.26 mmol) according to General  
23 Procedure A. Purification by FCC (eluent MeOH/DCM 0:100 to 5:95) followed by preparative  
24 HPLC (30% to 100% buffer B, 20 minutes) gave 19 mg of a yellow oil (29%).  $^1\text{H}$  NMR  $\delta$  8.63–  
25 8.59 (m, 2H), 7.77 (d,  $J = 8.2$  Hz, 3H), 7.69 (dd,  $J = 4.6/1.6$  Hz, 2H), 7.49 (d,  $J = 8.3$  Hz, 1H), 7.11–  
26 7.02 (m, 2H), 6.63 (ddd,  $J = 7.4/7.4/0.8$  Hz, 1H), 6.50 (d,  $J = 8.2$  Hz, 1H), 6.45 (d,  $J = 1.9$  Hz, 1H),  
27 6.34 (dd,  $J = 7.1/2.0$  Hz, 1H), 5.76 (t,  $J = 5.9$  Hz, 1H), 4.74 (d,  $J = 5.6$  Hz, 1H), 4.57 (br s, 1H), 4.41  
28 (d,  $J = 5.9$  Hz, 2H), 3.83 (br s, 1H), 2.06–1.95 (m, 1H), 1.84–1.66 (m, 3H), 1.57 (m, 1H), 1.43–1.26  
29 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.0, 150.2, 149.8, 146.8, 144.5, 141.6, 135.5, 135.4, 129.5, 129.1, 127.6,  
30 126.9, 123.9, 121.1, 118.1, 116.3, 111.1, 106.6, 69.3, 46.1, 35.3, 31.1, 25.1, 24.0; resonance at  $\delta$   
31 135.5 ppm was taken from HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>29</sub>H<sub>30</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> calcd  
32 452.2; found 452.3; LC-MS  $t_R$ : 3.33 min.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 **1-(2-Hydroxycyclohexyl)-4-(2-((4-(pyrimidin-5-yl)benzyl)amino)phenyl)pyridin-2(1H)-one**

50 (13c). 4-(2-((4-Bromobenzyl)amino)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (12) (80  
51 mg, 0.18 mmol) was coupled to pyrimidine-5-boronic acid (33 mg, 0.26 mmol) according to  
52 General Procedure A. Purification by FCC (eluent MeOH/DCM 0:100 to 5:95) followed by  
53 preparative HPLC (MeCN:H<sub>2</sub>O 40:60 to 100:0) gave 28 mg of a yellow oil (35%).  $^1\text{H}$  NMR  $\delta$  9.16  
54  
55  
56  
57  
58  
59  
60

(s, 1H), 9.12 (s, 2H), 7.77 (d,  $J = 8.2$  Hz, 3H), 7.51 (d,  $J = 8.3$  Hz, 2H), 7.11–7.02 (m, 2H), 6.63 (ddd,  $J = 7.4/7.4/0.9$  Hz, 1H), 6.51 (d,  $J = 8.0$  Hz, 1H), 6.45 (d,  $J = 1.9$  Hz, 1H), 6.34 (dd,  $J = 7.1/2.0$  Hz, 1H), 5.77 (t,  $J = 5.9$  Hz, 1H), 4.74 (d,  $J = 5.6$  Hz, 1H), 4.57 (br s, 1H), 4.41 (d,  $J = 5.9$  Hz, 2H), 3.82 (br s, 1H), 2.06–1.96 (m, 1H), 1.83–1.65 (m, 3H), 1.58 (m, 1H), 1.44–1.25 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.0, 157.1, 154.6, 149.8, 144.5, 141.3, 135.6, 133.1, 132.1, 129.5, 129.1, 127.7, 127.0, 123.9, 118.1, 116.3, 111.1, 106.6, 69.3, 46.0, 35.3, 31.1, 25.1, 24.0; resonance at  $\delta$  135.6 ppm was taken from HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>28</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> calcd 453.2; found 453.3; LC-MS  $t_{\text{R}}$ : 3.55 min.

**1-(2-Hydroxycyclohexyl)-4-(2-((4-(1-methyl-1*H*-pyrazol-4-yl)benzyl)amino)phenyl)pyridin-2(1*H*)-one (13d).** 4-(2-((4-Bromobenzyl)amino)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1*H*)-one (**12**) (80 mg, 0.18 mmol) was coupled to 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (55 mg, 0.26 mmol) according to General Procedure A. Purification by FCC (eluent MeOH/DCM 0:100 to 5:95) followed by preparative HPLC (40% to 100% buffer B, 20 minutes) gave 30 mg of a yellow oil (37%).  $^1\text{H}$  NMR  $\delta$  8.07 (s, 1H), 7.80 (d,  $J = 0.7$  Hz, 1H), 7.75 (d,  $J = 7.2$  Hz, 1H), 7.49 (d,  $J = 8.3$  Hz, 2H), 7.31 (d,  $J = 8.3$  Hz, 2H), 7.11–7.05 (m, 1H), 7.03 (dd,  $J = 7.5/1.6$  Hz, 1H), 6.62 (ddd,  $J = 7.4/7.4/0.9$  Hz, 1H), 6.52 (d,  $J = 8.2$  Hz, 1H), 6.43 (d,  $J = 1.9$  Hz, 1H), 6.33 (dd,  $J = 7.1/2.0$  Hz, 1H), 5.62 (t,  $J = 5.9$  Hz, 1H), 4.73 (d,  $J = 5.6$  Hz, 1H), 4.56 (br s, 1H), 4.31 (d,  $J = 5.8$  Hz, 2H), 3.90–3.76 (m, 4H), 2.06–1.95 (m, 1H), 1.83–1.64 (m, 3H), 1.56 (br s, 1H), 1.43–1.25 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.0, 149.8, 144.7, 137.7, 135.9, 135.5, 131.0, 129.5, 129.1, 127.6, 127.3, 125.0, 123.9, 121.8, 118.1, 116.2, 111.1, 106.5, 69.1, 46.2, 38.6, 35.3, 31.1, 25.0, 24.0; resonances at  $\delta$  135.5 and 69.1 ppm were taken from HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>28</sub>H<sub>31</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> calcd 455.2; found 455.3; LC-MS  $t_{\text{R}}$ : 3.22 min.

**4-(2-((1,1'-Biphenyl)-4-ylmethyl)amino)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1*H*)-one (13e).** 4-(2-((4-Bromobenzyl)amino)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1*H*)-one (**12**) (80 mg, 0.18 mmol) was coupled to phenylboronic acid (32 mg, 0.26 mmol) according to General

1  
2  
3 Procedure A. Purification by FCC (eluent MeOH/DCM 0:100 to 5:95) followed by preparative  
4 HPLC (40% to 100% buffer B, 20 minutes) gave 36 mg of a yellow oil (46%).  $^1\text{H}$  NMR  $\delta$  7.76 (d,  
5  $J = 7.2$  Hz, 1H), 7.68–7.58 (m, 4H), 7.49–7.40 (m, 4H), 7.34 (ddd,  $J = 8.5/4.5/1.2$  Hz, 1H), 7.12–  
6 7.06 (m, 1H), 7.04 (dd,  $J = 7.5/1.5$  Hz, 1H), 6.63 (ddd,  $J = 7.4/7.4/0.9$  Hz, 1H), 6.53 (d,  $J = 8.1$  Hz,  
7 1H), 6.44 (d,  $J = 1.9$  Hz, 1H), 6.34 (dd,  $J = 7.1/2.0$  Hz, 1H), 5.71 (t,  $J = 5.9$  Hz, 1H), 4.74 (d,  $J =$   
8 5.6 Hz, 1H), 4.57 (br s, 1H), 4.38 (d,  $J = 5.9$  Hz, 2H), 3.82 (br s, 1H), 2.06–1.96 (m, 1H), 1.83–1.65  
9 (m, 3H), 1.57 (m, 1H), 1.43–1.25 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.0, 149.8, 144.6, 140.0, 139.5, 138.6,  
10 135.5, 129.6, 129.1, 128.9, 127.4, 127.3, 126.7, 126.6, 123.9, 118.1, 116.3, 111.1, 106.6, 69.1, 46.1,  
11 35.3, 30.8, 25.1, 24.0; resonances at  $\delta$  135.5, 69.1 and 30.8 ppm were taken from HSQC  
12 experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{30}\text{H}_{31}\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$  calcd 451.2; found 451.3; LC-MS  $t_{\text{R}}$ : 4.00  
13 min.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 **4-(2-((4-(1H-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one**

29  
30 **(14)**. 4-(2-((4-Bromobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (**8t**) (200 mg,  
31 0.44 mmol) was coupled to 1-(*tert*-butoxycarbonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
32 yl)-1H-pyrazole (194 mg, 0.66 mmol) according to General Procedure A. LCMS analysis of the  
33 crude residue indicated loss of the Boc group during the reaction. Purification by FCC (eluent  
34 MeOH/DCM 0:100 to 10:90), gave 150 mg of a white solid (77%).  $^1\text{H}$  NMR  $\delta$  12.94 (s, 1H), 8.19  
35 (s, 1H), 7.92 (s, 1H), 7.67 (d,  $J = 7.3$  Hz, 1H), 7.63–7.53 (m, 2H), 7.47–7.33 (m, 4H), 7.21 (d,  $J =$   
36 8.2 Hz, 1H), 7.04 (ddd,  $J = 7.6/7.6/0.9$  Hz, 1H), 6.51 (d,  $J = 1.9$  Hz, 1H), 6.44 (dd,  $J = 7.2, 2.0$  Hz,  
37 1H), 5.17 (s, 2H), 4.75 (d,  $J = 6.0$  Hz, 1H), 4.53 (s, 1H), 3.80 (s, 1H), 1.99 (s, 1H), 1.81–1.62 (m,  
38 3H), 1.61–1.42 (m, 1H), 1.42–1.22 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.8, 155.3, 148.3, 136.2, 134.6, 134.3,  
39 132.5, 130.3, 129.9, 128.0, 127.1, 125.5, 125.1, 121.1, 120.8, 118.5, 113.5, 106.9, 69.5, 69.2, 35.4,  
40 31.0, 25.0, 24.0;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{27}\text{H}_{28}\text{N}_3\text{O}_3$   $[\text{MH}]^+$  calcd 442.2; found 442.3; LC-MS  $t_{\text{R}}$ : 3.47  
41 min.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **4-(2-((4-(1-Ethyl-1*H*-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-**  
4  
5 **2(1*H*)-one (15a).** 14-(2-((4-(1*H*-Pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-  
6  
7 2(1*H*)-one (**14**) (65mg, 147  $\mu\text{mol}$ ) was alkylated with 1-bromoethane (12  $\mu\text{L}$ , 161  $\mu\text{mol}$ ) according  
8  
9 to General Procedure B. Reaction progress was monitored via LC-MS analysis, additional  $\text{K}_2\text{CO}_3$   
10  
11 (22 mg, 162  $\mu\text{mol}$ ) and 1-bromoethane (61  $\mu\text{L}$ , 805  $\mu\text{mol}$ ) was added over 44 h at rt until the  
12  
13 reaction appeared complete. The crude product was dried on the freeze dryer to give 57 mg of  
14  
15 white solid (82%). No further purification was required.  $^1\text{H}$  NMR  $\delta$  8.19 (d,  $J = 0.5$  Hz, 1H), 7.87  
16  
17 (d,  $J = 0.7$  Hz, 1H), 7.67 (d,  $J = 7.2$  Hz, 1H), 7.59–7.55 (m, 2H), 7.42–7.36 (m, 4H), 7.24–7.19 (m,  
18  
19 1H), 7.05 (td,  $J = 7.6/0.9$  Hz, 1H), 6.52 (d,  $J = 1.9$  Hz, 1H), 6.45 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.17 (s,  
20  
21 2H), 4.75 (d,  $J = 5.9$  Hz, 1H), 4.54 (br s, 1H), 4.15 (q,  $J = 7.3$  Hz, 2H), 3.81 (br s, 1H), 2.05–1.95  
22  
23 (m, 1H), 1.80–1.65 (m, 3H), 1.65–1.45 (m, 1H), 1.40 (t,  $J = 7.3$  Hz, 3H), 1.33–1.22 (m, 3H);  $^{13}\text{C}$   
24  
25 NMR  $\delta$  162.3, 155.8, 148.8, 136.4, 134.8, 134.8, 132.7, 130.8, 130.3, 128.5, 127.5, 126.8, 125.4,  
26  
27 121.8, 121.6, 118.9, 113.9, 107.4, 70.0, 69.6, 46.8, 35.9, 31.5, 25.5, 24.5, 15.9; resonance at  $\delta$  134.8  
28  
29 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{29}\text{H}_{32}\text{N}_3\text{O}_3$   $[\text{M}+\text{H}]^+$  calcd 470.2;  
30  
31 found 470.3; LC-MS  $t_{\text{R}}$ : 3.58 min.  
32  
33  
34  
35  
36

37 **1-(2-Hydroxycyclohexyl)-4-(2-((4-(1-(2-hydroxyethyl)-1*H*-pyrazol-4-**  
38  
39 **yl)benzyl)oxy)phenyl)pyridin-2(1*H*)-one (15b).** 14-(2-((4-(1*H*-Pyrazol-4-yl)benzyl)oxy)phenyl)-  
40  
41 1-(2-hydroxycyclohexyl)pyridin-2(1*H*)-one (**14**) (80 mg, 181  $\mu\text{mol}$ ) was alkylated with  
42  
43 bromoethanol (14  $\mu\text{L}$ , 199  $\mu\text{mol}$ ) according to General Procedure B. Reaction progress was  
44  
45 monitored via LC-MS analysis, the reaction was stopped after 10 d at 100  $^\circ\text{C}$ . Purification by FCC  
46  
47 (eluent MeOH/DCM 0:100 to 10:90) gave 19 mg of a white solid (22%).  $^1\text{H}$  NMR  $\delta$  8.15 (s, 1H),  
48  
49 7.88 (d,  $J = 0.5$  Hz, 1H), 7.67 (d,  $J = 7.2$  Hz, 1H), 7.57 (d,  $J = 8.2$  Hz, 2H), 7.43–7.35 (m, 4H), 7.22  
50  
51 (d,  $J = 8.2$  Hz, 1H), 7.08–7.01 (m, 1H), 6.52 (d,  $J = 1.9$  Hz, 1H), 6.45 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.17  
52  
53 (s, 2H), 4.94 (t,  $J = 5.3$  Hz, 1H), 4.76 (d,  $J = 6.0$  Hz, 1H), 4.55 (br s, 1H), 4.16 (t,  $J = 5.6$  Hz, 2H),  
54  
55 3.86–3.72 (m, 3H), 2.05–1.96 (m, 1H), 1.78–1.65 (m, 3H), 1.62–1.45 (m, 1H), 1.40–1.26 (m, 3H).  
56  
57  
58  
59  
60

<sup>13</sup>C NMR δ 162.3, 155.8, 148.8, 136.5, 134.8, 134.6, 132.7, 130.7, 130.3, 128.5, 128.1, 127.5, 125.4, 121.6, 121.6, 118.9, 113.9, 107.4, 70.0, 69.7, 60.5, 55.4, 35.9, 31.5, 25.5, 24.5; resonance at δ 134.6 ppm was taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>29</sub>H<sub>32</sub>N<sub>3</sub>O<sub>4</sub> [M+H]<sup>+</sup> calcd 486.2; found 486.3; LC-MS *t*<sub>R</sub>: 3.42 min.

**1-(2-Hydroxycyclohexyl)-4-(2-((4-(1-propyl-1*H*-pyrazol-4-yl)benzyl)oxy)phenyl)pyridin-2(1*H*)-one (15c).** 14-(2-((4-(1*H*-Pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1*H*)-one (**14**) (60 mg, 136 μmol) was alkylated with 1-bromopropane (14 μL, 149 μmol) according to General Procedure B. Reaction progress was monitored via LC-MS analysis, additional 1-bromopropane (54 μL, 596 μmol) was added over 48 h at rt until the reaction appeared complete. The crude product was dried on the freeze dryer to give 51 mg of the desired product as of a white solid (77%). No further purification was required. <sup>1</sup>H NMR δ 8.18 (d, *J* = 0.5 Hz, 1H), 7.87 (d, *J* = 0.6 Hz, 1H), 7.67 (d, *J* = 7.3 Hz, 1H), 7.57 (d, *J* = 8.3 Hz, 2H), 7.43–7.35 (m, 4H), 7.22 (d, *J* = 8.2 Hz, 1H), 7.05 (td, *J* = 7.6/0.8 Hz, 1H), 6.52 (d, *J* = 1.9 Hz, 1H), 6.45 (dd, *J* = 7.2/2.0 Hz, 1H), 5.17 (s, 2H), 4.76 (d, *J* = 6.0 Hz, 1H), 4.54 (br s, 1H), 4.07 (t, *J* = 7.0 Hz, 2H), 3.80 (br s, 1H), 2.05–1.95 (m, 1H), 1.85–1.73 (m, 2H), 1.76–1.65 (m, 3H), 1.60–1.48 (m, 1H), 1.41–1.19 (m, 3H), 0.85 (t, *J* = 7.4 Hz, 3H). <sup>13</sup>C NMR δ 162.2, 155.8, 148.8, 136.4, 134.7, 134.8, 132.7, 130.8, 130.3, 128.5, 127.5, 125.4, 121.6, 121.6, 118.9, 113.9, 107.4, 70.0, 69.6, 53.5, 35.9, 31.5, 25.5, 24.5, 23.7, 11.4; resonance at δ 134.7 ppm was taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>30</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 484.3; found 484.3; LC-MS *t*<sub>R</sub>: 3.67 min.

**1-(2-Hydroxycyclohexyl)-4-(2-((4-(1-isopropyl-1*H*-pyrazol-4-yl)benzyl)oxy)phenyl)pyridin-2(1*H*)-one (15d).** 14-(2-((4-(1*H*-Pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1*H*)-one (**14**) (60 mg, 136 μmol) was alkylated with 2-bromopropane (14 μL, 149 μmol) according to General Procedure B. Reaction progress was monitored via LC-MS analysis, additional K<sub>2</sub>CO<sub>3</sub> (21 mg, 149 μmol) and 2-bromopropane (56 μL, 596 μmol) was added over 48 h at rt, then the reaction mixture was heated to 40 °C for another 5 d until the reaction appeared

complete. Purification by FCC (eluent MeOH/DCM 0:100 to 8:92) gave 28 mg of a white solid (42%).  $^1\text{H}$  NMR  $\delta$  8.22 (d,  $J = 0.5$  Hz, 1H), 7.87 (d,  $J = 0.6$  Hz, 1H), 7.67 (d,  $J = 7.3$  Hz, 1H), 7.59 (d,  $J = 8.3$  Hz, 2H), 7.44–7.33 (m, 4H), 7.26–7.18 (m, 1H), 7.05 (td,  $J = 7.5/0.8$  Hz, 1H), 6.54 (d,  $J = 1.9$  Hz, 1H), 6.46 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.17 (s, 2H), 4.78 (d,  $J = 6.0$  Hz, 1H), 4.63–4.43 (m, 2H), 3.80 (br s, 1H), 2.05–1.95 (m, 1H), 1.78–1.65 (m, 3H), 1.62–1.50 (m, 1H), 1.45 (d,  $J = 6.7$  Hz, 6H), 1.39–1.25 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.3, 155.8, 148.8, 136.0, 134.7, 134.7, 132.8, 130.8, 130.3, 128.5, 127.5, 125.4, 125.2, 121.6, 121.5, 119.0, 113.9, 107.4, 70.0, 69.7, 53.6, 35.9, 31.6, 25.5, 24.5, 23.1; resonance at  $\delta$  134.7 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>)  $\text{C}_{30}\text{H}_{34}\text{N}_3\text{O}_3$  [M+H]<sup>+</sup> calcd 484.3; found 484.3; LC-MS  $t_{\text{R}}$ : 3.63 min.

**4-(2-((4-(1-Butyl-1*H*-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1*H*)-one (15e).** 14-(2-((4-(1*H*-Pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1*H*)-one (**14**) (60 mg, 136  $\mu\text{mol}$ ) was alkylated with 1-bromobutane (16  $\mu\text{L}$ , 149  $\mu\text{mol}$ ) according to General Procedure B. Reaction progress was monitored via LC-MS analysis, additional  $\text{K}_2\text{CO}_3$  (21 mg, 149  $\mu\text{mol}$ ) and 1-bromobutane (54  $\mu\text{L}$ , 600  $\mu\text{mol}$ ) was added over 72 h at rt, then the reaction mixture was heated to 40  $^\circ\text{C}$  for another 4 d until the reaction appeared complete. Purification by FCC (eluent MeOH/DCM 0:100 to 8:92) gave 42 mg of a white solid (63%).  $^1\text{H}$  NMR  $\delta$  8.18 (d,  $J = 0.5$  Hz, 1H), 7.87 (d,  $J = 0.7$  Hz, 1H), 7.67 (d,  $J = 7.3$  Hz, 1H), 7.57 (d,  $J = 8.3$  Hz, 2H), 7.44–7.34 (m, 4H), 7.25–7.19 (m, 1H), 7.04 (td,  $J = 7.5/0.8$  Hz, 1H), 6.54 (d,  $J = 1.9$  Hz, 1H), 6.46 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.17 (s, 2H), 4.78 (d,  $J = 6.0$  Hz, 1H), 4.55 (br s, 1H), 4.11 (t,  $J = 7.0$  Hz, 2H), 3.81 (br s, 1H), 2.05–1.96 (m, 1H), 1.83–1.64 (m, 5H), 1.61–1.45 (m, 1H), 1.41–1.19 (m, 5H), 0.89 (t,  $J = 7.4$  Hz, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.3, 155.8, 148.8, 136.4, 134.8, 134.7, 132.7, 130.7, 130.3, 128.5, 127.5, 127.5, 125.4, 121.7, 121.6, 118.9, 113.9, 107.4, 70.0, 69.7, 51.5, 35.9, 32.3, 31.5, 25.5, 24.5, 19.7, 13.9; resonance at  $\delta$  134.7 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>)  $\text{C}_{31}\text{H}_{36}\text{N}_3\text{O}_3$  [M+H]<sup>+</sup> calcd 498.3; found 498.4; LC-MS  $t_{\text{R}}$ : 3.73 min.

1  
2  
3 **4-(2-((4-(1-Cyclopentyl-1H-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-**  
4  
5 **hydroxycyclohexyl)pyridin-2(1H)-one (15f).** 14-(2-((4-(1H-Pyrazol-4-yl)benzyl)oxy)phenyl)-1-  
6  
7 (2-hydroxycyclohexyl)pyridin-2(1H)-one (**14**) (72 mg, 163  $\mu\text{mol}$ ) was alkylated with  
8  
9 bromocyclopentane (19  $\mu\text{L}$ , 179  $\mu\text{mol}$ ) according to General Procedure B. Reaction progress was  
10  
11 monitored via LC-MS analysis, additional  $\text{K}_2\text{CO}_3$  (25 mg, 179  $\mu\text{mol}$ ) and bromocyclopentane  
12  
13 (58  $\mu\text{L}$ , 537  $\mu\text{mol}$ ) was added over 24 h at rt, then the reaction mixture was heated to 40  $^\circ\text{C}$  for  
14  
15 another 5 d until the reaction appeared complete. Purification by FCC (eluent MeOH/DCM 0:100  
16  
17 to 8:92) gave 33 mg of a white solid (40%).  $^1\text{H}$  NMR  $\delta$  8.22 (d,  $J = 0.5$  Hz, 1H), 7.87 (d,  $J = 0.6$  Hz,  
18  
19 1H), 7.67 (d,  $J = 7.3$  Hz, 1H), 7.58 (d,  $J = 8.3$  Hz, 2H), 7.45–7.33 (m, 4H), 7.28–7.18 (m, 1H), 7.05  
20  
21 (td,  $J = 7.5/0.8$  Hz, 1H), 6.53 (d,  $J = 1.9$  Hz, 1H), 6.45 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.17 (s, 2H), 4.77  
22  
23 (d,  $J = 6.0$  Hz, 1H), 4.73–4.62 (m, 1H), 4.55 (br s, 1H), 3.82 (br s, 1H), 2.16–2.05 (m, 2H), 2.04–  
24  
25 1.89 (m, 3H), 1.88–1.44 (m, 8H), 1.41–1.23 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.2, 155.8, 148.8, 136.3,  
26  
27 134.74, 134.7, 132.8, 130.7, 130.3, 128.5, 127.5, 126.2, 125.4, 121.6, 118.9, 113.9, 107.4, 70.0,  
28  
29 69.6, 62.7, 35.9, 33.1, 31.5, 25.5, 24.5, 24.2; resonance at  $\delta$  134.7 ppm was taken from the HSQC  
30  
31 experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{32}\text{H}_{36}\text{N}_3\text{O}_3$   $[\text{M}+\text{H}]^+$  calcd 510.3; found 510.4; LC-MS  $t_{\text{R}}$ : 3.80  
32  
33 min.  
34  
35  
36  
37  
38

39 **4-(2-((4-(1-Cyclohexyl-1H-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-**  
40  
41 **hydroxycyclohexyl)pyridin-2(1H)-one (15g).** 14-(2-((4-(1H-Pyrazol-4-yl)benzyl)oxy)phenyl)-1-  
42  
43 (2-hydroxycyclohexyl)pyridin-2(1H)-one (**14**) (72 mg, 163  $\mu\text{mol}$ ) was alkylated with  
44  
45 bromocyclohexane (22  $\mu\text{L}$ , 179  $\mu\text{mol}$ ) according to General Procedure B. Reaction progress was  
46  
47 monitored via LC-MS analysis, additional  $\text{K}_2\text{CO}_3$  (25 mg, 179  $\mu\text{mol}$ ), KI (3 mg, 16  $\mu\text{mol}$ ) and  
48  
49 bromocyclohexane (22  $\mu\text{L}$ , 179  $\mu\text{mol}$ ) was added over 24 h at rt, then the reaction mixture was  
50  
51 heated to 40  $^\circ\text{C}$  for another 5 d, then to 60  $^\circ\text{C}$  for 24 h, and 80  $^\circ\text{C}$  for another 24 h until the reaction  
52  
53 appeared complete. Purification by FCC (eluent MeOH/DCM 0:100 to 8:92) gave 6 mg of a white  
54  
55 solid (6%).  $^1\text{H}$  NMR  $\delta$  8.22 (s, 1H), 7.86 (d,  $J = 0.6$  Hz, 1H), 7.67 (d,  $J = 7.2$  Hz, 1H), 7.58 (d,  $J =$   
56  
57  
58  
59  
60



1  
2  
3 8.3 Hz, 2H), 7.38 (dd,  $J = 10.4/4.5$  Hz, 4H), 7.22 (d,  $J = 8.2$  Hz, 1H), 7.05 (td,  $J = 7.6/0.8$  Hz, 1H),  
4  
5 6.52 (d,  $J = 1.9$  Hz, 1H), 6.45 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.17 (s, 2H), 4.75 (d,  $J = 6.0$  Hz, 1H), 4.54  
6  
7 (br s, 1H), 4.20–4.05 (m, 1H), 3.82 (br s, 1H), 2.08–1.96 (m, 3H), 1.86–1.66 (m, 7H), 1.64–1.48 (m,  
8  
9 1H), 1.47–1.16 (m, 7H);  $^{13}\text{C}$  NMR  $\delta$  162.2, 155.8, 148.7, 135.9, 134.7, 132.8, 130.7, 130.3, 128.5,  
10  
11 127.5, 125.4, 125.3, 121.6, 118.9, 113.9, 107.4, 70.0, 69.8, 60.7, 35.9, 33.4, 25.5, 25.4, 25.3, 24.5;  
12  
13 resonances at  $\delta$  134.7, 69.8 and 31.7 ppm were taken from the HSQC experiment;  $m/z$  MS (TOF  
14  
15  $\text{ES}^+$ )  $\text{C}_{33}\text{H}_{38}\text{N}_3\text{O}_3$   $[\text{M}+\text{H}]^+$  calcd 524.3; found 524.4; LC-MS  $t_{\text{R}}$ : 3.89 min.

16  
17  
18  
19  
20 **4-(2-((4-(1-(Cyclopropylmethyl)-1H-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-**  
21  
22 **hydroxycyclohexyl)pyridin-2(1H)-one (15h).** Compound (15h) was the main “side” product when  
23  
24 alkylating 14-(2-((4-(1H-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-  
25  
26 one (14) with bromocyclobutane. The titled product was synthesized and isolated when the reaction  
27  
28 was performed at rt or at 40 °C. Purification by FCC (eluent MeOH/DCM 0:100 to 8:92) gave  
29  
30 10 mg of the titled compound as a white solid (12%).  $^1\text{H}$  NMR  $\delta$  8.21 (d,  $J = 0.6$  Hz, 1H), 7.87 (d,  $J$   
31  
32  $= 0.7$  Hz, 1H), 7.67 (d,  $J = 7.3$  Hz, 1H), 7.61–7.55 (m, 2H), 7.47–7.33 (m, 4H), 7.26–7.18 (m, 1H),  
33  
34 7.05 (td,  $J = 7.5/0.9$  Hz, 1H), 6.53 (d,  $J = 1.9$  Hz, 1H), 6.45 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.18 (s, 2H),  
35  
36 4.76 (d,  $J = 6.0$  Hz, 1H), 4.54 (br s, 1H), 3.98 (d,  $J = 7.1$  Hz, 2H), 3.82 (br s, 1H), 2.06–1.96 (m,  
37  
38 1H), 1.81–1.65 (m, 3H), 1.63–1.45 (m, 1H), 1.42–1.19 (m, 4H), 0.62–0.49 (m, 2H), 0.45–0.35 (m,  
39  
40 2H);  $^{13}\text{C}$  NMR  $\delta$  162.2, 155.8, 148.8, 136.3, 134.8, 134.8, 132.7, 130.8, 130.3, 128.5, 127.5, 127.1,  
41  
42 125.4, 121.8, 121.6, 118.9, 113.9, 107.4, 70.0, 69.6, 56.3, 35.9, 31.4, 25.5, 24.5, 12.0, 4.1;  
43  
44 resonances at  $\delta$  134.8 and 31.4 ppm were taken from the HSQC experiment;  $m/z$  MS (TOF  $\text{ES}^+$ )  
45  
46  $\text{C}_{31}\text{H}_{34}\text{N}_3\text{O}_3$   $[\text{M}+\text{H}]^+$  calcd 496.3; found 496.3; LC-MS  $t_{\text{R}}$ : 3.70 min.

47  
48  
49  
50  
51 **4-(2-((4-(1-(Cyclohexylmethyl)-1H-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-**  
52  
53 **hydroxycyclohexyl)pyridin-2(1H)-one (15i).** 14-(2-((4-(1H-Pyrazol-4-yl)benzyl)oxy)phenyl)-1-  
54  
55 (2-hydroxycyclohexyl)pyridin-2(1H)-one (14) (80 mg, 181  $\mu\text{mol}$ ) was alkylated with  
56  
57 bromomethylcyclohexane (29  $\mu\text{L}$ , 199  $\mu\text{mol}$ ) according to General Procedure B. Reaction progress  
58  
59  
60

1  
2  
3 was monitored via LC-MS analysis, additional bromocyclopentane (199  $\mu\text{L}$ , 597  $\mu\text{mol}$ ) was added  
4  
5 over 4 days at rt, then the reaction mixture was heated to 40  $^{\circ}\text{C}$  for another 2 d until the reaction  
6  
7 appeared complete. Purification by FCC (eluent MeOH/DCM 0:100 to 8:92) gave 65 mg of a white  
8  
9 solid (67%).  $^1\text{H}$  NMR  $\delta$  8.14 (s, 1H), 7.87 (s, 1H), 7.67 (d,  $J = 7.3$  Hz, 1H), 7.57 (d,  $J = 8.2$  Hz,  
10  
11 2H), 7.45–7.33 (m, 4H), 7.25–7.17 (m, 1H), 7.04 (dd,  $J = 10.9/4.1$  Hz, 1H), 6.53 (d,  $J = 1.9$  Hz,  
12  
13 1H), 6.45 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.17 (s, 2H), 4.76 (d,  $J = 6.0$  Hz, 1H), 4.54 (s, 1H), 3.95 (d,  $J =$   
14  
15 7.2 Hz, 2H), 3.88–3.74 (m, 1H), 2.06–1.95 (m, 1H), 1.90–1.78 (m, 1H), 1.77–1.47 (m, 9H), 1.41–  
16  
17 1.26 (m, 3H), 1.26–1.05 (m, 3H), 1.03–0.87 (m, 2H);  $^{13}\text{C}$  NMR  $\delta$  162.2, 155.8, 148.8, 136.5, 134.8,  
18  
19 134.7, 132.7, 130.7, 130.3, 128.5, 128.0, 127.5, 125.4, 121.6, 121.5, 118.9, 113.9, 107.4, 70.0, 69.7,  
20  
21 58.0, 38.7, 35.9, 31.5, 30.4, 26.4, 25.6, 25.5, 24.5; resonance at  $\delta$  134.7 ppm was taken from the  
22  
23 HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{34}\text{H}_{40}\text{N}_3\text{O}_3$   $[\text{M}+\text{H}]^+$  calcd 538.4; found 538.3; LC-MS  $t_{\text{R}}$ :  
24  
25 4.31 min.  
26  
27  
28  
29

30  
31 **4-(2-((4-(1-Benzyl-1H-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-**  
32  
33 **2(1H)-one (15j).** 14-(2-((4-(1H-Pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-  
34  
35 2(1H)-one (**14**) (80 mg, 181  $\mu\text{mol}$ ) was alkylated with benzyl bromide (24  $\mu\text{L}$ , 199  $\mu\text{mol}$ ) according  
36  
37 to General Procedure B. Reaction progress was monitored via LC-MS analysis, after 21 h at rt the  
38  
39 reaction appeared complete. Purification by FCC (eluent MeOH/DCM 0:100 to 8:92) gave 61 mg  
40  
41 of a white solid (63%).  $^1\text{H}$  NMR  $\delta$  8.30 (d,  $J = 0.5$  Hz, 1H), 7.93 (d,  $J = 0.6$  Hz, 1H), 7.67 (d,  $J =$   
42  
43 7.3 Hz, 1H), 7.58 (d,  $J = 8.3$  Hz, 2H), 7.43–7.25 (m, 9H), 7.21 (d,  $J = 8.2$  Hz, 1H), 7.09–7.01 (m,  
44  
45 1H), 6.52 (d,  $J = 1.9$  Hz, 1H), 6.45 (dd,  $J = 7.2/2.0$  Hz, 1H), 5.35 (s, 2H), 5.17 (s, 2H), 4.75 (d,  $J =$   
46  
47 6.0 Hz, 1H), 4.54 (br s, 1H), 3.80 (br s, 1H), 2.04–1.96 (m, 1H), 1.79–1.65 (m, 3H), 1.62–1.44 (m,  
48  
49 1H), 1.41–1.25 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.2, 155.8, 148.8, 138.0, 137.1, 135.0, 134.7, 132.5, 130.7,  
50  
51 130.3, 129.0, 128.5, 128.1, 128.0, 127.9, 127.5, 125.5, 122.3, 121.6, 118.9, 113.9, 107.4, 70.0, 69.6,  
52  
53 55.5, 35.9, 31.5, 25.5, 24.5; resonance at  $\delta$  134.7 ppm was taken from the HSQC experiment;  $m/z$   
54  
55 MS (TOF ES $^+$ )  $\text{C}_{34}\text{H}_{34}\text{N}_3\text{O}_3$   $[\text{M}+\text{H}]^+$  calcd 532.3; found 532.4; LC-MS  $t_{\text{R}}$ : 3.74 min.  
56  
57  
58  
59  
60

**4-(2-((6-Chloropyridin-3-yl)methoxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one**

(16). 1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (7) (200 mg, 0.70 mmol) was alkylated with 2-chloro-5-(chloromethyl)pyridine (125 mg, 0.77 mmol) according to General Procedure B. After a total of 40 h of stirring the mixture was worked up. Purification by FCC (eluent MeOH/DCM 0:100 to 8:92) gave 181 mg of a yellow oil (63%). <sup>1</sup>H NMR δ 8.48 (d, *J* = 1.9 Hz, 1H), 7.89 (dd, *J* = 8.2/2.5 Hz, 1H), 7.67 (d, *J* = 7.2 Hz, 1H), 7.54 (dd, *J* = 8.2/0.6 Hz, 1H), 7.46–7.35 (m, 2H), 7.23 (d, *J* = 7.7 Hz, 1H), 7.08 (td, *J* = 7.5/0.9 Hz, 1H), 6.48 (d, *J* = 1.9 Hz, 1H), 6.43 (dd, *J* = 7.2/2.0 Hz, 1H), 5.23 (s, 2H), 4.77 (d, *J* = 6.0 Hz, 1H), 4.54 (br s, 1H), 3.82 (br s, 1H), 2.10–1.92 (m, 1H), 1.83–1.64 (m, 3H), 1.61–1.46 (m, 1H), 1.44–1.24 (m, 3H); <sup>13</sup>C NMR δ 162.2, 155.4, 150.1, 149.4, 148.6, 139.5, 132.6, 134.7, 130.8, 130.4, 127.7, 124.7, 122.0, 118.9, 113.9, 107.4, 69.7, 67.1, 35.9, 31.5, 25.5, 24.5; resonance at δ 134.7 ppm was taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>23</sub>H<sub>24</sub>ClN<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 411.1; found 411.2; LC-MS *t*<sub>R</sub>: 3.74 min.

**1-(2-Hydroxycyclohexyl)-4-(2-((6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methoxy)phenyl)pyridin-2(1H)-one (17).** 4-(2-((6-Chloropyridin-3-yl)methoxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (16) (145 mg, 353 μmol) was coupled to 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (110 mg, 529 μmol) according to General Procedure A. Purification by FCC (eluent MeOH/DCM 0:100 to 8:92) gave 51 mg of a white solid (32%). <sup>1</sup>H NMR δ 8.56 (d, *J* = 1.7 Hz, 1H), 8.28 (s, 1H), 8.00 (d, *J* = 0.6 Hz, 1H), 7.79 (dd, *J* = 8.2/2.3 Hz, 1H), 7.71–7.61 (m, 2H), 7.44–7.35 (m, 2H), 7.26 (d, *J* = 7.9 Hz, 1H), 7.07 (td, *J* = 7.5/0.8 Hz, 1H), 6.52 (d, *J* = 1.9 Hz, 1H), 6.44 (dd, *J* = 7.2/2.0 Hz, 1H), 5.19 (s, 2H), 4.78 (d, *J* = 6.0 Hz, 1H), 4.55 (br s, 1H), 3.89 (s, 3H), 3.80 (br s, 1H), 2.06–1.96 (m, 1H), 1.79–1.64 (m, 3H), 1.63–1.41 (m, 1H), 1.41–1.22 (m, 3H); <sup>13</sup>C NMR δ 162.2, 155.6, 151.8, 149.2, 148.7, 137.6, 136.9, 134.7, 130.8, 130.4, 130.1, 129.8, 127.6, 123.0, 121.8, 119.4, 118.9, 114.0, 107.3, 69.7, 68.0, 39.2,

35.9, 31.5, 25.5, 24.5; resonance at  $\delta$  134.7 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>27</sub>H<sub>29</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 457.2; found 457.3; LC-MS  $t_R$ : 3.34 min.

**4-(2-((4-Bromo-2-fluorobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one**

**(18).** 1-(2-Hydroxycyclohexyl)-4-(2-hydroxyphenyl)pyridin-2(1H)-one (**7**) (300 mg, 1.05 mmol) was alkylated with 4-bromo-1-(bromomethyl)-2-fluorobenzene (310 mg, 1.16 mmol) according to General Procedure B. After a total of 64 h of stirring the mixture was worked up. Purification by FCC (eluent MeOH/DCM 0:100 to 6:94) gave 310 mg of a yellow oil (62%). <sup>1</sup>H NMR  $\delta$  7.65 (d,  $J$  = 7.2 Hz, 1H), 7.63–7.57 (m, 1H), 7.49–7.36 (m, 4H), 7.24 (d,  $J$  = 7.8 Hz, 1H), 7.08 (td,  $J$  = 7.5/0.9 Hz, 1H), 6.47 (d,  $J$  = 1.9 Hz, 1H), 6.40 (dd,  $J$  = 7.2/2.0 Hz, 1H), 5.19 (s, 2H), 4.76 (d,  $J$  = 5.9 Hz, 1H), 4.53 (br s, 1H), 3.84 (br s, 1H), 2.06–1.94 (m, 1H), 1.78–1.64 (m, 3H), 1.62–1.43 (m, 1H), 1.41–1.24 (m, 3H); <sup>13</sup>C NMR  $\delta$  162.2, 161.8, 160.5 (d,  $J_{CF}$  = 252 Hz), 148.6, 134.8, 132.2 (d,  $J_{CF}$  = 4.7 Hz), 130.8, 130.4, 128.2 (d,  $J_{CF}$  = 3.5 Hz), 127.6, 127.6, 123.9 (d,  $J_{CF}$  = 14.5 Hz), 122.1, 122.0, 119.3 (d,  $J_{CF}$  = 24.7 Hz), 118.9, 113.8, 107.3, 69.6, 64.1 (d,  $J_{CF}$  = 3.1 Hz), 35.9, 31.5, 25.5, 24.5; resonance at  $\delta$  134.8 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>24</sub>H<sub>24</sub>BrFNO<sub>3</sub> [M+H]<sup>+</sup> calcd 472.1; found 472.2; LC-MS  $t_R$ : 3.79 min.

**4-(2-((2-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-**

**hydroxycyclohexyl)pyridin-2(1H)-one (19).** 4-(2-((4-Bromo-2-fluorobenzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (**18**) (150 mg, 318  $\mu$ mol) was coupled to 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (99 mg, 476  $\mu$ mol) according to General Procedure A. Purification by FCC (eluent MeOH/DCM 0:100 to 8:92), followed freeze drying of the combined product fractions to remove the remaining pinacol, gave 45 mg of a white solid (30%). <sup>1</sup>H NMR  $\delta$  8.22 (s, 1H), 7.94 (s, 1H), 7.64 (d,  $J$  = 7.2 Hz, 1H), 7.51–7.36 (m, 5H), 7.27 (d,  $J$  = 8.2 Hz, 1H), 7.07 (t,  $J$  = 7.4 Hz, 1H), 6.49 (d,  $J$  = 1.6 Hz, 1H), 6.41 (dd,  $J$  = 7.2/1.8 Hz, 1H), 5.19 (s, 2H), 4.74 (d,  $J$  = 6.0 Hz, 1H), 4.52 (br s, 1H), 3.87 (s, 3H), 3.78 (br s, 1H), 2.04–1.92 (m, 1H), 1.79–1.62 (m, 3H), 1.60–1.39 (m, 1H), 1.39–1.19 (m, 3H); <sup>13</sup>C NMR  $\delta$  162.2, 161.3 (d,  $J_{CF}$  = 246

1  
2  
3 Hz), 155.7, 148.6, 136.9, 135.6 (d,  $J_{CF} = 10.0$  Hz), 134.6, 131.4 (d,  $J_{CF} = 4.7$  Hz), 130.8, 130.4,  
4  
5 128.9, 121.8, 121.2, 121.1, 121.0 (d,  $J_{CF} = 2.2$  Hz), 118.9, 113.8, 112.0 (d,  $J_{CF} = 4.7$  Hz), 107.2,  
6  
7 69.6, 64.5, 39.2, 35.9, 31.3, 25.5, 24.4; resonances at  $\delta$  134.6 ppm and 31.3 ppm were taken from  
8  
9 the HSQC experiment;  $m/z$  MS (TOF ES<sup>+</sup>) C<sub>28</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 474.2; found 474.3; LC-MS  
10  
11  $t_R$ : 3.55 min.

12  
13  
14 **4-(3,6-Difluoro-2-methoxyphenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (20).** 4-  
15  
16 Bromo-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (**4b**) (1.00 g, 3.67 mmol) was coupled to (3,6-  
17  
18 difluoro-2-methoxyphenyl)boronic acid (1.04 g, 5.51 mmol) according to General Procedure A.  
19  
20 The reaction was stirred for 5 h before work up. Purification by FCC (eluent MeOH/DCM 0:100 to  
21  
22 10:90) and (eluent EtOAc 100%) gave 285 mg of the desired compound as a white solid (23%) in a  
23  
24 1:1 mixture of the desired product and an unidentified impurity. <sup>1</sup>H NMR  $\delta$  7.77 (d,  $J = 7.2$  Hz,  
25  
26 1H), 7.41 (ddd,  $J = 11.3/9.3/5.3$  Hz, 1H), 7.11 (td,  $J = 9.2/3.9$  Hz, 1H), 6.39 (s, 1H), 6.26–6.20 (m,  
27  
28 1H), 4.82 (d,  $J = 6.1$  Hz, 1H), 4.55 (br s, 1H), 3.82 (d,  $J = 1.9$  Hz, 3H), 3.75 (br s, 1H), 2.06–1.90  
29  
30 (m, 1H), 1.81–1.64 (m, 3H), 1.62–1.46 (m, 1H), 1.42–1.21 (m, 3H).

31  
32  
33  
34  
35  
36 **4-(3,6-Difluoro-2-hydroxyphenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (21).** Boron  
37  
38 tribromide in hexane (1 M, 3.88 mL, 3.88 mmol) was added at 0 °C to a solution of 4-(3,6-difluoro-  
39  
40 2-methoxyphenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one (**20**) (260 mg, 775  $\mu$ mol) (1:1  
41  
42 mixture with unidentified impurity) in dichloromethane (8 mL). The mixture was stirred at rt under  
43  
44 N<sub>2</sub> for 1 h, and then poured into ice-water. The pH of the solution was adjusted to pH 6 by addition  
45  
46 of sat. NaHCO<sub>3</sub>. Dichloromethane (20 mL) was added and the layers were separated. The organic  
47  
48 layer was washed with water (2  $\times$  20 mL) and brine (20 mL) and then dried with Na<sub>2</sub>SO<sub>4</sub>, filtered  
49  
50 and the solvent was evaporated under reduced pressure. The desired compound was obtained as a  
51  
52 white solid (89 mg, 72%). No further purification was required. <sup>1</sup>H NMR  $\delta$  10.33 (br s, 1H), 7.73  
53  
54 (d,  $J = 7.2$  Hz, 1H), 7.27 (ddd,  $J = 10.4/9.2/5.3$  Hz, 1H), 6.78 (td,  $J = 9.3/3.8$  Hz, 1H), 6.38 (s, 1H),  
55  
56 6.27–6.20 (m, 1H), 4.80 (d,  $J = 6.0$  Hz, 1H), 4.51 (br s, 1H), 3.81 (br s, 1H), 2.07–1.95 (m, 1H),  
57  
58  
59  
60

1  
2  
3 1.82–1.66 (m, 3H), 1.63–1.45 (m, 1H), 1.43–1.25 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.0, 155.8 (dd,  $J_{\text{CF}} =$   
4 240.9/1.6 Hz), 148.8 (dd,  $J_{\text{CF}} = 234.9/2.7$  Hz), 143.6 (dd,  $J_{\text{CF}} = 17.1/7.0$  Hz), 142.0 (d,  $J_{\text{CF}} = 2.1$   
5 Hz), 135.1, 121.1, 117.0 (dd,  $J_{\text{CF}} = 19.0/2.8$  Hz), 116.4 (dd,  $J_{\text{CF}} = 21.1/11.0$  Hz), 107.9, 106.2 (dd,  
6  $J_{\text{CF}} = 25.5/7.3$  Hz), 69.6, 35.9, 31.5, 25.5, 24.5; resonance at  $\delta$  135.1 ppm was taken from the  
7 HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{17}\text{H}_{18}\text{F}_2\text{NO}_3$   $[\text{M}+\text{H}]^+$  calcd 322.1; found 322.1; LC-MS  
8  $t_{\text{R}}$ : 3.35 min.  
9  
10  
11  
12  
13  
14  
15  
16

17 **4-(2-((4-Bromobenzyl)oxy)-3,6-difluorophenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one**  
18  
19 **(22)**. 4-(3,6-Difluoro-2-hydroxyphenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one **(21)** (75 mg,  
20 233  $\mu\text{mol}$ , 1.0 eq),  $\text{K}_2\text{CO}_3$  (36 mg, 257  $\mu\text{mol}$ , 1.1 eq), KI (4 mg, 23  $\mu\text{mol}$ , 0.1 eq) and 1-bromo-4-  
21 (bromomethyl)benzene (64 mg, 257 mmol, 1.1 eq) were stirred in DMF (3 mL) at rt for 3 h. The  
22 reaction mixture was poured onto water and stirred for 30 min, before extraction with EtOAc (2  $\times$   
23 20 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried  
24 with  $\text{Na}_2\text{SO}_4$ , filtered and the solvent was removed under reduced pressure. Purification by FCC  
25 (eluent MeOH/DCM 0:100 to 10:90) gave 83 mg of the desired product as a white solid (73%).  $^1\text{H}$   
26 NMR  $\delta$  7.75 (d,  $J = 7.2$  Hz, 1H), 7.51–7.46 (m, 2H), 7.46–7.39 (m, 1H), 7.18–7.10 (m, 3H), 6.40–  
27 6.30 (m, 1H), 6.24–6.16 (m, 1H), 4.96 (s, 2H), 4.83 (d,  $J = 6.0$  Hz, 1H), 4.56 (br s, 1H), 3.86 (br s,  
28 1H), 2.11 – 1.97 (m, 1H), 1.83–1.67 (m, 3H), 1.67–1.48 (m, 1H), 1.44–1.29 (m, 3H);  $^{13}\text{C}$  NMR  
29 (101 MHz, DMSO)  $\delta$  161.7, 155.2 (dd,  $J_{\text{CF}} = 242.8/1.9$  Hz), 152.4 (dd,  $J_{\text{CF}} = 242.1/3.0$  Hz), 144.1  
30 (dd,  $J_{\text{CF}} = 13.4/5.8$  Hz), 141.5 (d,  $J_{\text{CF}} = 2.0$  Hz), 135.9, 135.5, 131.7, 130.8, 122.7 (dd,  $J_{\text{CF}} =$   
31 18.5/2.3 Hz), 122.0, 121.1, 117.8 (dd,  $J_{\text{CF}} = 21.8/10.6$  Hz), 112.0 (dd,  $J_{\text{CF}} = 25.1/8.1$  Hz), 107.6,  
32 75.3 (d,  $J = 5.3$  Hz), 69.7, 35.8, 31.5, 25.5, 24.5; resonance at  $\delta$  135.5 ppm was taken from the  
33 HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{24}\text{H}_{23}\text{BrF}_2\text{NO}_3$   $[\text{M}+\text{H}]^+$  calcd 490.1; found 490.2; LC-MS  
34  $t_{\text{R}}$ : 3.79 min.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 **4-(3,6-Difluoro-2-((4-(1-methyl-1H-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-**  
57 **hydroxycyclohexyl)pyridin-2(1H)-one (23)**. 4-(2-((4-Bromobenzyl)oxy)-3,6-difluorophenyl)-1-  
58  
59  
60

(2-hydroxycyclohexyl)pyridin-2(1*H*)-one (**22**) (77 mg, 157  $\mu$ mol) was coupled to 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (49 mg, 236  $\mu$ mol) according to General Procedure A. The reaction was stirred at reflux for 2 h before work up. Purification by FCC (eluent MeOH/DCM 0:100 to 10:90) gave 24 mg of a white solid (31%).  $^1\text{H}$  NMR  $\delta$  8.11 (s, 1H), 7.83 (d,  $J = 0.6$  Hz, 1H), 7.74 (d,  $J = 7.2$  Hz, 1H), 7.50–7.45 (m, 2H), 7.45–7.39 (m, 1H), 7.18–7.11 (m, 3H), 6.37 (d,  $J = 1.6$  Hz, 1H), 6.26–6.15 (m, 1H), 4.94 (s, 2H), 4.83 (d,  $J = 6.0$  Hz, 1H), 4.60 (br s, 1H), 3.86 (s, 3H), 3.81 (br s, 1H), 2.11–1.99 (m, 1H), 1.86–1.68 (m, 3H), 1.65–1.47 (m, 1H), 1.45–1.28 (m, 3H);  $^{13}\text{C}$  NMR  $\delta$  161.7, 155.2 (dd,  $J_{\text{CF}} = 243.1/2.0$  Hz), 152.5 (dd,  $J_{\text{CF}} = 242.0/2.9$  Hz), 144.2 (dd,  $J_{\text{CF}} = 13.6/5.9$  Hz), 141.6, 136.5, 135.4, 133.9, 133.1, 129.5, 128.4, 125.2, 122.8 (dd,  $J_{\text{CF}} = 18.2/2.2$  Hz), 121.9, 121.1, 117.7 (dd,  $J_{\text{CF}} = 21.8/10.3$  Hz), 111.9 (dd,  $J_{\text{CF}} = 25.1/8.1$  Hz), 107.6, 76.0 (d,  $J_{\text{CF}} = 5.0$  Hz), 69.7, 39.1, 35.9, 31.6, 25.5, 24.5; resonance at  $\delta$  135.4 ppm was taken from the HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{28}\text{H}_{28}\text{F}_2\text{N}_3\text{O}_3$   $[\text{M}+\text{H}]^+$  calcd 492.2; found 492.3; LC-MS  $t_{\text{R}}$ : 3.59 min.

**6-(2-Methoxyphenyl)pyrimidin-4(3*H*)-one (25).** 6-Chloropyrimidin-4(3*H*)-one (**24**) (1.00 g, 7.66 mmol) was coupled to (2-methoxyphenyl)boronic acid (1.85 g, 11.5 mmol) according to General Procedure A. The reaction was stirred for 48 h before work up. Purification by FCC (eluent MeOH/DCM 0:100 to 10:90) gave 315 mg of a white solid (20%).  $^1\text{H}$  NMR  $\delta$  12.48 (br s, 1H), 8.24 (d,  $J = 1.0$  Hz, 1H), 7.92 (dd,  $J = 7.8/1.8$  Hz, 1H), 7.50–7.40 (m, 1H), 7.21–7.13 (m, 1H), 7.06 (td,  $J = 7.7/1.0$  Hz, 1H), 6.90 (d,  $J = 1.0$  Hz, 1H), 3.87 (s, 3H);  $^{13}\text{C}$  NMR  $\delta$  162.0, 159.1, 158.1, 149.6, 131.9, 130.7, 125.4, 120.9, 115.0, 112.5, 56.1;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{11}\text{H}_{11}\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$  calcd 203.2; found 203.1; LC-MS  $t_{\text{R}}$ : 3.25 min.

**3-(2-Hydroxycyclohexyl)-6-(2-methoxyphenyl)pyrimidin-4(3*H*)-one (26).** A mixture of 6-(2-methoxyphenyl)pyrimidin-4(3*H*)-one (**25**) (274 mg, 1.36 mmol, 1.0 eq), 1,2-cyclohexene oxide (686  $\mu$ L, 6.78 mmol, 5.0 eq),  $\text{K}_2\text{CO}_3$  (468 mg, 3.39 mmol, 2.5 eq) was heated at 120  $^\circ\text{C}$  for 5 h. The reaction mixture was cooled to rt and concentrated to dryness under reduced pressure. The

1  
2  
3 remaining residue was taken up in EtOAc (50 mL) and washed with water. The organic layer was  
4  
5 dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was removed under reduced pressure. Purification by  
6  
7 FCC (eluent MeOH/DCM 0:100 to 10:90) and FCC eluent MeOH/DCM 0:100 to 6:94) yielded  
8  
9 153 mg of the desired compound as a colourless oil (38%). <sup>1</sup>H NMR δ 8.54 (br s, 1H), 7.95 (dd, *J* =  
10  
11 7.8/1.8 Hz, 1H), 7.68–7.53 (m, 1H), 7.16 (dd, *J* = 8.4/0.7 Hz, 1H), 7.07 (td, *J* = 7.7/1.0 Hz, 1H),  
12  
13 6.96 (d, *J* = 0.4 Hz, 1H), 4.98 (d, *J* = 5.7 Hz, 1H), 4.33 (br s, 1H), 3.97 (br s, 1H), 3.88 (s, 3H),  
14  
15 2.08–1.97 (m, 1H), 1.84–1.61 (m, 4H), 1.40–1.22 (m, 3H); <sup>13</sup>C NMR δ 161.5, 158.1, 157.0, 150.1,  
16  
17 131.8, 130.6, 125.2, 120.9, 113.9, 112.5, 69.2, 56.1, 35.7, 31.0, 25.4, 24.4; resonances at δ 150.1  
18  
19 and 31.0 ppm were taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>17</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup>  
20  
21 calcd 301.2; found 301.2; LC-MS *t*<sub>R</sub>: 3.42 min.  
22  
23  
24  
25

26 **3-(2-Hydroxycyclohexyl)-6-(2-hydroxyphenyl)pyrimidin-4(3H)-one (27)**. A 1 M solution  
27  
28 boron tribromide in hexane (2.37 mL, 2.37 mmol, 5.0 eq) was added at 0 °C to a solution of 3-(2-  
29  
30 hydroxycyclohexyl)-6-(2-methoxyphenyl)pyrimidin-4(3H)-one (**26**) (90 mg, 475 μmol, 1.0 eq) in  
31  
32 dichloromethane (4 mL). The mixture was stirred at rt under N<sub>2</sub> for 30 min, and then poured into  
33  
34 ice-water. The pH of the solution was adjusted to pH 6 by addition of sat. NaHCO<sub>3</sub>.  
35  
36 Dichloromethane (20 mL) was added and the layers were separated. The organic layer was washed  
37  
38 with water (2 × 20 mL) and brine (20 mL) and then dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was  
39  
40 evaporated under reduced pressure. The desired compound was obtained as a white solid (75 mg,  
41  
42 87%). No further purification was required. <sup>1</sup>H NMR δ 12.80–10.80 (br s, 1H), 8.61 (br s, 1H),  
43  
44 7.84 (dd, *J* = 7.9/1.6 Hz, 1H), 7.24 (ddd, *J* = 8.5/7.2/1.6 Hz, 1H), 6.99 (s, 1H), 6.87–6.77 (m, 2H),  
45  
46 4.78 (s, 1H), 4.25 (br s, 1H), 3.92–3.77 (br s, 1H), 1.96–1.88 (m, 1H), 1.79–1.53 (m, 4H), 1.31–1.16  
47  
48 (m, 3H); <sup>13</sup>C NMR δ 161.1, 158.8, 158.5, 150.4, 132.8, 128.8, 119.8, 118.2, 118.2, 109.3, 69.2,  
49  
50 35.6, 30.8, 25.4, 24.4; resonances at δ 150.4, 69.2 and 30.8 ppm were taken from the HSQC  
51  
52 experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>16</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 287.1; found 287.2; LC-MS *t*<sub>R</sub>: 3.46  
53  
54 min.  
55  
56  
57  
58  
59  
60



1  
2  
3 **6-(2-((4-Bromobenzyl)oxy)phenyl)-3-(2-hydroxycyclohexyl)pyrimidin-4(3H)-one (28).** 3-(2-  
4 Hydroxycyclohexyl)-6-(2-hydroxyphenyl)pyrimidin-4(3H)-one (**27**) (76 mg, 265  $\mu\text{mol}$ , 1.0 eq),  
5  $\text{K}_2\text{CO}_3$  (40 mg, 292  $\mu\text{mol}$ , 1.1 eq), KI (4 mg, 27  $\mu\text{mol}$ , 0.1 eq) and 1-bromo-4-  
6 (bromomethyl)benzene (73 mg, 292 mmol, 1.1 eq) were stirred in DMF (3 mL) at rt for 4 h. The  
7 reaction mixture was poured onto water and stirred for 30 min, before extraction with EtOAc (2  $\times$   
8 20 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried  
9 with  $\text{Na}_2\text{SO}_4$ , filtered and the solvent was removed under reduced pressure. Purification by FCC  
10 (eluent MeOH/DCM 0:100 to 10:90) gave 66 mg of the desired product as a beige solid (55%).  $^1\text{H}$   
11 NMR  $\delta$  8.54 (s, 1H), 7.96 (dd,  $J = 7.8/1.8$  Hz, 1H), 7.62–7.58 (m, 2H), 7.47–7.39 (m, 3H), 7.21 (d,  
12  $J = 7.7$  Hz, 1H), 7.12–7.06 (m, 1H), 6.98 (d,  $J = 0.6$  Hz, 1H), 5.24 (s, 2H), 4.96 (d,  $J = 5.8$  Hz, 1H),  
13 4.27 (br s, 1H), 3.95 (br s, 1H), 2.06–1.95 (m, 1H), 1.85–1.62 (m, 4H), 1.40–1.23 (m, 3H);  
14  $^{13}\text{C}$  NMR  $\delta$  161.4, 157.0, 156.9, 150.1, 136.7, 131.9, 131.4, 130.8, 130.2, 125.6, 121.5, 121.3,  
15 114.0, 113.9, 69.5, 69.1, 35.7, 31.0, 25.4, 24.4; resonances at  $\delta$  150.1, 69.1 and 31.0 ppm were  
16 taken from the HSQC experiment;  $m/z$  MS (TOF ES $^+$ )  $\text{C}_{23}\text{H}_{24}\text{BrN}_2\text{O}_3$   $[\text{M}+\text{H}]^+$  calcd 455.1; found  
17 455.2; LC-MS  $t_{\text{R}}$ : 3.77 min.

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37 **3-(2-Hydroxycyclohexyl)-6-(2-((4-(1-methyl-1H-pyrazol-4-yl)benzyl)oxy)phenyl)pyrimidin-**  
38 **4(3H)-one (29).** 6-(2-((4-Bromobenzyl)oxy)phenyl)-3-(2-hydroxycyclohexyl)pyrimidin-4(3H)-one  
39 (**28**) (66 mg, 145  $\mu\text{mol}$ ) was coupled to 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-  
40 1H-pyrazole (45 mg, 217  $\mu\text{mol}$ ) according to General Procedure A. The reaction was stirred at  
41 reflux for 25 h before the work up. Purification by FCC (eluent MeOH/DCM 0:100 to 8:92) gave 7  
42 mg of a white solid (11%).  $^1\text{H}$  NMR  $\delta$  8.54 (br s, 1H), 8.15 (s, 1H), 7.99 (dd,  $J = 7.8/1.8$  Hz, 1H),  
43 7.87 (d,  $J = 0.7$  Hz, 1H), 7.61–7.56 (m, 2H), 7.48–7.40 (m, 3H), 7.26 (d,  $J = 7.8$  Hz, 1H), 7.13–7.06  
44 (m, 1H), 7.05 (t,  $J = 3.1$  Hz, 1H), 5.24 (s, 2H), 4.95 (d,  $J = 5.7$  Hz, 1H), 4.39–4.22 (m, 1H), 3.99–  
45 3.91 (m, 1H), 3.87 (br s, 3H), 2.06–2.00 (m, 1H), 1.88–1.63 (m, 4H), 1.37–1.28 (m, 3H);  $^{13}\text{C}$  NMR  
46  $\delta$  161.4, 157.2, 156.9, 150.1, 136.5, 134.6, 132.8, 131.7, 130.8, 128.7, 128.3, 125.5, 122.0, 121.2,  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 120.8, 114.0, 113.9, 68.9, 39.1, 35.7, 29.4, 25.4, 21.2; resonances at  $\delta$  150.1, 114.0 and 69.9 ppm  
4  
5 were taken from the HSQC experiment; *m/z* MS (TOF ES<sup>+</sup>) C<sub>27</sub>H<sub>29</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> calcd 457.2;  
6  
7 found 457.3; LC-MS *t*<sub>R</sub>: 3.53 min.  
8  
9

10  
11  
12  
13 **Pharmacology.** *Intact cell radioligand binding assays.* Flp-In<sup>TM</sup> Chinese hamster ovary (CHO)  
14 cells expressing the human muscarinic acetylcholine M<sub>1-5</sub> receptor (hM<sub>1-5</sub> mAChR) were grown in  
15 Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with  
16 foetal bovine serum (FBS) (ThermoTrace (Melbourne, Australia) and 0.2 mg/mL hygromycin-B  
17 (Roche, Mannheim, Germany). The cells were plated at 10<sup>4</sup> cells per well in 96-well Isoplates  
18 (Perkin Elmer). Prior to assay the growth medium was removed and the attached cells were used to  
19 perform radioligand binding studies in the presence of 0.2 nM [<sup>3</sup>H]NMS and varying concentrations  
20 of acetylcholine (Sigma, St. Louis, MI) and PAMs in a total volume of 200  $\mu$ L of binding buffer (10  
21 mM HEPES, 145 mM NaCl, 1 mM MgSO<sub>4</sub>·7H<sub>2</sub>O, 10 mM glucose, 5 mM KCl, 2 mM CaCl<sub>2</sub>, 1.5  
22 mM NaHCO<sub>3</sub>, pH 7.4). The binding reaction mixtures were incubated for 1 h at 37°C, in a  
23 humidified incubator and terminated by rapid removal of radioligand followed by two 100  $\mu$ L-  
24 washes with ice-cold 0.9% NaCl buffer. Radioactivity was determined by addition of 100  $\mu$ L  
25 Microscint scintillation liquid (PerkinElmer Life Sciences) to each well and counting in a  
26 MicroBeta plate reader (PerkinElmer Life Sciences).  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45  
46 *IP-One accumulation assays.* The IP-One assay kit (Cisbio, France) was used for the direct  
47 quantitative measurement of myo-Inositol 1 phosphate (IP<sub>1</sub>) in FlpIn CHO cells stably expressing  
48 the hM<sub>1</sub> mAChR. The cells were detached and resuspended in IP<sub>1</sub> stimulation buffer (10 mM  
49 HEPES, 1 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub>, 4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose, 50 mM LiCl,  
50 pH 7.4). The stimulations were performed in 384-well Proxy-plates (PerkinElmer) in a total volume  
51 of 14  $\mu$ L, in the absence or presence of increasing concentrations of ACh and the PAMs, at cell  
52 density of 10<sup>6</sup> million cells/ml for 1 h at 37 °C, 5% CO<sub>2</sub>. The reactions were terminated by addition  
53  
54  
55  
56  
57  
58  
59  
60

of 6  $\mu\text{L}$  lysis buffer containing HTRF reagents (the anti-IP1 Tb cryptate conjugate and the IP1-D2 conjugate), followed by incubation for 1 h at room temperature. The emission signals were measured at 590 and 665 nm after excitation at 340 nm using an Envision multi-label plate reader (PerkinElmer) and the signal was expressed as the HTRF ratio:  $F = ((\text{fluorescence}_{665 \text{ nm}} / \text{fluorescence}_{590 \text{ nm}}) \times 10^4)$ .

*Data Analysis.* All data were analyzed using Prism 6.01 (GraphPad Software, San Diego, CA). Binding-interaction studies with allosteric ligands were fitted to the following allosteric ternary complex model (equation 1):<sup>39</sup>

$$Y = \frac{B_{\text{max}}[A]}{[A] + \left( \frac{K_A K_B}{\alpha' [B] + K_B} \right) \left( 1 + \frac{[I]}{K_I} + \frac{[B]}{K_B} + \frac{\alpha [I][B]}{K_I K_B} \right)} \quad (1)$$

Where Y is percentage (vehicle control) binding,  $B_{\text{max}}$  is the total number of receptors, [A], [B] and [I] are the concentrations of radioligand, allosteric modulator and the orthosteric ligand, respectively,  $K_A$  and  $K_B$  and  $K_I$  are the equilibrium dissociation constants of the radioligand, allosteric modulator orthosteric ligand, respectively.  $\alpha'$  and  $\alpha$  are the binding cooperativities between the allosteric ligand and [<sup>3</sup>H]NMS and the allosteric modulator and the agonist acetylcholine, respectively. Saturation binding experiments were used to determine the value of  $pK_A$  for [<sup>3</sup>H]NMS ( $pK_A = 9.70 \pm 0.01$ ,  $K_A = 0.2 \text{ nM}$ ). Values of  $\alpha$  (or  $\alpha'$ ) > 1 denote positive cooperativity; values < 1 (but > 0) denote negative cooperativity, and value = 1 denotes neutral cooperativity. For the majority of compounds an unlimited displacement of [<sup>3</sup>H]NMS by the allosteric modulator was observed consistent with a high level of negative cooperativity. In these cases to allow fitting of the data  $\log \alpha'$  was fixed to -3 to reflect this high negative cooperativity. The dissociation constant of ACh ( $K_I$ ) was not fixed in these analyses but rather determined for each separate experiment. No difference was observed in the value of  $K_I$  between experiments (mean  $pK_I = 4.56 \pm 0.02$ ,  $K_I = 28 \mu\text{M}$ ).

Concentration-response curves for the interaction between the allosteric ligand and the orthosteric ligand in the IP-One accumulation assays were globally fitted to the following operational model of allosterism and agonism (equation 2):<sup>40</sup>

$$E = \frac{E_m(\tau_A[A](K_B + \alpha\beta[B]) + \tau_B[B]K_A)^n}{([A]K_B + K_A K_B + [B]K_A + \alpha[A][B])^n + (\tau_A[A](K_B + \alpha\beta[B]) + \tau_B[B]K_A)^n} \quad (2)$$

Where  $E_m$  is the maximum possible cellular response, [A] and [B] are the concentrations of orthosteric and allosteric ligands, respectively,  $K_A$  and  $K_B$  are the equilibrium dissociation constant of the orthosteric and allosteric ligands, respectively,  $\tau_A$  and  $\tau_B$  are operational measures of orthosteric and allosteric ligand efficacy, respectively,  $\alpha$  is the binding cooperativity parameter between the orthosteric and allosteric ligand,  $\beta$  denotes the magnitude of the allosteric effect of the modulator on the efficacy of the orthosteric agonist and  $n$  denotes the transducer slope that describes the underlying stimulus-response coupling of the ligand-occupied receptor to the signal pathway. This parameter was constrained to be shared between all curves within a fitted dataset for each interaction study, and in all instances was not significantly different from unity (average across entire series,  $n = 1.04 \pm 0.04$ ). In many instances, the individual model parameters of equation 2 could not be directly estimated via the nonlinear regression algorithm by analysis of the functional data alone due to parameter redundancy. To facilitate model convergence, therefore, we fixed the equilibrium dissociation constant of each ligand to that determined from the whole cell binding assays. For compounds **9c**, **15h** and **17**, no agonism was observed and therefore  $\log\tau_B$  was fixed to -3.

All affinity, potency, and cooperativity values were estimated as logarithms and statistical comparisons between values were by one-way analysis of variance using a Dunnett's multiple comparison post test to determine significant differences between mutant receptors and the WT M<sub>1</sub> mAChR. A value of  $p < 0.05$  was considered statistically significant.

**■ ASSOCIATED CONTENT****Supporting Information**

The provided document comprises of representative NMR experiments of the compound **8p** in  $d_6$ -DMSO and  $CDCl_3$ .

**■ AUTHOR INFORMATION****Corresponding Author**

\*For P.J.S.: phone: +61 (0)3 9903 9542; E-mail: Peter.Scammells@monash.edu. For J.R.L. : +61 (0)3 9903 9095; E-Mail: Rob.Lane@monash.edu

**Author Contributions**

§These authors contributed equally to this work.

The manuscript was written through contributions of all authors and all authors have given approval to the final version of the manuscript.

**Notes**

#Current address: School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

The authors declare no competing financial interest.

**■ ACKNOWLEDGMENT**

This research was supported by Discovery grant DP110100687 of the Australian Research Council as well as Program grant APP1055134 and Project grant APP1049564 of the National Health and Medicinal Research Council (NHMRC) of Australia. J.R.L. is a R.D. Wright

1  
2  
3 Biomedical Career Development Fellow and a Larkin's Fellow (Monash University, Australia)  
4 while A.C. is Senior Principal Research Fellow and P.M.S. is a Principal Research Fellow of the  
5  
6  
7 NHMRC.  
8  
9

## 10 11 ■ ABBREVIATIONS

12  
13 ACh, acetylcholine; AD, Alzheimer's disease, Boc, *tert*-Butyloxycarbonyl; cat, catalytic; DCM,  
14 dichloromethane; DMF, dimethylformamide; eq, equivalent; EtOAc, ethyl acetate; FCC, flash  
15 column chromatography; M<sub>1</sub> mAChR, M<sub>1</sub> muscarinic acetylcholine receptor; PE, petroleum spirits  
16 40-60; rt, room temperature; SZ, schizophrenia; THF, tetrahydrofuran.  
17  
18  
19  
20  
21  
22  
23  
24

## 25 ■ REFERENCES

- 26  
27 (1) Langmead, C. J.; Watson, J.; Reavill, C. Muscarinic acetylcholine receptors as CNS drug  
28 targets. *Pharmacol. Ther.* **2008**, *117*, 232-243.  
29  
30  
31 (2) Conn, P. J.; Jones, C. K.; Lindsley, C. W. Subtype-selective allosteric modulators of  
32 muscarinic receptors for the treatment of CNS disorders. *Trends Pharmacol. Sci.* **2009**, *30*, 148-  
33 155.  
34  
35  
36 (3) Dean, B.; McLeod, M.; Keriakous, D.; McKenzie, J.; Scarr, E. Decreased muscarinic  
37 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. *Mol. Psychiatry* **2002**,  
38 7, 1083-1091.  
39  
40  
41 (4) Scarr, E.; Dean, B. Muscarinic receptors: do they have a role in the pathology and  
42 treatment of schizophrenia? *J. Neurochem.* **2008**, *107*, 1188-1195.  
43  
44  
45 (5) Medeiros, R.; Kitazawa, M.; Caccamo, A.; Baglietto-Vargas, D.; Estrada-Hernandez, T.;  
46 Cribbs, D. H.; Fisher, A.; LaFerla, F. M. Loss of muscarinic M1 receptor exacerbates Alzheimer's  
47 disease-like pathology and cognitive decline. *Am. J. Pathol.* **2011**, *179*, 980-991.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (6) Anagnostaras, S. G.; Murphy, G. G.; Hamilton, S. E.; Mitchell, S. L.; Rahnama, N. P.;  
4  
5 Nathanson, N. M.; Silva, A. J. Selective cognitive dysfunction in acetylcholine M1 muscarinic  
6  
7 receptor mutant mice. *Nat. Neurosci.* **2003**, *6*, 51-58.

9  
10 (7) Langmead, C. J.; Austin, N. E.; Branch, C. L.; Brown, J. T.; Buchanan, K. A.; Davies, C.  
11  
12 H.; Forbes, I. T.; Fry, V. A. H.; Hagan, J. J.; Herdon, H. J.; Jones, G. A.; Jeggo, R.; Kew, J. N. C.;  
13  
14 Mazzali, A.; Melarange, R.; Patel, N.; Pardoe, J.; Randall, A. D.; Roberts, C.; Roopun, A.; Starr, K.  
15  
16 R.; Teriakidis, A.; Wood, M. D.; Whittington, M.; Wu, Z.; Watson, J. Characterization of a CNS  
17  
18 penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. *Br. J. Pharmacol.* **2008**, *154*,  
19  
20 1104-1115.

21  
22 (8) Jones, C. K.; Brady, A. E.; Davis, A. A.; Xiang, Z.; Bubser, M.; Tantawy, M. N.; Kane, A.  
23  
24 S.; Bridges, T. M.; Kennedy, J. P.; Bradley, S. R.; Peterson, T. E.; Ansari, M. S.; Baldwin, R. M.;  
25  
26 Kessler, R. M.; Deutch, A. Y.; Lah, J. J.; Levey, A. I.; Lindsley, C. W.; Conn, P. J. Novel selective  
27  
28 allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and  
29  
30 produces antipsychotic-like activity in rats. *J. Neurosci.* **2008**, *28*, 10422-10433.

31  
32 (9) Ma, L.; Seager, M.; Wittmann, M.; Jacobson, M.; Bickel, D.; Burno, M.; Jones, K.;  
33  
34 Graufelds, V. K.; Xu, G.; Pearson, M.; McCampbell, A.; Gaspar, R.; Shughrue, P.; Danziger, A.;  
35  
36 Regan, C.; Flick, R.; Pascarella, D.; Garson, S.; Doran, S.; Kreatsoulas, C.; Veng, L.; Lindsley, C.  
37  
38 W.; Shipe, W.; Kuduk, S.; Sur, C.; Kinney, G.; Seabrook, G. R.; Ray, W. J. Selective activation of  
39  
40 the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. *Proc. Natl. Acad. Sci.*  
41  
42 *U. S. A.* **2009**, *106*, 15950-15955, S15950/1-S15950/9.

43  
44 (10) Pomara, N. Reduction in muscarinic M1-mediated hypercholinergic state and beneficial  
45  
46 cognitive effects of muscarinic agonists in schizophrenia. *Am. J. Psychiatry* **2009**, *166*, 111; author  
47  
48 reply 111-3.

49  
50 (11) Gould, R. W.; Dencker, D.; Grannan, M.; Bubser, M.; Zhan, X.; Wess, J.; Xiang, Z.;  
51  
52 Locuson, C.; Lindsley, C. W.; Conn, P. J.; Jones, C. K. Role for the M1 muscarinic acetylcholine  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice.  
4  
5 *ACS Chem. Neurosci.* **2015**, *6*, 1683-1695.

6  
7 (12) Thomsen, M.; Wess, J.; Fulton, B. S.; Fink-Jensen, A.; Caine, S. B. Modulation of  
8  
9 prepulse inhibition through both M1 and M4 muscarinic receptors in mice. *Psychopharmacology*  
10  
11 **2010**, *208*, 401-416.

12  
13 (13) Bradley, S. R.; Lamah, J.; Ohrmund, L.; Son, T.; Bajpai, A.; Nguyen, D.; Friberg, M.;  
14  
15 Burstein, E. S.; Spalding, T. A.; Ott, T. R.; Schiffer, H. H.; Tabatabaei, A.; McFarland, K.; Davis,  
16  
17 R. E.; Bonhaus, D. W. AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric  
18  
19 agonist, improves cognitive performance in an animal model. *Neuropharmacology* **2010**, *58*, 365-  
20  
21 73.

22  
23 (14) Digby, G. J.; Noetzel, M. J.; Bubser, M.; Utley, T. J.; Walker, A. G.; Byun, N. E.; Lebois,  
24  
25 E. P.; Xiang, Z.; Sheffler, D. J.; Cho, H. P.; Davis, A. A.; Nemirovsky, N. E.; Mennenga, S. E.;  
26  
27 Camp, B. W.; Bimonte-Nelson, H. A.; Bode, J.; Italiano, K.; Morrison, R.; Daniels, J. S.;  
28  
29 Niswender, C. M.; Olive, M. F.; Lindsley, C. W.; Jones, C. K.; Conn, P. J. Novel allosteric agonists  
30  
31 of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond  
32  
33 with behavioral effects in animal models. *J. Neurosci.* **2012**, *32*, 8532-8544.

34  
35 (15) Ghoshal, A.; Rook, J. M.; Dickerson, J. W.; Roop, G. N.; Morrison, R. D.; Jalan-Sakrikar,  
36  
37 N.; Lamsal, A.; Noetzel, M. J.; Poslusney, M. S.; Wood, M. R.; Melancon, B. J.; Stauffer, S. R.;  
38  
39 Xiang, Z.; Daniels, J. S.; Niswender, C. M.; Jones, C. K.; Lindsley, C. W.; Conn, P. J. Potentiation  
40  
41 of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a  
42  
43 schizophrenia mouse model. *Neuropsychopharmacology* **2015**, doi: 10.1038/npp.2015.189. [Epub  
44  
45 ahead of print]

46  
47 (16) Bodick, N. C.; Offen, W. W.; Levey, A. I.; Cutler, N. R.; Gauthier, S. G.; Satlin, A.;  
48  
49 Shannon, H. E.; Tollefson, G. D.; Rasmussen, K.; Bymaster, F. P.; Hurley, D. J.; Potter, W. Z.;  
50  
51 Paul, S. M. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function  
52  
53 and behavioral symptoms in Alzheimer disease. *Arch. Neurol.* **1997**, *54*, 465-73.  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 (17) Shekhar, A.; Potter, W. Z.; Lightfoot, J.; Lienemann, J.; Dube, S.; Mallinckrodt, C.;  
4  
5 Bymaster, F. P.; McKinzie, D. L.; Felder, C. C. Selective muscarinic receptor agonist xanomeline  
6  
7 as a novel treatment approach for schizophrenia. *Am. J. Psychiatry* **2008**, *165*, 1033-9.

8  
9  
10 (18) Massoud, F.; Gauthier, S. Update on the pharmacological treatment of Alzheimer's disease.  
11  
12 *Curr. Neuropharmacol.* **2010**, *8*, 69-80.

13  
14 (19) Davie, B. J.; Christopoulos, A.; Scammells, P. J. Development of M<sub>1</sub> mAChR allosteric  
15  
16 and bitopic ligands: Prospective therapeutics for the treatment of cognitive deficits. *ACS Chem.*  
17  
18 *Neurosci.* **2013**, *4*, 1026-1048.

19  
20 (20) Mistry, S. N.; Valant, C.; Sexton, P. M.; Capuano, B.; Christopoulos, A.; Scammells, P. J.  
21  
22 Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA)  
23  
24 as allosteric modulators of the M1 muscarinic receptor. *J. Med. Chem.* **2013**, *56*, 5151-5172.

25  
26 (21) Watt, M. L.; Schober, D. A.; Hitchcock, S.; Liu, B.; Chesterfield, A. K.; McKinzie, D.;  
27  
28 Felder, C. C. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine  
29  
30 receptor-selective partial orthosteric agonist. *J. Pharmacol. Exp. Ther.* **2011**, *338*, 622-632.

31  
32 (22) Canals, M.; Lane, J. R.; Wen, A.; Scammells, P. J.; Sexton, P. M.; Christopoulos, A. A  
33  
34 Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric  
35  
36 modulation. *J. Biol. Chem.* **2012**, *287*, 650-659.

37  
38 (23) Shirey, J. K.; Brady, A. E.; Jones, P. J.; Davis, A. A.; Bridges, T. M.; Kennedy, J. P.;  
39  
40 Jadhav, S. B.; Menon, U. N.; Xiang, Z.; Watson, M. L.; Christian, E. P.; Doherty, J. J.; Quirk, M.  
41  
42 C.; Snyder, D. H.; Lah, J. J.; Levey, A. I.; Nicolle, M. M.; Lindsley, C. W.; Conn, P. J. A selective  
43  
44 allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial  
45  
46 prefrontal cortical neurons and restores impairments in reversal learning. *J. Neurosci.* **2009**, *29*,  
47  
48 14271-14286.

49  
50 (24) Abdul-Ridha, A.; Lopez, L.; Keov, P.; Thal, D. M.; Mistry, S. N.; Sexton, P. M.; Lane, J.  
51  
52 R.; Canals, M.; Christopoulos, A. Molecular determinants of allosteric modulation at the M1  
53  
54 muscarinic acetylcholine receptor. *J. Biol. Chem.* **2014**, *289*, 6067-6079.  
55  
56  
57  
58  
59  
60

1  
2  
3 (25) Kuduk, S. D.; Di Marco, C. N.; Saffold, J. R.; Ray, W. J.; Ma, L.; Wittmann, M.;  
4  
5 Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M. T.; Beshore, D. C.  
6  
7 Identification of a methoxynaphthalene scaffold as a core replacement in quinolizidinone amide M1  
8  
9 positive allosteric modulators. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 1417-1420.

10  
11 (26) Eckhardt, M.; Himmelsbach, F. Oxazinanone derivatives as 11 $\beta$ -HSD1 inhibitors and their  
12  
13 preparation and use for the treatment of 11 $\beta$ -HSD1-mediated diseases. WO2010089303A1, 2010.

14  
15 (27) Penfold, B. R. The electron distribution in crystalline  $\alpha$ -pyridone. *Acta Crystallogr.* **1953**,  
16  
17 *6*, 591-600.

18  
19 (28) Yang, H. W.; Craven, R. M. Charge density study of 2-pyridone. *Acta Crystallogr., Sect.*  
20  
21 *B: Struct. Sci.* **1998**, *B54*, 912-920.

22  
23 (29) Aksnes, D. W.; Kryvi, H. Substituent and solvent effects in the proton magnetic resonance  
24  
25 (PMR) spectra of six 2-substituted pyridines. *Acta Chem. Scand.* **1972**, *26*, 2255-66.

26  
27 (30) Forlani, L.; Cristoni, G.; Boga, C.; Todesco, P. E.; Del Vecchio, E.; Selva, S.; Monari, M.  
28  
29 Reinvestigation of the tautomerism of some substituted 2-hydroxypyridines. *ARKIVOC* **2002**, 198-  
30  
31 215.

32  
33 (31) Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive  
34  
35 amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and  
36  
37 indirect reductive amination procedures. *J. Org. Chem.* **1996**, *61*, 3849-3862.

38  
39 (32) Christopoulos, A. Assessing the distribution of parameters in models of ligand-receptor  
40  
41 interaction: to log or not to log. *Trends Pharmacol. Sci.* **1998**, *19*, 351-357.

42  
43 (33) Yang, F. V.; Shipe, W. D.; Bunda, J. L.; Nolt, M. B.; Wisnoski, D. D.; Zhao, Z.; Barrow, J.  
44  
45 C.; Ray, W. J.; Ma, L.; Wittmann, M.; Seager, M. A.; Koeplinger, K. A.; Hartman, G. D.; Lindsley,  
46  
47 C. W. Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M1 positive allosteric  
48  
49 modulators. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 531-536.

50  
51 (34) Liljebris, C.; Larsen, S. D.; Ogg, D.; Palazuk, B. J.; Bleasdale, J. E. Investigation of  
52  
53 potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein  
54  
55

1  
2  
3 tyrosine phosphatase 1B: Identification of a tetrazole-containing inhibitor with cellular activity. *J.*  
4  
5 *Med. Chem.* **2002**, *45*, 1785-1798.

6  
7 (35) Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug  
8  
9 design. *J. Med. Chem.* **2011**, *54*, 2529-2591.

10  
11 (36) Gonzalez, A. Z.; Li, Z.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Duquette, J.;  
12  
13 Eksterowicz, J.; Fox, B. M.; Fu, J.; Huang, X.; Houze, J.; Jin, L.; Li, Y.; Ling, Y.; Lo, M.-C.; Long,  
14  
15 A. M.; McGee, L. R.; McIntosh, J.; Oliner, J. D.; Osgood, T.; Rew, Y.; Saiki, A. Y.; Shaffer, P.;  
16  
17 Wortman, S.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Olson, S. H.; Sun, D.;  
18  
19 Medina, J. C. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as  
20  
21 carboxylic acid isosteres. *J. Med. Chem.* **2014**, *57*, 2963-2988.

22  
23 (37) Huynh, T.; Valant, C.; Crosby, I. T.; Sexton, P. M.; Christopoulos, A.; Capuano, B.  
24  
25 Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor. *J.*  
26  
27 *Med. Chem.* **2013**, *56*, 8196-8200.

28  
29 (38) Spectra available in Supporting Information.

30  
31 (39) May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G  
32  
33 protein-coupled receptors. *Annu. Rev. Pharmacol. Toxicol.* **2007**, *47*, 1-51.

34  
35 (40) Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric GPCR modulators: taking  
36  
37 advantage of permissive receptor pharmacology. *Trends Pharmacol. Sci.* **2007**, *28*, 382-389.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## TABLE OF CONTENTS GRAPHIC

